1uwh › Citations

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R
Cell 116 855-67 (2004)
Cited: 1614 times
EuropePMC logo PMID: 15035987

Abstract

Over 30 mutations of the B-RAF gene associated with human cancers have been identified, the majority of which are located within the kinase domain. Here we show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo. Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells. The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by association with the P loop. The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation. The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.

Reviews - 1uwh mentioned but not cited (16)

  1. Dynamics-Driven Allostery in Protein Kinases. Kornev AP, Taylor SS. Trends Biochem Sci 40 628-647 (2015)
  2. Pseudokinases-remnants of evolution or key allosteric regulators? Zeqiraj E, van Aalten DM. Curr Opin Struct Biol 20 772-781 (2010)
  3. Substrate and docking interactions in serine/threonine protein kinases. Goldsmith EJ, Akella R, Min X, Zhou T, Humphreys JM. Chem Rev 107 5065-5081 (2007)
  4. Structural Basis for the Non-catalytic Functions of Protein Kinases. Kung JE, Jura N. Structure 24 7-24 (2016)
  5. In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs. Gagic Z, Ruzic D, Djokovic N, Djikic T, Nikolic K. Front Chem 7 873 (2019)
  6. Oligomerization and nanocluster organization render specificity. Nussinov R, Jang H, Tsai CJ. Biol Rev Camb Philos Soc 90 587-598 (2015)
  7. Anti-Hepatocellular Carcinoma Biomolecules: Molecular Targets Insights. Juaid N, Amin A, Abdalla A, Reese K, Alamri Z, Moulay M, Abdu S, Miled N. Int J Mol Sci 22 10774 (2021)
  8. Plasma membrane regulates Ras signaling networks. Chavan TS, Muratcioglu S, Marszalek R, Jang H, Keskin O, Gursoy A, Nussinov R, Gaponenko V. Cell Logist 5 e1136374 (2015)
  9. Impact of the Protein Data Bank on antineoplastic approvals. Westbrook JD, Soskind R, Hudson BP, Burley SK. Drug Discov Today 25 837-850 (2020)
  10. A structural perspective on targeting the RTK/Ras/MAP kinase pathway in cancer. Heppner DE, Eck MJ. Protein Sci 30 1535-1553 (2021)
  11. Oximes: Novel Therapeutics with Anticancer and Anti-Inflammatory Potential. Schepetkin IA, Plotnikov MB, Khlebnikov AI, Plotnikova TM, Quinn MT. Biomolecules 11 777 (2021)
  12. Principles and characteristics of biological assemblies in experimentally determined protein structures. Xu Q, Dunbrack RL. Curr Opin Struct Biol 55 34-49 (2019)
  13. Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma. Musumeci F, Cianciusi A, D'Agostino I, Grossi G, Carbone A, Schenone S. Molecules 26 7069 (2021)
  14. Looking lively: emerging principles of pseudokinase signaling. Sheetz JB, Lemmon MA. Trends Biochem Sci 47 875-891 (2022)
  15. Computer-Aided Identification of Kinase-Targeted Small Molecules for Cancer: A Review on AKT Protein. Primavera E, Palazzotti D, Barreca ML, Astolfi A. Pharmaceuticals (Basel) 16 993 (2023)
  16. Urea-based anticancer agents. Exploring 100-years of research with an eye to the future. Listro R, Rossino G, Piaggi F, Sonekan FF, Rossi D, Linciano P, Collina S. Front Chem 10 995351 (2022)

Articles - 1uwh mentioned but not cited (63)

  1. Identification of RIP1 kinase as a specific cellular target of necrostatins. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X, Abbott D, Cuny GD, Yuan C, Wagner G, Hedrick SM, Gerber SA, Lugovskoy A, Yuan J. Nat Chem Biol 4 313-321 (2008)
  2. Allosteric activation of functionally asymmetric RAF kinase dimers. Hu J, Stites EC, Yu H, Yu H, Germino EA, Meharena HS, Stork PJS, Kornev AP, Taylor SS, Shaw AS. Cell 154 1036-1046 (2013)
  3. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. Röring M, Herr R, Fiala GJ, Heilmann K, Braun S, Eisenhardt AE, Halbach S, Capper D, von Deimling A, Schamel WW, Saunders DN, Brummer T. EMBO J 31 2629-2647 (2012)
  4. Measuring and interpreting the selectivity of protein kinase inhibitors. Smyth LA, Collins I. J Chem Biol 2 131-151 (2009)
  5. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen SR, Enemark EJ, Shurtleff S, Rubnitz JE, Mullighan CG, Inaba H. Clin Cancer Res 19 5758-5768 (2013)
  6. Myricetin suppresses UVB-induced wrinkle formation and MMP-9 expression by inhibiting Raf. Jung SK, Lee KW, Kim HY, Oh MH, Byun S, Lim SH, Heo YS, Kang NJ, Bode AM, Dong Z, Lee HJ. Biochem Pharmacol 79 1455-1461 (2010)
  7. Identification of significantly mutated regions across cancer types highlights a rich landscape of functional molecular alterations. Araya CL, Cenik C, Reuter JA, Kiss G, Pande VS, Snyder MP, Greenleaf WJ. Nat Genet 48 117-125 (2016)
  8. The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase. Xie P, Streu C, Qin J, Bregman H, Pagano N, Meggers E, Marmorstein R. Biochemistry 48 5187-5198 (2009)
  9. Hydrogen bonding penalty upon ligand binding. Zhao H, Huang D. PLoS One 6 e19923 (2011)
  10. K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling. Yin Q, Han T, Fang B, Zhang G, Zhang C, Roberts ER, Izumi V, Zheng M, Jiang S, Yin X, Kim M, Cai J, Haura EB, Koomen JM, Smalley KSM, Wan L. Nat Commun 10 1870 (2019)
  11. Identification of a novel family of BRAF(V600E) inhibitors. Qin J, Xie P, Ventocilla C, Zhou G, Vultur A, Chen Q, Liu Q, Herlyn M, Winkler J, Marmorstein R. J Med Chem 55 5220-5230 (2012)
  12. A whole-animal platform to advance a clinical kinase inhibitor into new disease space. Sonoshita M, Scopton AP, Ung PMU, Murray MA, Silber L, Maldonado AY, Real A, Schlessinger A, Cagan RL, Dar AC. Nat Chem Biol 14 291-298 (2018)
  13. Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. Murphy EA, Shields DJ, Stoletov K, Dneprovskaia E, McElroy M, Greenberg JI, Lindquist J, Acevedo LM, Anand S, Majeti BK, Tsigelny I, Saldanha A, Walsh B, Hoffman RM, Bouvet M, Klemke RL, Vogt PK, Arnold L, Wrasidlo W, Cheresh DA. Proc Natl Acad Sci U S A 107 4299-4304 (2010)
  14. Cdc37 interacts with the glycine-rich loop of Hsp90 client kinases. Terasawa K, Yoshimatsu K, Iemura S, Natsume T, Tanaka K, Minami Y. Mol Cell Biol 26 3378-3389 (2006)
  15. Integration of signaling in the kinome: Architecture and regulation of the αC Helix. Taylor SS, Shaw AS, Kannan N, Kornev AP. Biochim Biophys Acta 1854 1567-1574 (2015)
  16. Delphinidin attenuates neoplastic transformation in JB6 Cl41 mouse epidermal cells by blocking Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling. Kang NJ, Lee KW, Kwon JY, Hwang MK, Rogozin EA, Heo YS, Bode AM, Lee HJ, Dong Z. Cancer Prev Res (Phila) 1 522-531 (2008)
  17. Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors. Lin X, Huang XP, Chen G, Whaley R, Peng S, Wang Y, Zhang G, Wang SX, Wang S, Roth BL, Huang N. J Med Chem 55 5749-5759 (2012)
  18. TRAF1 Is Critical for Regulating the BRAF/MEK/ERK Pathway in Non-Small Cell Lung Carcinogenesis. Wang Q, Gao G, Zhang T, Yao K, Chen H, Park MH, Yamamoto H, Wang K, Ma W, Malakhova M, Bode AM, Dong Z. Cancer Res 78 3982-3994 (2018)
  19. The energy landscape analysis of cancer mutations in protein kinases. Dixit A, Verkhivker GM. PLoS One 6 e26071 (2011)
  20. Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. Weisberg E, Roesel J, Furet P, Bold G, Imbach P, Flörsheimer A, Caravatti G, Jiang J, Manley P, Ray A, Griffin JD. Genes Cancer 1 1021-1032 (2010)
  21. Structures of the inactive and active states of RIP2 kinase inform on the mechanism of activation. Pellegrini E, Signor L, Singh S, Boeri Erba E, Cusack S. PLoS One 12 e0177161 (2017)
  22. Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF. Gunderwala AY, Nimbvikar AA, Cope NJ, Li Z, Wang Z. ACS Chem Biol 14 1471-1480 (2019)
  23. Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. Adamopoulos C, Ahmed TA, Tucker MR, Ung PMU, Xiao M, Karoulia Z, Amabile A, Wu X, Aaronson SA, Ang C, Rebecca VW, Brown BD, Schlessinger A, Herlyn M, Wang Q, Shaw DE, Poulikakos PI. Cancer Discov 11 1716-1735 (2021)
  24. Predicting inactive conformations of protein kinases using active structures: conformational selection of type-II inhibitors. Xu M, Yu L, Wan B, Yu L, Huang Q. PLoS One 6 e22644 (2011)
  25. Structure-functional prediction and analysis of cancer mutation effects in protein kinases. Dixit A, Verkhivker GM. Comput Math Methods Med 2014 653487 (2014)
  26. Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation. Grasso M, Estrada MA, Ventocilla C, Samanta M, Maksimoska J, Villanueva J, Winkler JD, Marmorstein R. ACS Chem Biol 11 2876-2888 (2016)
  27. Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways. Tse A, Verkhivker GM. PLoS One 11 e0166583 (2016)
  28. Identification of targetable BRAF ΔN486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a BRAF-mutant pancreatic adenocarcinoma. Wrzeszczynski KO, Rahman S, Frank MO, Arora K, Shah M, Geiger H, Felice V, Manaa D, Dikoglu E, Khaira D, Chimpiri AR, Michelini VV, Jobanputra V, Darnell RB, Powers S, Choi M. Cold Spring Harb Mol Case Stud 5 a004424 (2019)
  29. Ligand-target prediction by structural network biology using nAnnoLyze. Martínez-Jiménez F, Marti-Renom MA. PLoS Comput Biol 11 e1004157 (2015)
  30. Raf activation is regulated by tyrosine 510 phosphorylation in Drosophila. Xia F, Li J, Hickey GW, Tsurumi A, Larson K, Guo D, Yan SJ, Silver-Morse L, Li WX. PLoS Biol 6 e128 (2008)
  31. Co-conserved MAPK features couple D-domain docking groove to distal allosteric sites via the C-terminal flanking tail. Nguyen T, Ruan Z, Oruganty K, Kannan N. PLoS One 10 e0119636 (2015)
  32. ProtChemSI: a network of protein-chemical structural interactions. Kalinina OV, Wichmann O, Apic G, Russell RB, Russell RB. Nucleic Acids Res 40 D549-53 (2012)
  33. DROIDS 1.20: A GUI-Based Pipeline for GPU-Accelerated Comparative Protein Dynamics. Babbitt GA, Mortensen JS, Coppola EE, Adams LE, Liao JK. Biophys J 114 1009-1017 (2018)
  34. HI-511 overcomes melanoma drug resistance via targeting AURKB and BRAF V600E. Chang X, Zhang T, Wang Q, Rathore MG, Reddy K, Chen H, Shin SH, Ma WY, Bode AM, Dong Z. Theranostics 10 9721-9740 (2020)
  35. Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology. Yu JX, Craig AJ, Duffy ME, Villacorta-Martin C, Miguela V, Ruiz de Galarreta M, Scopton AP, Silber L, Maldonado AY, Rialdi A, Guccione E, Lujambio A, Villanueva A, Dar AC. Mol Cancer Ther 18 1506-1519 (2019)
  36. HSP90-CDC37-PP5 forms a structural platform for kinase dephosphorylation. Oberoi J, Guiu XA, Outwin EA, Schellenberger P, Roumeliotis TI, Choudhary JS, Pearl LH. Nat Commun 13 7343 (2022)
  37. The pseudokinase domains of guanylyl cyclase-A and -B allosterically increase the affinity of their catalytic domains for substrate. Edmund AB, Walseth TF, Levinson NM, Potter LR. Sci Signal 12 eaau5378 (2019)
  38. Molecular modeling, dynamics simulations, and binding efficiency of berberine derivatives: A new group of RAF inhibitors for cancer treatment. Jabbarzadeh Kaboli P, Ismail P, Ling KH. PLoS One 13 e0193941 (2018)
  39. An in silico study of the molecular basis of B-RAF activation and conformational stability. Fratev FF, Jónsdóttir SO. BMC Struct Biol 9 47 (2009)
  40. HPLC, FTIR and GC-MS Analyses of Thymus vulgaris Phytochemicals Executing In Vitro and In Vivo Biological Activities and Effects on COX-1, COX-2 and Gastric Cancer Genes Computationally. Saleem A, Afzal M, Naveed M, Makhdoom SI, Mazhar M, Aziz T, Khan AA, Kamal Z, Shahzad M, Alharbi M, Alshammari A. Molecules 27 8512 (2022)
  41. Protein-protein binding selectivity and network topology constrain global and local properties of interface binding networks. Holland DO, Shapiro BH, Xue P, Johnson ME. Sci Rep 7 5631 (2017)
  42. A quantitative structure-activity relationship (QSAR) study of some diaryl urea derivatives of B-RAF inhibitors. Sadeghian-Rizi S, Sakhteman A, Hassanzadeh F. Res Pharm Sci 11 445-453 (2016)
  43. Biological evaluation, docking and molecular dynamic simulation of some novel diaryl urea derivatives bearing quinoxalindione moiety. Sadeghian-Rizi S, Khodarahmi GA, Sakhteman A, Jahanian-Najafabadi A, Rostami M, Mirzaei M, Hassanzadeh F. Res Pharm Sci 12 500-509 (2017)
  44. Rigidification Dramatically Improves Inhibitor Selectivity for RAF Kinases. Assadieskandar A, Yu C, Maisonneuve P, Kurinov I, Sicheri F, Zhang C. ACS Med Chem Lett 10 1074-1080 (2019)
  45. Type II Binders Targeting the "GLR-Out" Conformation of the Pseudokinase STRADα. Smith RHB, Khan ZM, Ung PM, Scopton AP, Silber L, Mack SM, Real AM, Schlessinger A, Dar AC. Biochemistry 60 289-302 (2021)
  46. Can structural features of kinase receptors provide clues on selectivity and inhibition? A molecular modeling study. Ravichandran S, Luke BT, Collins JR. J Mol Graph Model 57 36-48 (2015)
  47. Computer-aided design and synthesis of 3-carbonyl-5-phenyl-1H-pyrazole as highly selective and potent BRAFV600E and CRAF inhibitor. Kim J, Choi B, Im D, Jung H, Moon H, Aman W, Hah JM. J Enzyme Inhib Med Chem 34 1314-1320 (2019)
  48. Discovery of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido) phenylurea-based thymidylate synthase (TS) inhibitor as a novel multi-effects antitumor drugs with minimal toxicity. Li XY, Zhang TJ, Kamara MO, Lu GQ, Xu HL, Wang DP, Meng FH. Cell Death Dis 10 532 (2019)
  49. BRAF mutation as a novel driver of eosinophilic cystitis. Choi MY, Tsigelny IF, Boichard A, Skjevik ÅA, Shabaik A, Kurzrock R. Cancer Biol Ther 18 655-659 (2017)
  50. Creation of a free, Internet-accessible database: the Multiple Target Ligand Database. Chen C, He Y, Wu J, Zhou J. J Cheminform 7 14 (2015)
  51. Template-based de novo design for type II kinase inhibitors and its extented application to acetylcholinesterase inhibitors. Su BH, Huang YS, Chang CY, Tu YS, Tseng YJ. Molecules 18 13487-13509 (2013)
  52. A critical evaluation of protein kinase regulation by activation loop autophosphorylation. Reinhardt R, Leonard TA. Elife 12 e88210 (2023)
  53. CB-RAF600E-1 exerts efficacy in vemurafenib-resistant and non-resistant-melanoma cells via dual inhibition of RAS/RAF/MEK/ERK and PI3K/Akt signaling pathways. Al Shahrani M, Rajagopalan P, Abohassan M, Alshahrani M, Alraey Y. Saudi J Biol Sci 29 103285 (2022)
  54. Study of Imidazolium Salt Derivatives as PIK3CA Inhibitors Using a Comprehensive in Silico Method. Wang MY, Liang JW, Li XY, Olounfeh KM, Li SL, Wang S, Wang L, Meng FH. Int J Mol Sci 19 E896 (2018)
  55. Analyzing Kinase Similarity in Small Molecule and Protein Structural Space to Explore the Limits of Multi-Target Screening. Schmidt D, Scharf MM, Sydow D, Aßmann E, Martí-Solano M, Keul M, Volkamer A, Kolb P. Molecules 26 629 (2021)
  56. COMA: efficient structure-constrained molecular generation using contractive and margin losses. Choi J, Seo S, Park S. J Cheminform 15 8 (2023)
  57. Conformational diversity and protein-protein interfaces in drug repurposing in Ras signaling pathway. Sayin AZ, Abali Z, Senyuz S, Cankara F, Gursoy A, Keskin O. Sci Rep 14 1239 (2024)
  58. GC-MS profiling of Bacillus spp. metabolites with an in vitro biological activity assessment and computational analysis of their impact on epithelial glioblastoma cancer genes. Naveed M, Ishfaq H, Rehman SU, Javed A, Waseem M, Makhdoom SI, Aziz T, Alharbi M, Alshammari A, Alasmari AF. Front Chem 11 1287599 (2023)
  59. Introduction of Mercaptoethyl at Sorafenib Pyridine-2-Amide Motif as a Potentially Effective Chain to Further get Sorafenib-PEG-DGL. Wang K, Kuerbana K, Wan Q, Yu Z, Ye L, Chen Y. Molecules 25 E573 (2020)
  60. Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases. Zhu Y, Hu X. Molecules 27 7124 (2022)
  61. Prediction of kinase-inhibitor binding affinity using energetic parameters. Usha S, Selvaraj S. Bioinformation 12 172-181 (2016)
  62. Regulatory spine RS3 residue of protein kinases: a lipophilic bystander or a decisive element in the small-molecule kinase inhibitor binding? Shevchenko E, Pantsar T. Biochem Soc Trans 50 633-648 (2022)
  63. Synthesis, molecular modeling, and biological evaluation of novel imatinib derivatives as anticancer agents. Günay F, Balta S, Ng YY, Ulucan Ö, Turgut Z, Günkara ÖT. Turk J Chem 46 86-102 (2022)


Reviews citing this publication (494)

  1. Cancer genes and the pathways they control. Vogelstein B, Kinzler KW. Nat Med 10 789-799 (2004)
  2. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Roberts PJ, Der CJ. Oncogene 26 3291-3310 (2007)
  3. MAP kinase signalling pathways in cancer. Dhillon AS, Hagan S, Rath O, Kolch W. Oncogene 26 3279-3290 (2007)
  4. Targeting cancer with small molecule kinase inhibitors. Zhang J, Yang PL, Gray NS. Nat Rev Cancer 9 28-39 (2009)
  5. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Taipale M, Jarosz DF, Lindquist S. Nat Rev Mol Cell Biol 11 515-528 (2010)
  6. Hyperactive Ras in developmental disorders and cancer. Schubbert S, Shannon K, Bollag G. Nat Rev Cancer 7 295-308 (2007)
  7. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S. Nat Rev Drug Discov 5 835-844 (2006)
  8. The RAF proteins take centre stage. Wellbrock C, Karasarides M, Marais R. Nat Rev Mol Cell Biol 5 875-885 (2004)
  9. Regulation of protein kinases; controlling activity through activation segment conformation. Nolen B, Taylor S, Ghosh G. Mol Cell 15 661-675 (2004)
  10. Targeting the mitogen-activated protein kinase cascade to treat cancer. Sebolt-Leopold JS, Herrera R. Nat Rev Cancer 4 937-947 (2004)
  11. Targeting RAS-ERK signalling in cancer: promises and challenges. Samatar AA, Poulikakos PI. Nat Rev Drug Discov 13 928-942 (2014)
  12. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Luke JJ, Flaherty KT, Ribas A, Long GV. Nat Rev Clin Oncol 14 463-482 (2017)
  13. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Xing M. Endocr Rev 28 742-762 (2007)
  14. Guilty as charged: B-RAF is a human oncogene. Garnett MJ, Marais R. Cancer Cell 6 313-319 (2004)
  15. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Santarpia L, Lippman SM, El-Naggar AK. Expert Opin Ther Targets 16 103-119 (2012)
  16. The MAPK pathway across different malignancies: a new perspective. Burotto M, Chiou VL, Lee JM, Kohn EC. Cancer 120 3446-3456 (2014)
  17. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Holderfield M, Deuker MM, McCormick F, McMahon M. Nat Rev Cancer 14 455-467 (2014)
  18. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Tidyman WE, Rauen KA. Curr Opin Genet Dev 19 230-236 (2009)
  19. FDA-approved small-molecule kinase inhibitors. Wu P, Nielsen TE, Clausen MH. Trends Pharmacol Sci 36 422-439 (2015)
  20. Vemurafenib: the first drug approved for BRAF-mutant cancer. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P. Nat Rev Drug Discov 11 873-886 (2012)
  21. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Morrison DK. Trends Cell Biol 19 16-23 (2009)
  22. Integrating signals from RTKs to ERK/MAPK. McKay MM, Morrison DK. Oncogene 26 3113-3121 (2007)
  23. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. Expert Opin Ther Targets 16 Suppl 2 S17-27 (2012)
  24. Tumor adaptation and resistance to RAF inhibitors. Lito P, Rosen N, Solit DB. Nat Med 19 1401-1409 (2013)
  25. Features of selective kinase inhibitors. Knight ZA, Shokat KM. Chem Biol 12 621-637 (2005)
  26. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Bäsecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M, McCubrey JA. Aging (Albany NY) 3 192-222 (2011)
  27. Regulation of RAF protein kinases in ERK signalling. Lavoie H, Therrien M. Nat Rev Mol Cell Biol 16 281-298 (2015)
  28. Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling. Caunt CJ, Keyse SM. FEBS J 280 489-504 (2013)
  29. The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Gurevich VV, Gurevich EV. Pharmacol Ther 110 465-502 (2006)
  30. Glioma Subclassifications and Their Clinical Significance. Chen R, Smith-Cohn M, Cohen AL, Colman H. Neurotherapeutics 14 284-297 (2017)
  31. Targeting the RAF-MEK-ERK pathway in cancer therapy. Montagut C, Settleman J. Cancer Lett 283 125-134 (2009)
  32. Targeting the ERK signaling pathway in cancer therapy. Kohno M, Pouyssegur J. Ann Med 38 200-211 (2006)
  33. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM, McCubrey JA. Leukemia 22 686-707 (2008)
  34. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Katz M, Amit I, Yarden Y. Biochim Biophys Acta 1773 1161-1176 (2007)
  35. The structural basis for control of eukaryotic protein kinases. Endicott JA, Noble ME, Johnson LN. Annu Rev Biochem 81 587-613 (2012)
  36. Cutaneous melanoma: From pathogenesis to therapy (Review). Leonardi GC, Falzone L, Salemi R, Zanghì A, Spandidos DA, Mccubrey JA, Candido S, Libra M. Int J Oncol 52 1071-1080 (2018)
  37. Inhibition of Ras for cancer treatment: the search continues. Baines AT, Xu D, Der CJ. Future Med Chem 3 1787-1808 (2011)
  38. Implementing Genome-Driven Oncology. Hyman DM, Taylor BS, Baselga J. Cell 168 584-599 (2017)
  39. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Gotink KJ, Verheul HM. Angiogenesis 13 1-14 (2010)
  40. Thyroid carcinoma: molecular pathways and therapeutic targets. Nikiforov YE. Mod Pathol 21 Suppl 2 S37-43 (2008)
  41. JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships. Zeke A, Misheva M, Reményi A, Bogoyevitch MA. Microbiol Mol Biol Rev 80 793-835 (2016)
  42. New targetable oncogenes in non-small-cell lung cancer. Oxnard GR, Binder A, Jänne PA. J Clin Oncol 31 1097-1104 (2013)
  43. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y. Hum Mutat 29 992-1006 (2008)
  44. Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Irish JM, Kotecha N, Nolan GP. Nat Rev Cancer 6 146-155 (2006)
  45. Kinase mutations in human disease: interpreting genotype-phenotype relationships. Lahiry P, Torkamani A, Schork NJ, Hegele RA. Nat Rev Genet 11 60-74 (2010)
  46. Molecular diagnostics and predictors in thyroid cancer. Nikiforova MN, Nikiforov YE. Thyroid 19 1351-1361 (2009)
  47. Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. Degirmenci U, Wang M, Hu J. Cells 9 E198 (2020)
  48. Mechanisms of drug inhibition of signalling molecules. Sebolt-Leopold JS, English JM. Nature 441 457-462 (2006)
  49. New perspectives for targeting RAF kinase in human cancer. Karoulia Z, Gavathiotis E, Poulikakos PI. Nat Rev Cancer 17 676-691 (2017)
  50. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Oncogene 37 3183-3199 (2018)
  51. Targeting Alterations in the RAF-MEK Pathway. Yaeger R, Corcoran RB. Cancer Discov 9 329-341 (2019)
  52. BRAF(E600) in benign and malignant human tumours. Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. Oncogene 27 877-895 (2008)
  53. New insight into BRAF mutations in cancer. Dhomen N, Marais R. Curr Opin Genet Dev 17 31-39 (2007)
  54. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Dar AC, Shokat KM. Annu Rev Biochem 80 769-795 (2011)
  55. Raf kinases: function, regulation and role in human cancer. Leicht DT, Balan V, Kaplun A, Singh-Gupta V, Kaplun L, Dobson M, Tzivion G. Biochim Biophys Acta 1773 1196-1212 (2007)
  56. Raf: a strategic target for therapeutic development against cancer. Beeram M, Patnaik A, Rowinsky EK. J Clin Oncol 23 6771-6790 (2005)
  57. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Nikiforova MN, Nikiforov YE. Expert Rev Mol Diagn 8 83-95 (2008)
  58. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Logue JS, Morrison DK. Genes Dev 26 641-650 (2012)
  59. Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? Zhao Z, Wu H, Wang L, Liu Y, Knapp S, Liu Q, Gray NS. ACS Chem Biol 9 1230-1241 (2014)
  60. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, Selvan SR. Immunol Res 51 170-182 (2011)
  61. BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. Sanz-Garcia E, Argiles G, Elez E, Tabernero J. Ann Oncol 28 2648-2657 (2017)
  62. Protein kinase inhibitors: contributions from structure to clinical compounds. Johnson LN. Q Rev Biophys 42 1-40 (2009)
  63. Biomarker-guided therapy for colorectal cancer: strength in complexity. Sveen A, Kopetz S, Lothe RA. Nat Rev Clin Oncol 17 11-32 (2020)
  64. MAPK pathway activation in pilocytic astrocytoma. Jones DT, Gronych J, Lichter P, Witt O, Pfister SM. Cell Mol Life Sci 69 1799-1811 (2012)
  65. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. PLoS One 7 e47054 (2012)
  66. Pathways and therapeutic targets in melanoma. Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE. Oncotarget 5 1701-1752 (2014)
  67. Molecular chaperones and protein kinase quality control. Caplan AJ, Mandal AK, Theodoraki MA. Trends Cell Biol 17 87-92 (2007)
  68. Which drug, and when, for patients with BRAF-mutant melanoma? Jang S, Atkins MB. Lancet Oncol 14 e60-9 (2013)
  69. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P, Yu Q, Yuan X. Oncotarget 8 3980-4000 (2017)
  70. BRAF signaling and targeted therapies in melanoma. Dhomen N, Marais R. Hematol Oncol Clin North Am 23 529-45, ix (2009)
  71. Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KS, Smalley KS. Nat Rev Clin Oncol 10 390-399 (2013)
  72. Control of life-or-death decisions by RIP1 kinase. Christofferson DE, Li Y, Yuan J. Annu Rev Physiol 76 129-150 (2014)
  73. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Pratilas CA, Solit DB. Clin Cancer Res 16 3329-3334 (2010)
  74. Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Brennan DJ, O'Connor DP, Rexhepaj E, Ponten F, Gallagher WM. Nat Rev Cancer 10 605-617 (2010)
  75. NF-kappaB activation in melanoma. Ueda Y, Richmond A. Pigment Cell Res 19 112-124 (2006)
  76. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Inamdar GS, Madhunapantula SV, Robertson GP. Biochem Pharmacol 80 624-637 (2010)
  77. Pediatric low-grade glioma in the era of molecular diagnostics. Ryall S, Tabori U, Hawkins C. Acta Neuropathol Commun 8 30 (2020)
  78. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Fedorenko IV, Paraiso KH, Smalley KS, Smalley KS. Biochem Pharmacol 82 201-209 (2011)
  79. Protein kinase signaling networks in cancer. Brognard J, Hunter T. Curr Opin Genet Dev 21 4-11 (2011)
  80. Raf kinase inhibitory protein: a signal transduction modulator and metastasis suppressor. Granovsky AE, Rosner MR. Cell Res 18 452-457 (2008)
  81. Main roads to melanoma. Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA. J Transl Med 7 86 (2009)
  82. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Dibb NJ, Dilworth SM, Mol CD. Nat Rev Cancer 4 718-727 (2004)
  83. Novel targeted therapies and immunotherapy for advanced thyroid cancers. Naoum GE, Morkos M, Kim B, Arafat W. Mol Cancer 17 51 (2018)
  84. Targeting protein-protein interaction by small molecules. Jin L, Wang W, Fang G. Annu Rev Pharmacol Toxicol 54 435-456 (2014)
  85. Intracellular signal transduction pathway proteins as targets for cancer therapy. Adjei AA, Hidalgo M. J Clin Oncol 23 5386-5403 (2005)
  86. KSR and CNK: two scaffolds regulating RAS-mediated RAF activation. Clapéron A, Therrien M. Oncogene 26 3143-3158 (2007)
  87. The role of B-RAF in melanoma. Gray-Schopfer VC, da Rocha Dias S, Marais R. Cancer Metastasis Rev 24 165-183 (2005)
  88. The genome and epigenome of malignant melanoma. Dahl C, Guldberg P. APMIS 115 1161-1176 (2007)
  89. Second nature: biological functions of the Raf-1 "kinase". Baccarini M. FEBS Lett 579 3271-3277 (2005)
  90. Ras and Rap signaling in synaptic plasticity and mental disorders. Stornetta RL, Zhu JJ. Neuroscientist 17 54-78 (2011)
  91. Phosphate recognition in structural biology. Hirsch AK, Fischer FR, Diederich F. Angew Chem Int Ed Engl 46 338-352 (2007)
  92. Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target. Zeng L, Imamoto A, Rosner MR. Expert Opin Ther Targets 12 1275-1287 (2008)
  93. Clinical development of targeted and immune based anti-cancer therapies. Seebacher NA, Stacy AE, Porter GM, Merlot AM. J Exp Clin Cancer Res 38 156 (2019)
  94. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Corcoran RB, Settleman J, Engelman JA. Oncotarget 2 336-346 (2011)
  95. Targeting BRAF for patients with melanoma. Arkenau HT, Kefford R, Long GV. Br J Cancer 104 392-398 (2011)
  96. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Fedorenko IV, Gibney GT, Smalley KS, Smalley KS. Oncogene 32 3009-3018 (2013)
  97. Genetic alterations of PTEN in human melanoma. Aguissa-Touré AH, Li G. Cell Mol Life Sci 69 1475-1491 (2012)
  98. Mechanisms of drug resistance in kinases. Barouch-Bentov R, Sauer K. Expert Opin Investig Drugs 20 153-208 (2011)
  99. KRAS and BRAF: drug targets and predictive biomarkers. Vakiani E, Solit DB. J Pathol 223 219-229 (2011)
  100. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Yokota T. Anticancer Agents Med Chem 12 163-171 (2012)
  101. Deregulation of microRNA expression in thyroid neoplasias. Pallante P, Battista S, Pierantoni GM, Fusco A. Nat Rev Endocrinol 10 88-101 (2014)
  102. Flavonoids as protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modeling. Hou DX, Kumamoto T. Antioxid Redox Signal 13 691-719 (2010)
  103. The ERK signaling cascade--views from different subcellular compartments. Yao Z, Seger R. Biofactors 35 407-416 (2009)
  104. Targets of Raf in tumorigenesis. Niault TS, Baccarini M. Carcinogenesis 31 1165-1174 (2010)
  105. Deregulated Ras signaling in developmental disorders: new tricks for an old dog. Schubbert S, Bollag G, Shannon K. Curr Opin Genet Dev 17 15-22 (2007)
  106. Analysis of the genome to personalize therapy for melanoma. Davies MA, Samuels Y. Oncogene 29 5545-5555 (2010)
  107. Targeting the ERK Signaling Pathway in Melanoma. Savoia P, Fava P, Casoni F, Cremona O. Int J Mol Sci 20 E1483 (2019)
  108. Molecular pathogenesis of cutaneous melanocytic neoplasms. Ibrahim N, Haluska FG. Annu Rev Pathol 4 551-579 (2009)
  109. Raf kinases: oncogenesis and drug discovery. Schreck R, Rapp UR. Int J Cancer 119 2261-2271 (2006)
  110. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Morkel M, Riemer P, Bläker H, Sers C. Oncotarget 6 20785-20800 (2015)
  111. Targeting Oncogenic BRAF: Past, Present, and Future. Zaman A, Wu W, Bivona TG. Cancers (Basel) 11 E1197 (2019)
  112. Geldanamycin and its anti-cancer activities. Fukuyo Y, Hunt CR, Horikoshi N. Cancer Lett 290 24-35 (2010)
  113. Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression. Awad RM, De Vlaeminck Y, Maebe J, Goyvaerts C, Breckpot K. Front Immunol 9 1977 (2018)
  114. Alterations of the BRAF gene in thyroid tumors. Ciampi R, Nikiforov YE. Endocr Pathol 16 163-172 (2005)
  115. BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Nucera C, Lawler J, Parangi S. Cancer Res 71 2417-2422 (2011)
  116. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway. Tidyman WE, Rauen KA. Expert Rev Mol Med 10 e37 (2008)
  117. Emerging molecular targets in melanoma invasion and metastasis. Orgaz JL, Sanz-Moreno V. Pigment Cell Melanoma Res 26 39-57 (2013)
  118. Genetic risk factors for melanoma. Meyle KD, Guldberg P. Hum Genet 126 499-510 (2009)
  119. Ras-Mediated Activation of the Raf Family Kinases. Terrell EM, Morrison DK. Cold Spring Harb Perspect Med 9 a033746 (2019)
  120. The p38 MAPK stress pathway as a tumor suppressor or more? Loesch M, Chen G. Front Biosci 13 3581-3593 (2008)
  121. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O'Shea JJ. Immunol Rev 203 127-142 (2005)
  122. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma. Kim A, Cohen MS. Expert Opin Drug Discov 11 907-916 (2016)
  123. Molecular analysis of thyroid tumors. Bhaijee F, Nikiforov YE. Endocr Pathol 22 126-133 (2011)
  124. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Yap TA, Workman P. Annu Rev Pharmacol Toxicol 52 549-573 (2012)
  125. How Do Protein Kinases Take a Selfie (Autophosphorylate)? Beenstock J, Mooshayef N, Engelberg D. Trends Biochem Sci 41 938-953 (2016)
  126. MEK1/2 inhibitors in the treatment of gynecologic malignancies. Miller CR, Oliver KE, Farley JH. Gynecol Oncol 133 128-137 (2014)
  127. The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer. Wellbrock C, Arozarena I. Front Cell Dev Biol 4 33 (2016)
  128. Intragenic mutations in thyroid cancer. Sobrinho-Simões M, Máximo V, Rocha AS, Trovisco V, Castro P, Preto A, Lima J, Soares P. Endocrinol Metab Clin North Am 37 333-62, viii (2008)
  129. Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. Holderfield M, Nagel TE, Stuart DD. Br J Cancer 111 640-645 (2014)
  130. KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. Cicenas J, Tamosaitis L, Kvederaviciute K, Tarvydas R, Staniute G, Kalyan K, Meskinyte-Kausiliene E, Stankevicius V, Valius M. Med Oncol 34 26 (2017)
  131. On the molecular mechanisms of mitotic kinase activation. Bayliss R, Fry A, Haq T, Yeoh S. Open Biol 2 120136 (2012)
  132. Principles of allosteric interactions in cell signaling. Nussinov R, Tsai CJ, Liu J. J Am Chem Soc 136 17692-17701 (2014)
  133. Unraveling structural mechanisms of allosteric drug action. Nussinov R, Tsai CJ. Trends Pharmacol Sci 35 256-264 (2014)
  134. Sprouty and cancer: the first terms report. Lo TL, Fong CW, Yusoff P, McKie AB, Chua MS, Leung HY, Guy GR. Cancer Lett 242 141-150 (2006)
  135. BRAF somatic mutations in malignant melanoma and melanocytic naevi. Thomas NE. Melanoma Res 16 97-103 (2006)
  136. Cancer driver mutations in protein kinase genes. Torkamani A, Verkhivker G, Schork NJ. Cancer Lett 281 117-127 (2009)
  137. Emerging insights into resistance to BRAF inhibitors in melanoma. Bucheit AD, Davies MA. Biochem Pharmacol 87 381-389 (2014)
  138. Catalytic mechanisms and regulation of protein kinases. Wang Z, Cole PA. Methods Enzymol 548 1-21 (2014)
  139. The mutational landscape of mucosal melanoma. Nassar KW, Tan AC. Semin Cancer Biol 61 139-148 (2020)
  140. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician. Afrăsânie VA, Marinca MV, Alexa-Stratulat T, Gafton B, Păduraru M, Adavidoaiei AM, Miron L, Rusu C. Radiol Oncol 53 265-274 (2019)
  141. Mechanistic principles of RAF kinase signaling. Udell CM, Rajakulendran T, Sicheri F, Therrien M. Cell Mol Life Sci 68 553-565 (2011)
  142. An update on molecular biology of thyroid cancers. Omur O, Baran Y. Crit Rev Oncol Hematol 90 233-252 (2014)
  143. Extracellular-Signal Regulated Kinase: A Central Molecule Driving Epithelial-Mesenchymal Transition in Cancer. Olea-Flores M, Zuñiga-Eulogio MD, Mendoza-Catalán MA, Rodríguez-Ruiz HA, Castañeda-Saucedo E, Ortuño-Pineda C, Padilla-Benavides T, Navarro-Tito N. Int J Mol Sci 20 E2885 (2019)
  144. Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas. Penman CL, Faulkner C, Lowis SP, Kurian KM. Front Oncol 5 54 (2015)
  145. Clinical implications of BRAF mutation in thyroid carcinoma. Puxeddu E, Durante C, Avenia N, Filetti S, Russo D. Trends Endocrinol Metab 19 138-145 (2008)
  146. Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Kudchadkar R, Paraiso KH, Smalley KS. Cancer J 18 124-131 (2012)
  147. BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oikonomou E, Koustas E, Goulielmaki M, Pintzas A. Oncotarget 5 11752-11777 (2014)
  148. Cutaneous melanoma: prognostic factors. Homsi J, Kashani-Sabet M, Messina JL, Daud A. Cancer Control 12 223-229 (2005)
  149. BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors. Schreck KC, Grossman SA, Pratilas CA. Cancers (Basel) 11 E1262 (2019)
  150. Prospects for pharmacological targeting of pseudokinases. Kung JE, Jura N. Nat Rev Drug Discov 18 501-526 (2019)
  151. Targeting BRAF in advanced melanoma: a first step toward manageable disease. Vultur A, Villanueva J, Herlyn M. Clin Cancer Res 17 1658-1663 (2011)
  152. Renal effects of targeted anticancer therapies. Porta C, Cosmai L, Gallieni M, Pedrazzoli P, Malberti F. Nat Rev Nephrol 11 354-370 (2015)
  153. Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development. Chung E, Kondo M. Immunol Res 49 248-268 (2011)
  154. BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. Hall RD, Kudchadkar RR. Cancer Control 21 221-230 (2014)
  155. Current targeted therapies in the treatment of advanced colorectal cancer: a review. Moriarity A, O'Sullivan J, Kennedy J, Mehigan B, McCormick P. Ther Adv Med Oncol 8 276-293 (2016)
  156. Interdependent epidermal growth factor receptor signalling and trafficking. Jones S, Rappoport JZ. Int J Biochem Cell Biol 51 23-28 (2014)
  157. MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance. Rauch N, Rukhlenko OS, Kolch W, Kholodenko BN. Curr Opin Struct Biol 41 151-158 (2016)
  158. Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature. Guerini AE, Triggiani L, Maddalo M, Bonù ML, Frassine F, Baiguini A, Alghisi A, Tomasini D, Borghetti P, Pasinetti N, Bresciani R, Magrini SM, Buglione M. Cancers (Basel) 11 E1284 (2019)
  159. Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Ilieva KM, Correa I, Josephs DH, Karagiannis P, Egbuniwe IU, Cafferkey MJ, Spicer JF, Harries M, Nestle FO, Lacy KE, Karagiannis SN. Mol Cancer Ther 13 2769-2783 (2014)
  160. Molecular pathology of well-differentiated thyroid carcinomas. Sobrinho-Simões M, Preto A, Rocha AS, Castro P, Máximo V, Fonseca E, Soares P. Virchows Arch 447 787-793 (2005)
  161. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Trovisco V, Soares P, Sobrinho-Simões M. Hum Pathol 37 781-786 (2006)
  162. Developmental pathways activated in melanocytes and melanoma. Liu J, Fukunaga-Kalabis M, Li L, Herlyn M. Arch Biochem Biophys 563 13-21 (2014)
  163. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Smalley KS, Herlyn M. Ann N Y Acad Sci 1059 16-25 (2005)
  164. Comparison of human cell signaling pathway databases--evolution, drawbacks and challenges. Chowdhury S, Sarkar RR. Database (Oxford) 2015 bau126 (2015)
  165. Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges. Millet A, Martin AR, Ronco C, Ronco C, Rocchi S, Benhida R. Med Res Rev 37 98-148 (2017)
  166. Prognostic and predictive response factors in colorectal cancer patients: between hope and reality. De Divitiis C, Nasti G, Montano M, Fisichella R, Iaffaioli RV, Berretta M. World J Gastroenterol 20 15049-15059 (2014)
  167. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. Haluska F, Pemberton T, Ibrahim N, Kalinsky K. Semin Oncol 34 546-554 (2007)
  168. BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. Proietti I, Skroza N, Michelini S, Mambrin A, Balduzzi V, Bernardini N, Marchesiello A, Tolino E, Volpe S, Maddalena P, Di Fraia M, Mangino G, Romeo G, Potenza C. Cancers (Basel) 12 E1823 (2020)
  169. A review of novel therapies for melanoma. Karimkhani C, Gonzalez R, Dellavalle RP. Am J Clin Dermatol 15 323-337 (2014)
  170. Structure-based design of molecular cancer therapeutics. van Montfort RL, Workman P. Trends Biotechnol 27 315-328 (2009)
  171. BuCy RAFs drive cells into MEK addiction. Rapp UR, Götz R, Albert S. Cancer Cell 9 9-12 (2006)
  172. Personalized therapy on the horizon for squamous cell carcinoma of the lung. Kim HS, Mitsudomi T, Soo RA, Cho BC. Lung Cancer 80 249-255 (2013)
  173. The molecular therapy of colorectal cancer. Waldner MJ, Neurath MF. Mol Aspects Med 31 171-178 (2010)
  174. Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Angelbello AJ, Chen JL, Childs-Disney JL, Zhang P, Wang ZF, Disney MD. Chem Rev 118 1599-1663 (2018)
  175. BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies. van Brummelen EMJ, de Boer A, Beijnen JH, Schellens JHM. Oncologist 22 864-872 (2017)
  176. Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma. Wang JX, Fukunaga-Kalabis M, Herlyn M. J Cell Commun Signal 10 191-196 (2016)
  177. Molecular markers of glioma: an update on recent progress and perspectives. Gupta K, Salunke P. J Cancer Res Clin Oncol 138 1971-1981 (2012)
  178. Strategies to design clinical studies to identify predictive biomarkers in cancer research. Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I. Cancer Treat Rev 53 79-97 (2017)
  179. Targeting signaling pathways in epithelial ovarian cancer. Smolle E, Taucher V, Pichler M, Petru E, Lax S, Haybaeck J. Int J Mol Sci 14 9536-9555 (2013)
  180. Therapy for metastatic melanoma: an overview and update. Boyle GM. Expert Rev Anticancer Ther 11 725-737 (2011)
  181. BRAF V600E mutation in hairy cell leukemia: from bench to bedside. Falini B, Martelli MP, Tiacci E. Blood 128 1918-1927 (2016)
  182. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience. Khunger A, Khunger M, Velcheti V. Ther Adv Respir Dis 12 1753466618767611 (2018)
  183. Genetic progression of metastatic melanoma. Rodolfo M, Daniotti M, Vallacchi V. Cancer Lett 214 133-147 (2004)
  184. Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma. Chan XY, Singh A, Osman N, Piva TJ. Int J Mol Sci 18 E1527 (2017)
  185. Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation. Gilsbach BK, Kortholt A. Front Mol Neurosci 7 32 (2014)
  186. BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Li ZN, Zhao L, Yu LF, Wei MJ. Gastroenterol Rep (Oxf) 8 192-205 (2020)
  187. Partner exchange: protein-protein interactions in the Raf pathway. Wimmer R, Baccarini M. Trends Biochem Sci 35 660-668 (2010)
  188. Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Nucera C, Goldfarb M, Hodin R, Parangi S. Biochim Biophys Acta 1795 152-161 (2009)
  189. Signal control through Raf: in sickness and in health. Osborne JK, Zaganjor E, Cobb MH. Cell Res 22 14-22 (2012)
  190. Small-molecule inhibitors of the ERK signaling pathway: Towards novel anticancer therapeutics. Yap JL, Worlikar S, MacKerell AD, Shapiro P, Fletcher S. ChemMedChem 6 38-48 (2011)
  191. G-protein-coupled receptors and melanoma. Lee HJ, Wall B, Chen S. Pigment Cell Melanoma Res 21 415-428 (2008)
  192. B-Raf mutation: a key player in molecular biology of cancer. Rahman MA, Salajegheh A, Smith RA, Lam AK. Exp Mol Pathol 95 336-342 (2013)
  193. Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. MacConaill LE, Van Hummelen P, Meyerson M, Hahn WC. Cancer Discov 1 297-311 (2011)
  194. Exploring the best treatment options for BRAF-mutant metastatic colon cancer. Taieb J, Lapeyre-Prost A, Laurent Puig P, Zaanan A. Br J Cancer 121 434-442 (2019)
  195. Genomics of Hairy Cell Leukemia. Tiacci E, Pettirossi V, Schiavoni G, Falini B. J Clin Oncol 35 1002-1010 (2017)
  196. New strategies in melanoma: molecular testing in advanced disease. Woodman SE, Lazar AJ, Aldape KD, Davies MA. Clin Cancer Res 18 1195-1200 (2012)
  197. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. Girotti MR, Saturno G, Lorigan P, Marais R. Mol Oncol 8 1140-1158 (2014)
  198. Noonan syndrome-causing genes: Molecular update and an assessment of the mutation rate. El Bouchikhi I, Belhassan K, Moufid FZ, Iraqui Houssaini M, Bouguenouch L, Samri I, Atmani S, Ouldim K. Int J Pediatr Adolesc Med 3 133-142 (2016)
  199. Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future? Lorigan P, Eisen T, Hauschild A. Exp Dermatol 17 383-394 (2008)
  200. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. Eck MJ, Manley PW. Curr Opin Cell Biol 21 288-295 (2009)
  201. BRAF and MEK inhibition in melanoma. Dossett LA, Kudchadkar RR, Zager JS. Expert Opin Drug Saf 14 559-570 (2015)
  202. Genetics and epigenetics of sporadic thyroid cancer. Vu-Phan D, Koenig RJ. Mol Cell Endocrinol 386 55-66 (2014)
  203. New drug targets in metastatic melanoma. Homet B, Ribas A. J Pathol 232 134-141 (2014)
  204. The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Nucera C, Lawler J, Hodin R, Parangi S. Oncotarget 1 751-756 (2010)
  205. The Role of Immune Checkpoint Blockade in Uveal Melanoma. Wessely A, Steeb T, Erdmann M, Heinzerling L, Vera J, Schlaak M, Berking C, Heppt MV. Int J Mol Sci 21 E879 (2020)
  206. Toxicity of sorafenib: clinical and molecular aspects. Blanchet B, Billemont B, Barete S, Garrigue H, Cabanes L, Coriat R, Francès C, Knebelmann B, Goldwasser F. Expert Opin Drug Saf 9 275-287 (2010)
  207. BRAF gene: From human cancers to developmental syndromes. Hussain MR, Baig M, Mohamoud HS, Ulhaq Z, Hoessli DC, Khogeer GS, Al-Sayed RR, Al-Aama JY. Saudi J Biol Sci 22 359-373 (2015)
  208. Mast Cells, microRNAs and Others: The Role of Translational Research on Colorectal Cancer in the Forthcoming Era of Precision Medicine. Sammarco G, Gallo G, Vescio G, Picciariello A, De Paola G, Trompetto M, Currò G, Ammendola M. J Clin Med 9 E2852 (2020)
  209. Pilocytic astrocytoma: a disease with evolving molecular heterogeneity. Sadighi Z, Slopis J. J Child Neurol 28 625-632 (2013)
  210. Rb/E2F: a two-edged sword in the melanocytic system. Halaban R. Cancer Metastasis Rev 24 339-356 (2005)
  211. Recent progress on MAP kinase pathway inhibitors. Uehling DE, Harris PA. Bioorg Med Chem Lett 25 4047-4056 (2015)
  212. The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. Fanelli GN, Dal Pozzo CA, Depetris I, Schirripa M, Brignola S, Biason P, Balistreri M, Dal Santo L, Lonardi S, Munari G, Loupakis F, Fassan M. Cancer Cell Int 20 30 (2020)
  213. BRAF mutation testing in clinical practice. Ziai J, Hui P. Expert Rev Mol Diagn 12 127-138 (2012)
  214. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events. Huss S, Pasternack H, Ihle MA, Merkelbach-Bruse S, Heitkötter B, Hartmann W, Trautmann M, Gevensleben H, Büttner R, Schildhaus HU, Wardelmann E. Hum Pathol 62 206-214 (2017)
  215. Melanoma Treatments: Advances and Mechanisms. Marzuka A, Huang L, Theodosakis N, Bosenberg M. J Cell Physiol 230 2626-2633 (2015)
  216. Phytochemicals for the Management of Melanoma. Pal HC, Hunt KM, Diamond A, Elmets CA, Afaq F. Mini Rev Med Chem 16 953-979 (2016)
  217. BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors. Sánchez-Torres JM, Viteri S, Molina MA, Rosell R. Transl Lung Cancer Res 2 244-250 (2013)
  218. Does Ras Activate Raf and PI3K Allosterically? Nussinov R, Tsai CJ, Jang H. Front Oncol 9 1231 (2019)
  219. Melanoma biology and the promise of zebrafish. Ceol CJ, Houvras Y, White RM, Zon LI. Zebrafish 5 247-255 (2008)
  220. Small molecule inhibitors of BRAF in clinical trials. Zambon A, Niculescu-Duvaz I, Niculescu-Duvaz D, Marais R, Springer CJ. Bioorg Med Chem Lett 22 789-792 (2012)
  221. Targeted therapy for NSCLC with driver mutations. Minuti G, D'Incecco A, Cappuzzo F. Expert Opin Biol Ther 13 1401-1412 (2013)
  222. Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers. Ichimura K, Narita Y, Hawkins CE. Acta Neuropathol 129 789-808 (2015)
  223. Intrinsic protein disorder in oncogenic KRAS signaling. Nussinov R, Jang H, Tsai CJ, Liao TJ, Li S, Fushman D, Zhang J. Cell Mol Life Sci 74 3245-3261 (2017)
  224. Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy. Savonarola A, Palmirotta R, Guadagni F, Silvestris F. Pharmacogenomics J 12 277-286 (2012)
  225. Recombinant expression and reconstitution of multiprotein complexes by the USER cloning method in the insect cell-baculovirus expression system. Zhang Z, Yang J, Barford D. Methods 95 13-25 (2016)
  226. Sorafenib in melanoma. Mangana J, Levesque MP, Karpova MB, Dummer R. Expert Opin Investig Drugs 21 557-568 (2012)
  227. Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. McCubrey JA, Abrams SL, Stadelman K, Chappell WH, Lahair M, Ferland RA, Steelman LS. Adv Enzyme Regul 50 285-307 (2010)
  228. H2O2 Metabolism in Normal Thyroid Cells and in Thyroid Tumorigenesis: Focus on NADPH Oxidases. Szanto I, Pusztaszeri M, Mavromati M. Antioxidants (Basel) 8 E126 (2019)
  229. Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. Bhatia P, Friedlander P, Zakaria EA, Kandil E. Ann Transl Med 3 24 (2015)
  230. It takes two to tango--signalling by dimeric Raf kinases. Baljuls A, Kholodenko BN, Kolch W. Mol Biosyst 9 551-558 (2013)
  231. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Wu Q, Qian W, Sun X, Jiang S. J Hematol Oncol 15 143 (2022)
  232. The discovery and development of sorafenib for the treatment of thyroid cancer. White PT, Cohen MS. Expert Opin Drug Discov 10 427-439 (2015)
  233. The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy. Wu CP, V Ambudkar S. Acta Pharm Sin B 4 105-111 (2014)
  234. Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Swaika A, Crozier JA, Joseph RW. Drug Des Devel Ther 8 775-787 (2014)
  235. Atypical BRAF and NRAS Mutations in Mucosal Melanoma. Dumaz N, Jouenne F, Delyon J, Mourah S, Bensussan A, Lebbé C. Cancers (Basel) 11 E1133 (2019)
  236. Autoinhibition in Ras effectors Raf, PI3Kα, and RASSF5: a comprehensive review underscoring the challenges in pharmacological intervention. Nussinov R, Zhang M, Tsai CJ, Liao TJ, Fushman D, Jang H. Biophys Rev 10 1263-1282 (2018)
  237. Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection. Sukswai N, Khoury JD. Curr Hematol Malig Rep 14 368-375 (2019)
  238. LRRK2 in Parkinson's disease: function in cells and neurodegeneration. Webber PJ, West AB. FEBS J 276 6436-6444 (2009)
  239. Leucine-rich repeat kinase 2: relevance to Parkinson's disease. Guo L, Wang W, Chen SG. Int J Biochem Cell Biol 38 1469-1475 (2006)
  240. Medical management of metastatic medullary thyroid cancer. Maxwell JE, Sherman SK, O'Dorisio TM, Howe JR. Cancer 120 3287-3301 (2014)
  241. Targeting the MAPK Pathway in RAS Mutant Cancers. Hymowitz SG, Malek S. Cold Spring Harb Perspect Med 8 a031492 (2018)
  242. The integration of signaling by multiprotein complexes containing Raf kinases. Kyriakis JM. Biochim Biophys Acta 1773 1238-1247 (2007)
  243. BRAF Gene and Melanoma: Back to the Future. Ottaviano M, Giunta EF, Tortora M, Curvietto M, Attademo L, Bosso D, Cardalesi C, Rosanova M, De Placido P, Pietroluongo E, Riccio V, Mucci B, Parola S, Vitale MG, Palmieri G, Daniele B, Simeone E, On Behalf Of Scito Youth. Int J Mol Sci 22 3474 (2021)
  244. Doing more than just the structure-structural genomics in kinase drug discovery. Marsden BD, Knapp S. Curr Opin Chem Biol 12 40-45 (2008)
  245. Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications. Busser B, Lupo J, Sancey L, Mouret S, Faure P, Plumas J, Chaperot L, Leccia MT, Coll JL, Hurbin A, Hainaut P, Charles J. Biomed Res Int 2017 5986129 (2017)
  246. A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma. Tian Y, Guo W. Med Sci Monit 26 e920957 (2020)
  247. Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review. You Z, Liu SP, Du J, Wu YH, Zhang SZ. J Oral Pathol Med 48 201-205 (2019)
  248. Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations. Spain L, Julve M, Larkin J. Expert Opin Pharmacother 17 1031-1038 (2016)
  249. Mouse models for BRAF-induced cancers. Pritchard C, Carragher L, Aldridge V, Giblett S, Jin H, Foster C, Andreadi C, Kamata T. Biochem Soc Trans 35 1329-1333 (2007)
  250. Resistance to Molecularly Targeted Therapies in Melanoma. Patel M, Eckburg A, Gantiwala S, Hart Z, Dein J, Lam K, Puri N. Cancers (Basel) 13 1115 (2021)
  251. Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor). Torres-Collado AX, Knott J, Jazirehi AR. Cancers (Basel) 10 E157 (2018)
  252. The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape. Vanni I, Tanda ET, Spagnolo F, Andreotti V, Bruno W, Ghiorzo P. Front Mol Biosci 7 113 (2020)
  253. The multifaceted anti-cancer effects of BRAF-inhibitors. Croce L, Croce L, Coperchini F, Magri F, Chiovato L, Rotondi M. Oncotarget 10 6623-6640 (2019)
  254. Clinical Pharmacokinetics of Vemurafenib. Zhang W, Heinzmann D, Grippo JF. Clin Pharmacokinet 56 1033-1043 (2017)
  255. Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks. Śmiech M, Leszczyński P, Kono H, Wardell C, Taniguchi H. Genes (Basel) 11 E1342 (2020)
  256. Molecular Pathways and Mechanisms of BRAF in Cancer Therapy. Poulikakos PI, Sullivan RJ, Yaeger R. Clin Cancer Res 28 4618-4628 (2022)
  257. Quercetin as an Emerging Anti-Melanoma Agent: A Four-Focus Area Therapeutic Development Strategy. Harris Z, Donovan MG, Branco GM, Limesand KH, Burd R. Front Nutr 3 48 (2016)
  258. The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. Kondapalli L, Soltani K, Lacouture ME. J Am Acad Dermatol 53 291-302 (2005)
  259. A Review of Epidemiology and Cancer Biology of Malignant Melanoma. Davey MG, Miller N, McInerney NM. Cureus 13 e15087 (2021)
  260. BRAF inhibitors: From the laboratory to clinical trials. Rahman MA, Salajegheh A, Smith RA, Lam AK. Crit Rev Oncol Hematol 90 220-232 (2014)
  261. Biological challenges of BRAF inhibitor therapy. Puzanov I, Burnett P, Flaherty KT. Mol Oncol 5 116-123 (2011)
  262. MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma. Facciorusso A, Licinio R, Carr BI, Di Leo A, Barone M. Expert Rev Gastroenterol Hepatol 9 993-1003 (2015)
  263. Molecular Genetics of Thyroid Cancer in Children and Adolescents. Bauer AJ. Endocrinol Metab Clin North Am 46 389-403 (2017)
  264. Molecular genetics of papillary thyroid carcinoma: great expectations. Trovisco V, Soares P, Preto A, Castro P, Máximo V, Sobrinho-Simões M. Arq Bras Endocrinol Metabol 51 643-653 (2007)
  265. Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics. Kim DH, Sim T. Arch Pharm Res 35 605-615 (2012)
  266. Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers. Dillon M, Lopez A, Lin E, Sales D, Perets R, Jain P. Cancers (Basel) 13 5059 (2021)
  267. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Matsuda Y, Fukumoto M. Med Mol Morphol 44 183-189 (2011)
  268. The biology and clinical development of MEK inhibitors for cancer. Luke JJ, Ott PA, Shapiro GI. Drugs 74 2111-2128 (2014)
  269. Trametinib (GSK1120212) in the treatment of melanoma. Salama AK, Kim KB. Expert Opin Pharmacother 14 619-627 (2013)
  270. BRAF mutation and its inhibitors in sarcoma treatment. Liu H, Nazmun N, Hassan S, Liu X, Yang J. Cancer Med 9 4881-4896 (2020)
  271. Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients. Richtig G, Hoeller C, Kashofer K, Aigelsreiter A, Heinemann A, Kwong LN, Pichler M, Richtig E. Br J Dermatol 177 936-944 (2017)
  272. Biology and treatment of BRAF mutant metastatic melanoma. Kong BY, Carlino MS, Menzies AM. Melanoma Manag 3 33-45 (2016)
  273. Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers. Yadav V, Chen SH, Yue YG, Buchanan S, Beckmann RP, Peng SB. Pharmacol Ther 149 139-149 (2015)
  274. Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: An Overview Comparing Pediatric and Adult Populations. Rangel-Pozzo A, Sisdelli L, Cordioli MIV, Vaisman F, Caria P, Mai S, Cerutti JM. Cancers (Basel) 12 E3146 (2020)
  275. Inhibition of RAF dimers: it takes two to tango. Cook FA, Cook SJ. Biochem Soc Trans 49 237-251 (2021)
  276. Mechanisms of immunogenicity in colorectal cancer. Sillo TO, Beggs AD, Morton DG, Middleton G. Br J Surg 106 1283-1297 (2019)
  277. PLX4032: does it keep its promise for metastatic melanoma treatment? Livingstone E, Zimmer L, Piel S, Schadendorf D. Expert Opin Investig Drugs 19 1439-1449 (2010)
  278. The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography. Gill A, Cleasby A, Jhoti H. Chembiochem 6 506-512 (2005)
  279. B-RAF and melanocytic neoplasia. Gill M, Celebi JT. J Am Acad Dermatol 53 108-114 (2005)
  280. Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy. Huss S, Elges S, Trautmann M, Sperveslage J, Hartmann W, Wardelmann E. Expert Rev Anticancer Ther 15 623-628 (2015)
  281. Current and emerging biomarkers in metastatic colorectal cancer. Lee MKC, Loree JM. Curr Oncol 26 S7-S15 (2019)
  282. Harnessing the predictive power of preclinical models for oncology drug development. Honkala A, Malhotra SV, Kummar S, Junttila MR. Nat Rev Drug Discov 21 99-114 (2022)
  283. Implications of the small number of distinct ligand binding pockets in proteins for drug discovery, evolution and biochemical function. Skolnick J, Gao M, Roy A, Srinivasan B, Zhou H. Bioorg Med Chem Lett 25 1163-1170 (2015)
  284. MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer. Stefan E, Bister K. Curr Top Microbiol Immunol 407 117-151 (2017)
  285. Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer. Haghgoo SM, Allameh A, Mortaz E, Garssen J, Folkerts G, Barnes PJ, Adcock IM. Eur J Pharmacol 754 82-91 (2015)
  286. Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. Shankaran V, Obel J, Benson AB. Oncologist 15 157-167 (2010)
  287. Recent approaches to identifying biomarkers for high-risk stage II colon cancer. Akiyoshi T, Kobunai T, Watanabe T. Surg Today 42 1037-1045 (2012)
  288. Resistance to Raf inhibition in cancer. Haarberg HE, Smalley KS. Drug Discov Today Technol 11 27-32 (2014)
  289. Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors. Carter CA, Giaccone G. Curr Opin Oncol 24 123-129 (2012)
  290. BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Nakayama I, Hirota T, Shinozaki E. Cancers (Basel) 12 E3236 (2020)
  291. BRAF--a new player in hematological neoplasms. Machnicki MM, Stoklosa T. Blood Cells Mol Dis 53 77-83 (2014)
  292. Current and future trials of targeted therapies in cutaneous melanoma. Evans MS, Madhunapantula SV, Robertson GP, Drabick JJ. Adv Exp Med Biol 779 223-255 (2013)
  293. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. Lelliott EJ, McArthur GA, Oliaro J, Sheppard KE. Front Immunol 12 661737 (2021)
  294. MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. Tran KA, Cheng MY, Mitra A, Ogawa H, Shi VY, Olney LP, Kloxin AM, Maverakis E. Drug Des Devel Ther 10 43-52 (2016)
  295. Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. Lau PK, Ascierto PA, McArthur G. Curr Opin Immunol 39 30-38 (2016)
  296. Molecular Markers Guiding Thyroid Cancer Management. Nylén C, Mechera R, Maréchal-Ross I, Tsang V, Chou A, Gill AJ, Clifton-Bligh RJ, Robinson BG, Sywak MS, Sidhu SB, Glover AR. Cancers (Basel) 12 E2164 (2020)
  297. RASopathy Gene Mutations in Melanoma. Halaban R, Krauthammer M. J Invest Dermatol 136 1755-1759 (2016)
  298. Scaffolding during the cell cycle by A-kinase anchoring proteins. Han B, Poppinga WJ, Schmidt M. Pflugers Arch 467 2401-2411 (2015)
  299. Somatic alterations as the basis for resistance to targeted therapies. Blair BG, Bardelli A, Park BH. J Pathol 232 244-254 (2014)
  300. Targeted therapy resistance mechanisms and therapeutic implications in melanoma. Chen G, Davies MA. Hematol Oncol Clin North Am 28 523-536 (2014)
  301. Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. Mizukami T, Izawa N, Nakajima TE, Sunakawa Y. Drugs 79 633-645 (2019)
  302. The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both? Nissan MH, Solit DB. Curr Oncol Rep 13 479-487 (2011)
  303. The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity. Chekmarev J, Azad MG, Richardson DR. Cells 10 2382 (2021)
  304. Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma. Nathanson KL. Biochem Pharmacol 80 755-761 (2010)
  305. Applications of genomics in melanoma oncogene discovery. Berger MF, Garraway LA. Hematol Oncol Clin North Am 23 397-414, vii (2009)
  306. Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer. Grassi E, Corbelli J, Papiani G, Barbera MA, Gazzaneo F, Tamberi S. Front Oncol 11 601722 (2021)
  307. Emerging Raf inhibitors. McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M. Expert Opin Emerg Drugs 14 633-648 (2009)
  308. Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency. Khaliq M, Fallahi-Sichani M. Cancers (Basel) 11 E1480 (2019)
  309. Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Keutgen XM, Filicori F, Fahey TJ. Expert Rev Mol Diagn 13 613-623 (2013)
  310. The current state of targeted therapy in melanoma: this time it's personal. Smalley KS, McArthur GA. Semin Oncol 39 204-214 (2012)
  311. Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications. de Langen AJ, Smit EF. Ther Adv Med Oncol 9 46-58 (2017)
  312. A-Raf: A new star of the family of raf kinases. An S, Yang Y, Ward R, Liu Y, Guo XX, Xu TR. Crit Rev Biochem Mol Biol 50 520-531 (2015)
  313. BRAF-mutant colorectal cancer, a different breed evolving. Lai E, Pretta A, Impera V, Mariani S, Giampieri R, Casula L, Pusceddu V, Coni P, Fanni D, Puzzoni M, Demurtas L, Ziranu P, Faa G, Scartozzi M. Expert Rev Mol Diagn 18 499-512 (2018)
  314. Melanoma mutagenesis and aberrant cell signaling. Bello DM, Ariyan CE, Carvajal RD. Cancer Control 20 261-281 (2013)
  315. Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors. Roy M, Luo YH, Ye M, Liu J. Biomed Res Int 2013 964743 (2013)
  316. Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations. Giunta EF, De Falco V, Napolitano S, Argenziano G, Brancaccio G, Moscarella E, Ciardiello D, Ciardiello F, Troiani T. Ther Adv Med Oncol 12 1758835920925219 (2020)
  317. Recent progress in the identification of BRAF inhibitors as anti-cancer agents. El-Nassan HB. Eur J Med Chem 72 170-205 (2014)
  318. Update on systemic therapy for colorectal cancer: biologics take sides. Gbolahan O, O'Neil B. Transl Gastroenterol Hepatol 4 9 (2019)
  319. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. Richman J, Martin-Liberal J, Diem S, Larkin J. Expert Opin Pharmacother 16 1285-1297 (2015)
  320. Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. Guarini C, Grassi T, Pezzicoli G, Porta C. Int J Mol Sci 22 6813 (2021)
  321. Cobimetinib and vemurafenib for the treatment of melanoma. Boespflug A, Thomas L. Expert Opin Pharmacother 17 1005-1011 (2016)
  322. New molecular targeted therapies in thyroid cancer. Milano A, Chiofalo MG, Basile M, Salzano de Luna A, Pezzullo L, Caponigro F. Anticancer Drugs 17 869-879 (2006)
  323. The biology and pathology of the familial Parkinson's disease protein LRRK2. Dauer W, Ho CC. Mov Disord 25 Suppl 1 S40-3 (2010)
  324. Understanding the genotype of follicular thyroid tumors. Hunt J. Endocr Pathol 16 311-321 (2005)
  325. Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here? Bruce D, Tan PH. Cell Commun Adhes 18 85-103 (2011)
  326. Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma. Saei A, Eichhorn PJA. Cancers (Basel) 11 E1176 (2019)
  327. BRAF kinase in melanoma development and progression. DeLuca AM, Srinivas A, Alani RM. Expert Rev Mol Med 10 e6 (2008)
  328. Influencers on Thyroid Cancer Onset: Molecular Genetic Basis. Luzón-Toro B, Fernández RM, Villalba-Benito L, Torroglosa A, Antiñolo G, Borrego S. Genes (Basel) 10 E913 (2019)
  329. Signaling threshold regulation by the Ras effector IMP. Matheny SA, White MA. J Biol Chem 284 11007-11011 (2009)
  330. Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Mekel M, Nucera C, Hodin RA, Parangi S. Am J Surg 200 136-143 (2010)
  331. The therapeutic potential of inhibiting PPARγ phosphorylation to treat type 2 diabetes. Frkic RL, Richter K, Bruning JB. J Biol Chem 297 101030 (2021)
  332. cfDNA analysis from blood in melanoma. Molina-Vila MA, de-Las-Casas CM, Bertran-Alamillo J, Jordana-Ariza N, González-Cao M, Rosell R. Ann Transl Med 3 309 (2015)
  333. Challenges in developing targeted therapy for pancreatic adenocarcinoma. Mahalingam D, Giles F. Expert Opin Ther Targets 12 1389-1401 (2008)
  334. Clinical prognosis in BRAF-mutated PTC. Puxeddu E, Moretti S. Arq Bras Endocrinol Metabol 51 736-747 (2007)
  335. Copper suppression as cancer therapy: the rationale for copper chelating agents in BRAFV600 mutated melanoma. Sammons S, Brady D, Vahdat L, Salama AK. Melanoma Manag 3 207-216 (2016)
  336. Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer. Pan JH, Zhou H, Zhu SB, Huang JL, Zhao XX, Ding H, Pan YL. Cancer Manag Res 10 2289-2301 (2018)
  337. MAPK pathway inhibition in melanoma: resistance three ways. Wellbrock C. Biochem Soc Trans 42 727-732 (2014)
  338. Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. Chen G, Yang Z, Eshleman JR, Netto GJ, Lin MT. Biomed Res Int 2016 9850690 (2016)
  339. Molecular rearrangements in papillary thyroid carcinomas. Zitzelsberger H, Bauer V, Thomas G, Unger K. Clin Chim Acta 411 301-308 (2010)
  340. Precision medicine for metastatic colorectal cancer in clinical practice. Riedesser JE, Ebert MP, Betge J. Ther Adv Med Oncol 14 17588359211072703 (2022)
  341. Somatic V600E BRAF Mutation in Linear and Sporadic Syringocystadenoma Papilliferum. Levinsohn JL, Sugarman JL, Bilguvar K, McNiff JM, Choate KA, The Yale Center For Mendelian Genomics. J Invest Dermatol 135 2536-2538 (2015)
  342. The preclinical development of regorafenib for the treatment of colorectal cancer. Miura K, Satoh M, Kinouchi M, Yamamoto K, Hasegawa Y, Philchenkov A, Kakugawa Y, Fujiya T. Expert Opin Drug Discov 9 1087-1101 (2014)
  343. Adjuvant Therapy of Melanoma. Davar D, Kirkwood JM. Cancer Treat Res 167 181-208 (2016)
  344. BRAF mutations in non-small cell lung cancer: has finally Janus opened the door? Caparica R, de Castro G, Gil-Bazo I, Caglevic C, Calogero R, Giallombardo M, Santos ES, Raez LE, Rolfo C. Crit Rev Oncol Hematol 101 32-39 (2016)
  345. Emerging roles of the αC-β4 loop in protein kinase structure, function, evolution, and disease. Yeung W, Ruan Z, Kannan N. IUBMB Life 72 1189-1202 (2020)
  346. Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy-Paradoxical ERK Activation and Beyond. Jung T, Haist M, Kuske M, Grabbe S, Bros M. Int J Mol Sci 22 9890 (2021)
  347. Somatic DNA mutation analysis in targeted therapy of solid tumours. Yu B, O'Toole SA, Trent RJ. Transl Pediatr 4 125-138 (2015)
  348. Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma. Pérez-Lorenzo R, Zheng B. Biosci Rep 32 25-33 (2012)
  349. Advances in molecular biology of lung disease: aiming for precision therapy in non-small cell lung cancer. Rooney C, Sethi T. Chest 148 1063-1072 (2015)
  350. Autophagy Inhibition in BRAF-Driven Cancers. Foth M, McMahon M. Cancers (Basel) 13 3498 (2021)
  351. Braf V600E mutation in melanoma: translational current scenario. Guadarrama-Orozco JA, Ortega-Gómez A, Ruiz-García EB, Astudillo-de la Vega H, Meneses-García A, Lopez-Camarillo C. Clin Transl Oncol 18 863-871 (2016)
  352. Dabrafenib for treatment of BRAF-mutant melanoma. Kainthla R, Kim KB, Falchook GS. Pharmgenomics Pers Med 7 21-29 (2014)
  353. Deregulation of microRNA expression in thyroid tumors. Yuan ZM, Yang ZL, Zheng Q. J Zhejiang Univ Sci B 15 212-224 (2014)
  354. Kinase dysfunction and kinase inhibitors. London CA. Vet Dermatol 24 181-7.e39-40 (2013)
  355. Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma. Glen H. Future Oncol 12 2195-2204 (2016)
  356. Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review. Acosta AM, Kadkol SS. Arch Pathol Lab Med 140 1290-1296 (2016)
  357. Molecular targets in melanoma: strategies and challenges for diagnosis and therapy. Herlyn M. Int J Cancer 118 523-526 (2006)
  358. Sonic Hedgehog Signaling in Thyroid Cancer. Xu X, Lu Y, Li Y, Prinz RA. Front Endocrinol (Lausanne) 8 284 (2017)
  359. Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors. Arter C, Trask L, Ward S, Yeoh S, Bayliss R. J Biol Chem 298 102247 (2022)
  360. Translational research in endocrine surgery. Sherman SK, Howe JR. Surg Oncol Clin N Am 22 857-884 (2013)
  361. Advances in anti-BRAF therapies for lung cancer. Roviello G, D'Angelo A, Sirico M, Pittacolo M, Conter FU, Sobhani N. Invest New Drugs 39 879-890 (2021)
  362. Allosteric modulators of MEK1: drug design and discovery. Shang J, Lu S, Jiang Y, Zhang J. Chem Biol Drug Des 88 485-497 (2016)
  363. Assessing the utility of a mutational assay for B-RAF as an adjunct to conventional fine needle aspiration of the thyroid gland. Tetzlaff MT, LiVolsi V, Baloch ZW. Adv Anat Pathol 13 228-237 (2006)
  364. Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review. Glen C, Tan YY, Waterston A, Evans TRJ, Jones RJ, Petrie MC, Lang NN. JACC CardioOncol 4 1-18 (2022)
  365. Oncogenic mutations in B-Raf: some losses yield gains. Hubbard SR. Cell 116 764-766 (2004)
  366. Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemia. Levis M. Curr Opin Hematol 12 55-61 (2005)
  367. The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review. Johansen LL, Lock-Andersen J, Hviid TV. J Immunol Res 2016 6829283 (2016)
  368. The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib. Medina TM, Lewis KD. Onco Targets Ther 9 3739-3752 (2016)
  369. Bruton's TK inhibitors: structural insights and evolution of clinical candidates. Xing L, Huang A. Future Med Chem 6 675-695 (2014)
  370. Colorectal cancer: a researcher's perspective of the molecular angel's gone eccentric in the Vale of Kashmir. Sameer AS. Tumour Biol 34 1301-1315 (2013)
  371. Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation. Rutkowski P, Blank C. Expert Opin Drug Saf 13 1249-1258 (2014)
  372. Discovery of Raf Family Is a Milestone in Deciphering the Ras-Mediated Intracellular Signaling Pathway. Zhao J, Luo Z. Int J Mol Sci 23 5158 (2022)
  373. Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects. Pilla L, Alberti A, Di Mauro P, Gemelli M, Cogliati V, Cazzaniga ME, Bidoli P, Maccalli C. Cancers (Basel) 12 E3456 (2020)
  374. Molecular genetic and immunotherapeutic targets in metastatic melanoma. Melis C, Rogiers A, Bechter O, van den Oord JJ. Virchows Arch 471 281-293 (2017)
  375. New targeted therapies in melanoma. Kudchadkar RR, Gonzalez R, Lewis K. Cancer Control 20 282-288 (2013)
  376. Reading between the lines; understanding drug response in the post genomic era. Alifrangis CC, McDermott U. Mol Oncol 8 1112-1119 (2014)
  377. A patent review of RAF kinase inhibitors (2010-2018). Man RJ, Zhang YL, Jiang AQ, Zhu HL. Expert Opin Ther Pat 29 675-688 (2019)
  378. A pickup in pseudokinase activity. Dar AC. Biochem Soc Trans 41 987-994 (2013)
  379. BRAF Mutation in Hairy Cell Leukemia. Ahmadzadeh A, Shahrabi S, Jaseb K, Norozi F, Shahjahani M, Vosoughi T, Hajizamani S, Saki N. Oncol Rev 8 253 (2014)
  380. BRAF as a therapeutic target: a patent review (2006 - 2012). Zambon A, Niculescu-Duvaz D, Niculescu-Duvaz I, Marais R, Springer CJ. Expert Opin Ther Pat 23 155-164 (2013)
  381. Daily Lifestyle and Cutaneous Malignancies. Sawada Y, Nakamura M. Int J Mol Sci 22 5227 (2021)
  382. Loitering with intent: new evidence for the role of BRAF mutations in the proliferation of melanocytic lesions. Smalley KS, Herlyn M. J Invest Dermatol 123 xvi-xvii (2004)
  383. Melanoma genetics: the other side. Bis S, Tsao H. Clin Dermatol 31 148-155 (2013)
  384. New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond. Wang E, Karedan T, Perez CA. Anticancer Drugs 26 689-697 (2015)
  385. Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours. Paton EL, Turner JA, Schlaepfer IR. J Oncol 2020 1079827 (2020)
  386. Perspectives in drug development for metastatic renal cell cancer. Basu B, Eisen T. Target Oncol 5 139-156 (2010)
  387. Phase I/II RAF kinase inhibitors in cancer therapy. Turajlic S, Ali Z, Yousaf N, Larkin J. Expert Opin Investig Drugs 22 739-749 (2013)
  388. Post-translational modifications at the ATP-positioning G-loop that regulate protein kinase activity. Steinberg SF. Pharmacol Res 135 181-187 (2018)
  389. RAF signaling in neuroendocrine neoplasms: from bench to bedside. Fazio N, Abdel-Rahman O, Spada F, Galdy S, De Dosso S, Capdevila J, Scarpa A. Cancer Treat Rev 40 974-979 (2014)
  390. Regulation of LncRNAs in Melanoma and Their Functional Roles in the Metastatic Process. Melixetian M, Pelicci PG, Lanfrancone L. Cells 11 577 (2022)
  391. The GIST of targeted therapy for malignant melanoma. Bello DM, Dematteo RP, Ariyan CE. Ann Surg Oncol 21 2059-2067 (2014)
  392. The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors. Scartozzi M, Giampieri R, Aprile G, Iacono D, Santini D, dell'Aquila E, Silvestris N, Gnoni A, Bonotto M, Puzzoni M, Demurtas L, Cascinu S. Expert Rev Mol Diagn 15 979-987 (2015)
  393. Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer. Dervisis N, Klahn S. Vet Sci 3 E4 (2016)
  394. Vemurafenib in melanoma. Shaw HM, Nathan PD. Expert Rev Anticancer Ther 13 513-522 (2013)
  395. NRAS mutant melanoma: an overview for the clinician for melanoma management. Jenkins RW, Sullivan RJ. Melanoma Manag 3 47-59 (2016)
  396. BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review. Suzuki Y, Takahashi-Fujigasaki J, Akasaki Y, Matsushima S, Mori R, Karagiozov K, Joki T, Ikeuchi S, Ikegami M, Manome Y, Murayama Y. Brain Tumor Pathol 33 40-49 (2016)
  397. Biomarkers in Melanoma: Lessons from Translational Medicine. Buchbinder EI, Flaherty KT. Trends Cancer 2 305-312 (2016)
  398. Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset. Filitis DC, Mahalingam M. Am J Clin Dermatol 14 461-471 (2013)
  399. Drug resistance in targeted cancer therapies with RAF inhibitors. Degirmenci U, Yap J, Sim YRM, Qin S, Hu J. Cancer Drug Resist 4 665-683 (2021)
  400. From Bench to Bedside and Back: Improving Diagnosis and Treatment of Craniofacial Malformations Utilizing Animal Models. Goodwin AF, Kim R, Bush JO, Klein OD. Curr Top Dev Biol 115 459-492 (2015)
  401. Novel agents in the treatment of metastatic colorectal cancer. Leong S, Messersmith WA, Tan AC, Eckhardt SG. Cancer J 16 273-282 (2010)
  402. Pathway perturbations in signaling networks: Linking genotype to phenotype. Li Y, McGrail DJ, Latysheva N, Yi S, Babu MM, Sahni N. Semin Cell Dev Biol 99 3-11 (2020)
  403. Pre-analytic steps for molecular testing on thyroid fine-needle aspirations: The goal of good results. Rossi ED, Schmitt F, Schmitt F. Cytojournal 10 24 (2013)
  404. RAS pathway regulation in melanoma. Al Mahi A, Ablain J. Dis Model Mech 15 dmm049229 (2022)
  405. Scaffold-based design of kinase inhibitors for cancer therapy. Zhang C, Bollag G. Curr Opin Genet Dev 20 79-86 (2010)
  406. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma. Breaker K, Naam M, La Rosa FG, Flaig IP, Flaig TW. Dermatol Surg 39 981-987 (2013)
  407. Sorafenib for the treatment of multiple myeloma. Gentile M, Martino M, Recchia AG, Vigna E, Morabito L, Morabito F. Expert Opin Investig Drugs 25 743-749 (2016)
  408. Structural flexibility of small GTPases. Can it explain their functional versatility? Helmreich EJ. Biol Chem 385 1121-1136 (2004)
  409. The Potential of Targeting P53 and HSP90 Overcoming Acquired MAPKi-Resistant Melanoma. Hsieh CC, Shen CH. Curr Treat Options Oncol 20 22 (2019)
  410. Well differentiated follicular thyroid neoplasia: impact of molecular and technological advances on detection, monitoring and treatment. Gianoukakis AG, Giannelli SM, Salameh WA, McPhaul LW. Mol Cell Endocrinol 332 9-20 (2011)
  411. Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. Orlandi P, Solini A, Banchi M, Brunetto MR, Cioni D, Ghiadoni L, Bocci G. Pharmaceuticals (Basel) 14 995 (2021)
  412. Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer. Johnson B, Kopetz S. Target Oncol 15 567-577 (2020)
  413. BRAF inhibitor therapy in HCL. Dietrich S, Zenz T. Best Pract Res Clin Haematol 28 246-252 (2015)
  414. Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look? Bruce D, Tan PH. Expert Opin Investig Drugs 20 1413-1434 (2011)
  415. Evolving Treatment Approaches to Mucosal Melanoma. Zhang S, Zhang J, Guo J, Si L, Bai X. Curr Oncol Rep 24 1261-1271 (2022)
  416. Future of combination therapy with dabrafenib and trametinib in metastatic melanoma. Zia Y, Chen L, Daud A. Expert Opin Pharmacother 16 2257-2263 (2015)
  417. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. Al Bitar S, El-Sabban M, Doughan S, Abou-Kheir W. World J Gastroenterol 29 1395-1426 (2023)
  418. New treatments and shifting paradigms in differentiated thyroid cancer management. Carter WB, Tourtelot JB, Savell JG, Lilienfeld H. Cancer Control 18 96-103 (2011)
  419. Oncogenic Tyrosine Phosphatases: Novel Therapeutic Targets for Melanoma Treatment. Pardella E, Pranzini E, Leo A, Taddei ML, Paoli P, Raugei G. Cancers (Basel) 12 E2799 (2020)
  420. Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer. Aboubakar Nana F, Ocak S. Pharmaceutics 13 1478 (2021)
  421. Approaches to identify kinase dependencies in cancer signalling networks. Dermit M, Dokal A, Cutillas PR. FEBS Lett 591 2577-2592 (2017)
  422. Biological agents in head and neck cancer. Bossi P, Locati LD, Licitra L. Expert Rev Anticancer Ther 7 1643-1650 (2007)
  423. Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer. Leone GM, Candido S, Lavoro A, Vivarelli S, Gattuso G, Calina D, Libra M, Falzone L. Pharmaceutics 15 1252 (2023)
  424. Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations. Kanat O, Ertas H, Caner B. World J Gastrointest Oncol 12 1080-1090 (2020)
  425. Contextual signaling in cancer. Smithson LJ, Anastasaki C, Chen R, Toonen JA, Williams SB, Gutmann DH. Semin Cell Dev Biol 58 118-126 (2016)
  426. Drug targeting of oncogenic pathways in melanoma. Fecher LA, Amaravadi RK, Schuchter LM, Flaherty KT. Hematol Oncol Clin North Am 23 599-618, x (2009)
  427. Molecular genetics of thyroid cancer. Rebaї M, Rebaї A. Genet Res (Camb) 98 e7 (2016)
  428. Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers. Hofmann MC, Kunnimalaiyaan M, Wang JR, Busaidy NL, Sherman SI, Lai SY, Zafereo M, Cabanillas ME. Endocr Relat Cancer 29 R173-R190 (2022)
  429. Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. Silvestris N, Vincenzi B, Brunetti AE, Loupakis F, Dell'Aquila E, Russo A, Scartozzi M, Giampieri R, Cascinu S, Lorusso V, Tonini G, Falcone A, Santini D. Pharmacogenomics 15 1701-1715 (2014)
  430. Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials. Song Y, Bi Z, Liu Y, Qin F, Wei Y, Wei X. Genes Dis 10 76-88 (2023)
  431. BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it. Tsamis I, Gomatou G, Chachali SP, Trontzas IP, Patriarcheas V, Panagiotou E, Kotteas E. Clin Transl Oncol 25 10-20 (2023)
  432. Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma. Rajakulendran T, Adam DN. Int J Dermatol 53 1428-1433 (2014)
  433. Emerging BRAF inhibitors for melanoma. Sabbatino F, Wang Y, Wang X, Ferrone S, Ferrone CR. Expert Opin Emerg Drugs 18 431-443 (2013)
  434. Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer. Li S, de Camargo Correia GS, Wang J, Manochakian R, Zhao Y, Lou Y. Cancers (Basel) 15 2899 (2023)
  435. Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution. Di Nunno V, Gatto L, Tosoni A, Bartolini S, Franceschi E. Front Oncol 12 1067252 (2022)
  436. Metabolism heterogeneity in melanoma fuels deactivation of immunotherapy: Predict before protect. Zhang X, Tai Z, Miao F, Huang H, Zhu Q, Bao L, Chen Z. Front Oncol 12 1046102 (2022)
  437. Novel biomarkers and the future of targeted therapies in cholangiocarcinoma: a narrative review. Munugala N, Maithel SK, Shroff RT. Hepatobiliary Surg Nutr 11 253-266 (2022)
  438. RAS-targeted cancer therapy: Advances in drugging specific mutations. Liu C, Ye D, Yang H, Chen X, Su Z, Li X, Ding M, Liu Y. MedComm (2020) 4 e285 (2023)
  439. Selection of Oral Therapeutics in China for the Treatment of Colorectal Cancer. Li J, Cai Y, Deng Y. Curr Treat Options Oncol 22 55 (2021)
  440. Swimming toward solutions: Using fish and frogs as models for understanding RASopathies. Patterson VL, Burdine RD. Birth Defects Res 112 749-765 (2020)
  441. Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside. Abdel-Rahman O. Future Oncol 12 25-30 (2016)
  442. Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer. Kocoglu H, Velibeyoglu FM, Karaca M, Tural D. World J Gastrointest Oncol 8 1-7 (2016)
  443. Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients. Zhou S, Sikorski D, Xu H, Zubarev A, Chergui M, Lagacé F, Miller WH, Redpath M, Ghazal S, Butler MO, Petrella TM, Claveau J, Nessim C, Salopek TG, Gniadecki R, Litvinov IV. Cancers (Basel) 13 2282 (2021)
  444. Drug safety evaluation of vemurafenib in the treatment of melanoma. Tsai KY, Nowroozi S, Kim KB. Expert Opin Drug Saf 12 767-775 (2013)
  445. Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer. Ros J, Saoudi N, Baraibar I, Salva F, Tabernero J, Elez E. Therap Adv Gastroenterol 15 17562848221110644 (2022)
  446. From Uniplex to Multiplex Molecular Profiling in Advanced Non-Small Cell Lung Carcinoma. Ileana EE, Wistuba II, Izzo JG. Cancer J 21 413-424 (2015)
  447. Genetics and RNA Regulation of Uveal Melanoma. Barbagallo C, Stella M, Broggi G, Russo A, Caltabiano R, Ragusa M. Cancers (Basel) 15 775 (2023)
  448. Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy. Jazirehi AR. Int J Mol Sci 22 11726 (2021)
  449. Pharmacogenetics of anticancer monoclonal antibodies. Shek D, Read SA, Ahlenstiel G, Piatkov I. Cancer Drug Resist 2 69-81 (2019)
  450. Response and resistance to BRAFV600E inhibition in gliomas: Roadblocks ahead? Capogiri M, De Micheli AJ, Lassaletta A, Muñoz DP, Coppé JP, Mueller S, Guerreiro Stucklin AS. Front Oncol 12 1074726 (2022)
  451. Review: low-grade gliomas as neurodevelopmental disorders: insights from mouse models of neurofibromatosis-1. Thangarajh M, Gutmann DH. Neuropathol Appl Neurobiol 38 241-253 (2012)
  452. Targeted Therapy for BRAF Mutant Brain Tumors. Rayi A, Alnahhas I, Ong S, Giglio P, Puduvalli VK. Curr Treat Options Oncol 22 105 (2021)
  453. Targeted Therapy for Melanomas Without BRAF V600 Mutations. Menzer C, Hassel JC. Curr Treat Options Oncol 23 831-842 (2022)
  454. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Bahar ME, Kim HJ, Kim DR. Signal Transduct Target Ther 8 455 (2023)
  455. Targets for therapy in biliary tract cancers: the new horizon of personalized medicine. Iyer P, Chen MH, Goyal L, Denlinger CS. Chin Clin Oncol 9 7 (2020)
  456. Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer. Kato S. Diagnostics (Basel) 11 252 (2021)
  457. [Mutation of the BRAF genes in non-small cell lung cancer]. Huang Z, Wu Y. Zhongguo Fei Ai Za Zhi 15 183-186 (2012)
  458. [Regulation of cell survival by RAF kinases]. Galmiche A, Ezzoukhry Z. Med Sci (Paris) 26 729-733 (2010)
  459. [The short history of protein kinase inhibitors. New, competitive, successful]. Kunick C, Egert-Schmidt AM. Pharm Unserer Zeit 37 360-368 (2008)
  460. BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers. Castellani G, Buccarelli M, Arasi MB, Rossi S, Pisanu ME, Bellenghi M, Lintas C, Tabolacci C. Cancers (Basel) 15 4026 (2023)
  461. Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies. Kitsel Y, Cooke T, Sotirchos V, Sofocleous CT. Cancers (Basel) 15 1679 (2023)
  462. Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. Rachiglio AM, Sacco A, Forgione L, Esposito C, Chicchinelli N, Normanno N. Explor Target Antitumor Ther 1 53-70 (2020)
  463. New Approaches with Precision Medicine in Adult Brain Tumors. Leibetseder A, Preusser M, Berghoff AS. Cancers (Basel) 14 712 (2022)
  464. Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma. Cerqueira OLD, Antunes F, Assis NG, Cardoso EC, Clavijo-Salomón MA, Domingues AC, Tessarollo NG, Strauss BE. Front Mol Biosci 9 777775 (2022)
  465. Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges. Al-Hujaily EM, Al-Sowayan BS, Alyousef Z, Uddin S, Alammari F. Int J Mol Sci 23 13696 (2022)
  466. Signaling Pathways That Regulate Normal and Aberrant Red Blood Cell Development. Wilkes MC, Shibuya A, Sakamoto KM. Genes (Basel) 12 1646 (2021)
  467. Systems biology approaches to macromolecules: the role of dynamic protein assemblies in information processing. Rukhlenko O, Kholodenko BN, Kolch W. Curr Opin Struct Biol 67 61-68 (2021)
  468. The Genomics of Hairy Cell Leukaemia and Splenic Diffuse Red Pulp Lymphoma. Oscier D, Stamatopoulos K, Mirandari A, Strefford J. Cancers (Basel) 14 697 (2022)
  469. [Research Progress of Targeted Therapy for BRAF Mutation 
in Advanced Non-small Cell Lung Cancer]. Liu X, Zhong D. Zhongguo Fei Ai Za Zhi 21 635-640 (2018)
  470. An updated literature on BRAF inhibitors (2018-2023). Maji L, Teli G, Raghavendra NM, Sengupta S, Pal R, Ghara A, Matada GSP. Mol Divers (2023)
  471. Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer. Huang L, Liao Z, Liu Z, Chen Y, Huang T, Xiao H. Front Pharmacol 13 900825 (2022)
  472. BRAF Non-V600 Mutations in Metastatic Colorectal Cancer. Liu J, Xie H. Cancers (Basel) 15 4604 (2023)
  473. BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience. Trinder SM, McKay C, Power P, Topp M, Chan B, Valvi S, McCowage G, Govender D, Kirby M, Ziegler DS, Manoharan N, Hassall T, Kellie S, Heath J, Alvaro F, Wood P, Laughton S, Tsui K, Dodgshun A, Eisenstat DD, Endersby R, Luen SJ, Koh ES, Sim HW, Kong B, Gottardo NG, Whittle JR, Khuong-Quang DA, Hansford JR. Front Oncol 13 1154246 (2023)
  474. Cellular senescence in glioma. Chojak R, Fares J, Petrosyan E, Lesniak MS. J Neurooncol 164 11-29 (2023)
  475. Clinical research progress on BRAF V600E-mutant advanced colorectal cancer. Zeng C, Wang M, Xie S, Wang N, Wang Z, Yi D, Kong F, Chen L. J Cancer Res Clin Oncol 149 16111-16121 (2023)
  476. Cutaneous Melanoma: A Review of Multifactorial Pathogenesis, Immunohistochemistry, and Emerging Biomarkers for Early Detection and Management. Gosman LM, Țăpoi DA, Costache M. Int J Mol Sci 24 15881 (2023)
  477. From targeted therapy to a novel way: Immunogenic cell death in lung cancer. Xu J, Xiong Y, Xu Z, Xing H, Zhou L, Zhang X. Front Med (Lausanne) 9 1102550 (2022)
  478. Hotspots of Somatic Genetic Variation in Pituitary Neuroendocrine Tumors. Torres-Morán M, Franco-Álvarez AL, Rebollar-Vega RG, Hernández-Ramírez LC. Cancers (Basel) 15 5685 (2023)
  479. Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkers. Zhong J, Sun Z, Li S, Yang L, Cao Y, Bao J. Discov Oncol 14 94 (2023)
  480. Management of acute kidney injury in gastrointestinal tumor: An overview. Su YQ, Yu YY, Shen B, Yang F, Nie YX. World J Clin Cases 9 10746-10764 (2021)
  481. Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements. Cann CG, LaPelusa MB, Cimino SK, Eng C. Front Oncol 13 1176950 (2023)
  482. Navigating the ERK1/2 MAPK Cascade. Martin-Vega A, Cobb MH. Biomolecules 13 1555 (2023)
  483. New biomarkers: prospect for diagnosis and monitoring of thyroid disease. Macvanin MT, Gluvic ZM, Zaric BL, Essack M, Gao X, Isenovic ER. Front Endocrinol (Lausanne) 14 1218320 (2023)
  484. RASopathies and cardiac manifestations. Hilal N, Chen Z, Chen MH, Choudhury S. Front Cardiovasc Med 10 1176828 (2023)
  485. Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. Dazio G, Epistolio S, Frattini M, Saletti P. J Clin Med 11 7523 (2022)
  486. Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. Tang YL, Li DD, Duan JY, Sheng LM, Wang X. World J Gastroenterol 29 926-948 (2023)
  487. Successes and challenges in modeling heterogeneous BRAFV600E mutated central nervous system neoplasms. Xing YL, Panovska D, Petritsch CK. Front Oncol 13 1223199 (2023)
  488. Targeted therapies in non-small cell lung cancer: present and future. McLaughlin J, Berkman J, Nana-Sinkam P. Fac Rev 12 22 (2023)
  489. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities. Wang P, Laster K, Jia X, Dong Z, Liu K. Mol Cancer 22 208 (2023)
  490. The Interplay between T Cells and Cancer: The Basis of Immunotherapy. Chen C, Liu X, Chang CY, Wang HY, Wang RF. Genes (Basel) 14 1008 (2023)
  491. The Role of BRAF Inhibitors in the Management of Ameloblastoma: A Literature Review. Malakar A, Kumar VR, Yadav P, Bhardwaj V, Barua CG, Bhardwaj G. Cureus 15 e47682 (2023)
  492. The Value of Cell-Free Circulating DNA Profiling in Patients with Skin Diseases. Ma J, Teng Y, Youming H, Tao X, Fan Y. Methods Mol Biol 2695 247-262 (2023)
  493. The role of small molecule inhibitors for veterinary patients. London CA. Vet Clin North Am Small Anim Pract 37 1121-36; vii (2007)
  494. Unlocking the power of precision medicine for pediatric low-grade gliomas: molecular characterization for targeted therapies with enhanced safety and efficacy. Cipri S, Del Baldo G, Fabozzi F, Boccuto L, Carai A, Mastronuzzi A. Front Oncol 13 1204829 (2023)

Articles citing this publication (1041)

  1. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. Proc Natl Acad Sci U S A 101 13306-13311 (2004)
  2. Patterns of somatic mutation in human cancer genomes. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, Stratton MR. Nature 446 153-158 (2007)
  3. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. Nature 464 427-430 (2010)
  4. Chemokine signaling via the CXCR2 receptor reinforces senescence. Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, Fumagalli M, Da Costa M, Brown C, Popov N, Takatsu Y, Melamed J, d'Adda di Fagagna F, d'Adda di Fagagna F, Bernard D, Hernando E, Gil J. Cell 133 1006-1018 (2008)
  5. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S. Nature 464 431-435 (2010)
  6. Initial genome sequencing and analysis of multiple myeloma. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR. Nature 471 467-472 (2011)
  7. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA. Nature 468 968-972 (2010)
  8. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R. Cell 140 209-221 (2010)
  9. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, Thomas AG, Gleason CE, Tatonetti NP, Slusher BS, Stockwell BR. Elife 3 e02523 (2014)
  10. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M, Bollag G. Proc Natl Acad Sci U S A 105 3041-3046 (2008)
  11. High-throughput oncogene mutation profiling in human cancer. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. Nat Genet 39 347-351 (2007)
  12. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R. N Engl J Med 366 207-215 (2012)
  13. BRAF mutations in hairy-cell leukemia. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Foà R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B. N Engl J Med 364 2305-2315 (2011)
  14. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A. Lancet Oncol 15 323-332 (2014)
  15. Rational design of inhibitors that bind to inactive kinase conformations. Liu Y, Gray NS. Nat Chem Biol 2 358-364 (2006)
  16. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, Wargo JA, Song JS, Fisher DE, Arany Z, Widlund HR. Cancer Cell 23 302-315 (2013)
  17. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B. J Clin Oncol 24 5034-5042 (2006)
  18. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Jones DT, Hutter B, Jäger N, Korshunov A, Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DA, Fontebasso AM, Stütz AM, Hutter S, Zuckermann M, Sturm D, Gronych J, Lasitschka B, Schmidt S, Seker-Cin H, Witt H, Sultan M, Ralser M, Northcott PA, Hovestadt V, Bender S, Pfaff E, Stark S, Faury D, Schwartzentruber J, Majewski J, Weber UD, Zapatka M, Raeder B, Schlesner M, Worth CL, Bartholomae CC, von Kalle C, Imbusch CD, Radomski S, Lawerenz C, van Sluis P, Koster J, Volckmann R, Versteeg R, Lehrach H, Monoranu C, Winkler B, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, Ebinger M, Schuhmann MU, Cho YJ, Pomeroy SL, von Deimling A, Witt O, Taylor MD, Wolf S, Karajannis MA, Eberhart CG, Scheurlen W, Hasselblatt M, Ligon KL, Kieran MW, Korbel JO, Yaspo ML, Brors B, Felsberg J, Reifenberger G, Collins VP, Jabado N, Eils R, Lichter P, Pfister SM, International Cancer Genome Consortium PedBrain Tumor Project. Nat Genet 45 927-932 (2013)
  19. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP. Nature 485 260-263 (2012)
  20. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, Pogna EA, Schackwitz W, Ustaszewska A, Landstrom A, Bos JM, Ommen SR, Esposito G, Lepri F, Faul C, Mundel P, López Siguero JP, Tenconi R, Selicorni A, Rossi C, Mazzanti L, Torrente I, Marino B, Digilio MC, Zampino G, Ackerman MJ, Dallapiccola B, Tartaglia M, Gelb BD. Nat Genet 39 1007-1012 (2007)
  21. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M. Adv Enzyme Regul 46 249-279 (2006)
  22. Regulation of Raf-1 by direct feedback phosphorylation. Dougherty MK, Müller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, Conrads TP, Veenstra TD, Lu KP, Morrison DK. Mol Cell 17 215-224 (2005)
  23. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, Ladanyi M, Riely GJ. J Clin Oncol 29 2046-2051 (2011)
  24. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F. Br J Cancer 101 715-721 (2009)
  25. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ, Ferré F, Bourque C, Burke CJ, Turner L, Uong A, Johnson LA, Beroukhim R, Mermel CH, Loda M, Ait-Si-Ali S, Garraway LA, Young RA, Zon LI. Nature 471 513-517 (2011)
  26. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J. Cancer Res 68 4853-4861 (2008)
  27. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. Genes Dev 21 379-384 (2007)
  28. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N. Proc Natl Acad Sci U S A 107 14903-14908 (2010)
  29. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A. Acta Neuropathol 122 11-19 (2011)
  30. A dimerization-dependent mechanism drives RAF catalytic activation. Rajakulendran T, Sahmi M, Lefrançois M, Sicheri F, Therrien M. Nature 461 542-545 (2009)
  31. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, Pagani E, Casula M, Manca A, Sini M, Franco R, Botti G, Caracò C, Mozzillo N, Ascierto PA, Palmieri G. J Clin Oncol 30 2522-2529 (2012)
  32. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N. Cancer Cell 8 287-297 (2005)
  33. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Garnett MJ, Rana S, Paterson H, Barford D, Marais R. Mol Cell 20 963-969 (2005)
  34. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, Kondo C, Mizota A, Utsunomiya S, Muro K, Yatabe Y. Br J Cancer 104 856-862 (2011)
  35. Regulation and role of Raf-1/B-Raf heterodimerization. Rushworth LK, Hindley AD, O'Neill E, Kolch W. Mol Cell Biol 26 2262-2272 (2006)
  36. B-RAF is a therapeutic target in melanoma. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R. Oncogene 23 6292-6298 (2004)
  37. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Yao Z, Torres NM, Tao A, Gao Y, Luo L, Li Q, de Stanchina E, Abdel-Wahab O, Solit DB, Poulikakos PI, Rosen N. Cancer Cell 28 370-383 (2015)
  38. Copper is required for oncogenic BRAF signalling and tumorigenesis. Brady DC, Crowe MS, Turski ML, Hobbs GA, Yao X, Chaikuad A, Knapp S, Xiao K, Campbell SL, Thiele DJ, Counter CM. Nature 509 492-496 (2014)
  39. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, Cantley LC. Mol Cell 33 237-247 (2009)
  40. The role of erk1 and erk2 in multiple stages of T cell development. Fischer AM, Katayama CD, Pagès G, Pouysségur J, Hedrick SM. Immunity 23 431-443 (2005)
  41. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, Nikiforov YE. J Clin Invest 115 94-101 (2005)
  42. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. Proc Natl Acad Sci U S A 102 18443-18448 (2005)
  43. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizée G, Hwu P. Clin Cancer Res 19 393-403 (2013)
  44. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A. J Clin Oncol 31 1767-1774 (2013)
  45. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, Drosten M, Zhao H, Cecchi F, Hembrough T, Michels J, Baumert H, Miles L, Campbell NM, de Stanchina E, Solit DB, Barbacid M, Taylor BS, Rosen N. Nature 548 234-238 (2017)
  46. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA. J Clin Oncol 23 866-873 (2005)
  47. Letter BRAF mutation in metastatic colorectal cancer. Tol J, Nagtegaal ID, Punt CJ. N Engl J Med 361 98-99 (2009)
  48. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H. J Natl Cancer Inst 97 981-989 (2005)
  49. A genomics-based classification of human lung tumors. Clinical Lung Cancer Genome Project (CLCGP), Network Genomic Medicine (NGM). Sci Transl Med 5 209ra153 (2013)
  50. Raf family kinases: old dogs have learned new tricks. Matallanas D, Birtwistle M, Romano D, Zebisch A, Rauch J, von Kriegsheim A, Kolch W. Genes Cancer 2 232-260 (2011)
  51. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F, Souquet PJ, Smit EF, Groen HJ, Kelly RJ, Cho BC, Socinski MA, Pandite L, Nase C, Ma B, D'Amelio A, Mookerjee B, Curtis CM, Johnson BE. Lancet Oncol 17 642-650 (2016)
  52. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ. Blood 132 587-597 (2018)
  53. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Jänne PA. Clin Cancer Res 19 4532-4540 (2013)
  54. Structure of an Hsp90-Cdc37-Cdk4 complex. Vaughan CK, Gohlke U, Sobott F, Good VM, Ali MM, Prodromou C, Robinson CV, Saibil HR, Pearl LH. Mol Cell 23 697-707 (2006)
  55. A Src-like inactive conformation in the abl tyrosine kinase domain. Levinson NM, Kuchment O, Shen K, Young MA, Koldobskiy M, Karplus M, Cole PA, Kuriyan J. PLoS Biol 4 e144 (2006)
  56. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Mandelker D, Gabelli SB, Schmidt-Kittler O, Zhu J, Cheong I, Huang CH, Kinzler KW, Vogelstein B, Amzel LM. Proc Natl Acad Sci U S A 106 16996-17001 (2009)
  57. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R. Clin Cancer Res 18 555-567 (2012)
  58. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won H, Liu C, Tiwari S, Kong L, Hanrahan AJ, Yao Z, Merghoub T, Ribas A, Chapman PB, Yaeger R, Taylor BS, Schultz N, Berger MF, Rosen N, Solit DB. Cancer Res 74 2340-2350 (2014)
  59. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Clin Cancer Res 19 657-667 (2013)
  60. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R. PLoS One 3 e2734 (2008)
  61. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D, Rosen N. Proc Natl Acad Sci U S A 103 57-62 (2006)
  62. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D. Eur J Cancer 51 2792-2799 (2015)
  63. Genetic predictors of MEK dependence in non-small cell lung cancer. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, Taylor BS, Pao W, Toyooka S, Ladanyi M, Gazdar A, Rosen N, Solit DB. Cancer Res 68 9375-9383 (2008)
  64. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Brennan DF, Dar AC, Hertz NT, Chao WC, Burlingame AL, Shokat KM, Barford D. Nature 472 366-369 (2011)
  65. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, Saborowski M, Kastenhuber E, Fellmann C, Ohara K, Morikami K, Miura T, Lukacs C, Ishii N, Lowe S, Rosen N. Cancer Cell 25 697-710 (2014)
  66. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, Resnick AC. Proc Natl Acad Sci U S A 110 5957-5962 (2013)
  67. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, Rutkoski TJ, Wise S, Chun L, Zhang Y, Van Horn RD, Yin T, Zhang X, Yadav V, Chen SH, Gong X, Ma X, Webster Y, Buchanan S, Mochalkin I, Huber L, Kays L, Donoho GP, Walgren J, McCann D, Patel P, Conti I, Plowman GD, Starling JJ, Flynn DL. Cancer Cell 28 384-398 (2015)
  68. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. Ihle MA, Fassunke J, König K, Grünewald I, Schlaak M, Kreuzberg N, Tietze L, Schildhaus HU, Büttner R, Merkelbach-Bruse S. BMC Cancer 14 13 (2014)
  69. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, Lo RS, Ribas A. J Transl Med 8 39 (2010)
  70. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Ritt DA, Monson DM, Specht SI, Morrison DK. Mol Cell Biol 30 806-819 (2010)
  71. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, Cimminiello M, Kim E, Rossi D, Stone RM, Motta G, Saven A, Varettoni M, Altman JK, Anastasia A, Grever MR, Ambrosetti A, Rai KR, Fraticelli V, Lacouture ME, Carella AM, Levine RL, Leoni P, Rambaldi A, Falzetti F, Ascani S, Capponi M, Martelli MP, Park CY, Pileri SA, Rosen N, Foà R, Berger MF, Zinzani PL, Abdel-Wahab O, Falini B, Tallman MS. N Engl J Med 373 1733-1747 (2015)
  72. Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, Kasi PM, Voss JS, Leal AD, Sun J, Ross J, Ali SM, Hubbard JM, Kipp BR, McWilliams RR, Kopetz S, Wolff RA, Grothey A. J Clin Oncol 35 2624-2630 (2017)
  73. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S. Proc Natl Acad Sci U S A 110 4015-4020 (2013)
  74. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Haq R, Yokoyama S, Hawryluk EB, Jönsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, Anderson DG, Garraway LA, Duncan LM, Morton DL, Hoon DS, Wargo JA, Song JS, Fisher DE. Proc Natl Acad Sci U S A 110 4321-4326 (2013)
  75. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Sia D, Losic B, Moeini A, Cabellos L, Hao K, Revill K, Bonal D, Miltiadous O, Zhang Z, Hoshida Y, Cornella H, Castillo-Martin M, Pinyol R, Kasai Y, Roayaie S, Thung SN, Fuster J, Schwartz ME, Waxman S, Cordon-Cardo C, Schadt E, Mazzaferro V, Llovet JM. Nat Commun 6 6087 (2015)
  76. ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. Vantaggiato C, Formentini I, Bondanza A, Bonini C, Naldini L, Brambilla R. J Biol 5 14 (2006)
  77. Progression of RAS-mutant leukemia during RAF inhibitor treatment. Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T, Wolchok JD, Solit DB, Rosen N, Abdel-Wahab O, Levine RL, Chapman PB. N Engl J Med 367 2316-2321 (2012)
  78. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Willmore-Payne C, Holden JA, Tripp S, Layfield LJ. Hum Pathol 36 486-493 (2005)
  79. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Cin H, Meyer C, Herr R, Janzarik WG, Lambert S, Jones DT, Jacob K, Benner A, Witt H, Remke M, Bender S, Falkenstein F, Van Anh TN, Olbrich H, von Deimling A, Pekrun A, Kulozik AE, Gnekow A, Scheurlen W, Witt O, Omran H, Jabado N, Collins VP, Brummer T, Marschalek R, Lichter P, Korshunov A, Pfister SM. Acta Neuropathol 121 763-774 (2011)
  80. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y, Nathanson KL, Herlyn M. Oncogene 28 85-94 (2009)
  81. BRAF targeted therapy changes the treatment paradigm in melanoma. Ribas A, Flaherty KT. Nat Rev Clin Oncol 8 426-433 (2011)
  82. A mechanism for the evolution of phosphorylation sites. Pearlman SM, Serber Z, Ferrell JE. Cell 147 934-946 (2011)
  83. News Stops along the RAS pathway in human genetic disease. Bentires-Alj M, Kontaridis MI, Neel BG. Nat Med 12 283-285 (2006)
  84. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Freeman AK, Ritt DA, Morrison DK. Mol Cell 49 751-758 (2013)
  85. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Capper D, Berghoff AS, Magerle M, Ilhan A, Wöhrer A, Hackl M, Pichler J, Pusch S, Meyer J, Habel A, Petzelbauer P, Birner P, von Deimling A, Preusser M. Acta Neuropathol 123 223-233 (2012)
  86. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Fröhling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Döhner H, Döhner K, Ebert BL, Teckie S, Golub TR, Jiang J, Schittenhelm MM, Lee BH, Griffin JD, Stone RM, Heinrich MC, Deininger MW, Druker BJ, Gilliland DG. Cancer Cell 12 501-513 (2007)
  87. Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors. Wang L, Perera BG, Hari SB, Bhhatarai B, Backes BJ, Seeliger MA, Schürer SC, Oakes SA, Papa FR, Maly DJ. Nat Chem Biol 8 982-989 (2012)
  88. Structural basis of RIP1 inhibition by necrostatins. Xie T, Peng W, Liu Y, Yan C, Maki J, Degterev A, Yuan J, Shi Y. Structure 21 493-499 (2013)
  89. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. Pardo OE, Wellbrock C, Khanzada UK, Aubert M, Arozarena I, Davidson S, Bowen F, Parker PJ, Filonenko VV, Gout IT, Sebire N, Marais R, Downward J, Seckl MJ. EMBO J 25 3078-3088 (2006)
  90. Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Mercer K, Giblett S, Green S, Lloyd D, DaRocha Dias S, Plumb M, Marais R, Pritchard C. Cancer Res 65 11493-11500 (2005)
  91. BRAF mutations in an Italian cohort of thyroid cancers. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, Beck-Peccoz P. Clin Endocrinol (Oxf) 61 239-243 (2004)
  92. Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling. Haling JR, Sudhamsu J, Yen I, Sideris S, Sandoval W, Phung W, Bravo BJ, Giannetti AM, Peck A, Masselot A, Morales T, Smith D, Brandhuber BJ, Hymowitz SG, Malek S. Cancer Cell 26 402-413 (2014)
  93. MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation. Chadee DN, Kyriakis JM. Nat Cell Biol 6 770-776 (2004)
  94. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, Buchanan S, Henry JR, Starling JJ, Peng SB. J Biol Chem 287 28087-28098 (2012)
  95. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. Atwell S, Adams JM, Badger J, Buchanan MD, Feil IK, Froning KJ, Gao X, Hendle J, Keegan K, Leon BC, Müller-Dieckmann HJ, Nienaber VL, Noland BW, Post K, Rajashankar KR, Ramos A, Russell M, Burley SK, Buchanan SG. J Biol Chem 279 55827-55832 (2004)
  96. Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Hall A, Meyle KD, Lange MK, Klima M, Sanderhoff M, Dahl C, Abildgaard C, Thorup K, Moghimi SM, Jensen PB, Bartek J, Guldberg P, Christensen C. Oncotarget 4 584-599 (2013)
  97. IQGAP1 modulates activation of B-Raf. Ren JG, Li Z, Sacks DB. Proc Natl Acad Sci U S A 104 10465-10469 (2007)
  98. Letter Moyamoya disease and moyamoya syndrome. Pollak L. N Engl J Med 361 98; author reply 98 (2009)
  99. NRAS mutations are rare in colorectal cancer. Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM, Ogino S. Diagn Mol Pathol 19 157-163 (2010)
  100. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Karajannis MA, Legault G, Fisher MJ, Milla SS, Cohen KJ, Wisoff JH, Harter DH, Goldberg JD, Hochman T, Merkelson A, Bloom MC, Sievert AJ, Resnick AC, Dhall G, Jones DT, Korshunov A, Pfister SM, Eberhart CG, Zagzag D, Allen JC. Neuro Oncol 16 1408-1416 (2014)
  101. Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes. Park E, Rawson S, Li K, Kim BW, Ficarro SB, Pino GG, Sharif H, Marto JA, Jeon H, Eck MJ. Nature 575 545-550 (2019)
  102. Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Fritsche-Guenther R, Witzel F, Sieber A, Herr R, Schmidt N, Braun S, Brummer T, Sers C, Blüthgen N. Mol Syst Biol 7 489 (2011)
  103. Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine. Smith G, Bounds R, Wolf H, Steele RJ, Carey FA, Wolf CR. Br J Cancer 102 693-703 (2010)
  104. Did protein kinase regulatory mechanisms evolve through elaboration of a simple structural component? Kannan N, Neuwald AF. J Mol Biol 351 956-972 (2005)
  105. Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Jacob K, Albrecht S, Sollier C, Faury D, Sader E, Montpetit A, Serre D, Hauser P, Garami M, Bognar L, Hanzely Z, Montes JL, Atkinson J, Farmer JP, Bouffet E, Hawkins C, Tabori U, Jabado N. Br J Cancer 101 722-733 (2009)
  106. Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2. Foster SA, Whalen DM, Özen A, Wongchenko MJ, Yin J, Yen I, Schaefer G, Mayfield JD, Chmielecki J, Stephens PJ, Albacker LA, Yan Y, Song K, Hatzivassiliou G, Eigenbrot C, Yu C, Shaw AS, Manning G, Skelton NJ, Hymowitz SG, Malek S. Cancer Cell 29 477-493 (2016)
  107. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf J, Jaehde U. Clin Pharmacokinet 50 551-603 (2011)
  108. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. King AJ, Arnone MR, Bleam MR, Moss KG, Yang J, Fedorowicz KE, Smitheman KN, Erhardt JA, Hughes-Earle A, Kane-Carson LS, Sinnamon RH, Qi H, Rheault TR, Uehling DE, Laquerre SG. PLoS One 8 e67583 (2013)
  109. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. J Pharmacol Exp Ther 342 33-40 (2012)
  110. A general strategy for creating "inactive-conformation" abl inhibitors. Okram B, Nagle A, Adrián FJ, Lee C, Ren P, Wang X, Sim T, Xie Y, Wang X, Xia G, Spraggon G, Warmuth M, Liu Y, Gray NS. Chem Biol 13 779-786 (2006)
  111. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C, Lee WM. Am J Pathol 169 1875-1885 (2006)
  112. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ. Int J Cancer 125 2332-2341 (2009)
  113. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R. Thyroid 25 71-77 (2015)
  114. The secret life of kinases: functions beyond catalysis. Rauch J, Volinsky N, Romano D, Kolch W. Cell Commun Signal 9 23 (2011)
  115. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Hu J, Yu H, Yu H, Kornev AP, Zhao J, Filbert EL, Taylor SS, Shaw AS. Proc Natl Acad Sci U S A 108 6067-6072 (2011)
  116. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Bloethner S, Chen B, Hemminki K, Müller-Berghaus J, Ugurel S, Schadendorf D, Kumar R. Carcinogenesis 26 1224-1232 (2005)
  117. Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Old WM, Shabb JB, Houel S, Wang H, Couts KL, Yen CY, Litman ES, Croy CH, Meyer-Arendt K, Miranda JG, Brown RA, Witze ES, Schweppe RE, Resing KA, Ahn NG. Mol Cell 34 115-131 (2009)
  118. Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors. Beeser A, Jaffer ZM, Hofmann C, Chernoff J. J Biol Chem 280 36609-36615 (2005)
  119. The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavida B. Genes Cancer 1 409-420 (2010)
  120. AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade. Smith FD, Langeberg LK, Cellurale C, Pawson T, Morrison DK, Davis RJ, Scott JD. Nat Cell Biol 12 1242-1249 (2010)
  121. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Lavoie H, Thevakumaran N, Gavory G, Li JJ, Padeganeh A, Guiral S, Duchaine J, Mao DY, Bouvier M, Sicheri F, Therrien M. Nat Chem Biol 9 428-436 (2013)
  122. Genomic Profiling of Small-Bowel Adenocarcinoma. Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ, Ross JS, Wilson R, Miller VA, Ali SM, Overman MJ. JAMA Oncol 3 1546-1553 (2017)
  123. Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. Baenke F, Chaneton B, Smith M, Van Den Broek N, Hogan K, Tang H, Viros A, Martin M, Galbraith L, Girotti MR, Dhomen N, Gottlieb E, Marais R. Mol Oncol 10 73-84 (2016)
  124. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. Satoh T, Smith A, Sarde A, Lu HC, Mian S, Trouillet C, Mufti G, Emile JF, Fraternali F, Donadieu J, Geissmann F. PLoS One 7 e33891 (2012)
  125. Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF. Andreu-Pérez P, Esteve-Puig R, de Torre-Minguela C, López-Fauqued M, Bech-Serra JJ, Tenbaum S, García-Trevijano ER, Canals F, Merlino G, Avila MA, Recio JA. Sci Signal 4 ra58 (2011)
  126. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Shinozaki M, O'Day SJ, Kitago M, Amersi F, Kuo C, Kim J, Wang HJ, Hoon DS. Clin Cancer Res 13 2068-2074 (2007)
  127. Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Packer LM, Rana S, Hayward R, O'Hare T, Eide CA, Rebocho A, Heidorn S, Zabriskie MS, Niculescu-Duvaz I, Druker BJ, Springer C, Marais R. Cancer Cell 20 715-727 (2011)
  128. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile G, Lonardi S, Sartore-Bianchi A, Fontanini G, Milione M, Lauricella C, Siena S, Falcone A, de Braud F, Loupakis F, Pietrantonio F. Ann Oncol 26 2092-2097 (2015)
  129. Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation. Thevakumaran N, Lavoie H, Critton DA, Tebben A, Marinier A, Sicheri F, Therrien M. Nat Struct Mol Biol 22 37-43 (2015)
  130. The mutational landscape of phosphorylation signaling in cancer. Reimand J, Wagih O, Bader GD. Sci Rep 3 2651 (2013)
  131. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Ascierto PA, Testori A, Lorigan PC, Dummer R, Sosman JA, Flaherty KT, Chang I, Coleman S, Caro I, Hauschild A, McArthur GA. Ann Oncol 28 2581-2587 (2017)
  132. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Christiansen DH, Andersen MK, Desta F, Pedersen-Bjergaard J. Leukemia 19 2232-2240 (2005)
  133. Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. Rheault TR, Stellwagen JC, Adjabeng GM, Hornberger KR, Petrov KG, Waterson AG, Dickerson SH, Mook RA, Laquerre SG, King AJ, Rossanese OW, Arnone MR, Smitheman KN, Kane-Carson LS, Han C, Moorthy GS, Moss KG, Uehling DE. ACS Med Chem Lett 4 358-362 (2013)
  134. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. Margonis GA, Buettner S, Andreatos N, Kim Y, Wagner D, Sasaki K, Beer A, Schwarz C, Løes IM, Smolle M, Kamphues C, He J, Pawlik TM, Kaczirek K, Poultsides G, Lønning PE, Cameron JL, Burkhart RA, Gerger A, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ. JAMA Surg 153 e180996 (2018)
  135. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. J Invest Dermatol 135 508-515 (2015)
  136. Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper. Wang Z, Liu J, Sudom A, Ayres M, Li S, Wesche H, Powers JP, Walker NP. Structure 14 1835-1844 (2006)
  137. Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Whittaker S, Kirk R, Hayward R, Zambon A, Viros A, Cantarino N, Affolter A, Nourry A, Niculescu-Duvaz D, Springer C, Marais R. Sci Transl Med 2 35ra41 (2010)
  138. Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution. Shain AH, Joseph NM, Yu R, Benhamida J, Liu S, Prow T, Ruben B, North J, Pincus L, Yeh I, Judson R, Bastian BC. Cancer Cell 34 45-55.e4 (2018)
  139. Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish. Dovey M, White RM, Zon LI. Zebrafish 6 397-404 (2009)
  140. Quantitative Missense Variant Effect Prediction Using Large-Scale Mutagenesis Data. Gray VE, Hause RJ, Luebeck J, Shendure J, Fowler DM. Cell Syst 6 116-124.e3 (2018)
  141. Understanding melanoma signaling networks as the basis for molecular targeted therapy. Smalley KS. J Invest Dermatol 130 28-37 (2010)
  142. ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Polier S, Samant RS, Clarke PA, Workman P, Prodromou C, Pearl LH. Nat Chem Biol 9 307-312 (2013)
  143. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Cartlidge RA, Thomas GR, Cagnol S, Jong KA, Molton SA, Finch AJ, McMahon M. Pigment Cell Melanoma Res 21 534-544 (2008)
  144. Colorectal cancer: molecular mutations and polymorphisms. Sameer AS. Front Oncol 3 114 (2013)
  145. Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. Kumar A, Mandiyan V, Suzuki Y, Zhang C, Rice J, Tsai J, Artis DR, Ibrahim P, Bremer R. J Mol Biol 348 183-193 (2005)
  146. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR, Alliance for Clinical Trials in Oncology. J Natl Cancer Inst 106 dju106 (2014)
  147. Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms. Su X, Shen Z, Yang Q, Sui F, Pu J, Ma J, Ma S, Yao D, Ji M, Hou P. Theranostics 9 4461-4473 (2019)
  148. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. Jaiswal BS, Janakiraman V, Kljavin NM, Eastham-Anderson J, Cupp JE, Liang Y, Davis DP, Hoeflich KP, Seshagiri S. PLoS One 4 e5717 (2009)
  149. DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. Berg M, Danielsen SA, Ahlquist T, Merok MA, Ågesen TH, Vatn MH, Mala T, Sjo OH, Bakka A, Moberg I, Fetveit T, Mathisen Ø, Husby A, Sandvik O, Nesbakken A, Thiis-Evensen E, Lothe RA. PLoS One 5 e13978 (2010)
  150. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations. Tissot C, Couraud S, Tanguy R, Bringuier PP, Girard N, Souquet PJ. Lung Cancer 91 23-28 (2016)
  151. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, Panka D, Manoukian G, Percy A, Bassett RL, Ng CS, Radvanyi L, Hwu P, Atkins MB, Davies MA. J Immunother 35 66-72 (2012)
  152. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H, Tellew J, Hardy S, Hekmat-Nejad M, Stuart DD, McCormick F, Nagel TE. Cancer Cell 23 594-602 (2013)
  153. An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu X, Zhang C, Bollag G, Herlyn M, Fagin JA, Lujambio A, Gavathiotis E, Poulikakos PI. Cancer Cell 30 485-498 (2016)
  154. Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. Smith CC, Zhang C, Lin KC, Lasater EA, Zhang Y, Massi E, Damon LE, Pendleton M, Bashir A, Sebra R, Perl A, Kasarskis A, Shellooe R, Tsang G, Carias H, Powell B, Burton EA, Matusow B, Zhang J, Spevak W, Ibrahim PN, Le MH, Hsu HH, Habets G, West BL, Bollag G, Shah NP. Cancer Discov 5 668-679 (2015)
  155. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ilie M, Long E, Hofman V, Dadone B, Marquette CH, Mouroux J, Vignaud JM, Begueret H, Merlio JP, Capper D, von Deimling A, Emile JF, Hofman P. Ann Oncol 24 742-748 (2013)
  156. NMR characterization of kinase p38 dynamics in free and ligand-bound forms. Vogtherr M, Saxena K, Hoelder S, Grimme S, Betz M, Schieborr U, Pescatore B, Robin M, Delarbre L, Langer T, Wendt KU, Schwalbe H. Angew Chem Int Ed Engl 45 993-997 (2006)
  157. Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. Spittle C, Ward MR, Nathanson KL, Gimotty PA, Rappaport E, Brose MS, Medina A, Letrero R, Herlyn M, Edwards RH. J Mol Diagn 9 464-471 (2007)
  158. The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder. Schneider EV, Böttcher J, Blaesse M, Neumann L, Huber R, Maskos K. J Mol Biol 412 251-266 (2011)
  159. Human tumor genomics and zebrafish modeling identify SPRED1 loss as a driver of mucosal melanoma. Ablain J, Xu M, Rothschild H, Jordan RC, Mito JK, Daniels BH, Bell CF, Joseph NM, Wu H, Bastian BC, Zon LI, Yeh I. Science 362 1055-1060 (2018)
  160. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Kaplan FM, Shao Y, Mayberry MM, Aplin AE. Oncogene 30 366-371 (2011)
  161. Navigating cancer network attractors for tumor-specific therapy. Creixell P, Schoof EM, Erler JT, Linding R. Nat Biotechnol 30 842-848 (2012)
  162. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Deng W, Gopal YN, Scott A, Chen G, Woodman SE, Davies MA. Pigment Cell Melanoma Res 25 248-258 (2012)
  163. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. Molhoek KR, Brautigan DL, Slingluff CL. J Transl Med 3 39 (2005)
  164. Cryo-EM structure of a dimeric B-Raf:14-3-3 complex reveals asymmetry in the active sites of B-Raf kinases. Kondo Y, Ognjenović J, Banerjee S, Karandur D, Merk A, Kulhanek K, Wong K, Roose JP, Subramaniam S, Kuriyan J. Science 366 109-115 (2019)
  165. Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Chadee DN, Xu D, Hung G, Andalibi A, Lim DJ, Luo Z, Gutmann DH, Kyriakis JM. Proc Natl Acad Sci U S A 103 4463-4468 (2006)
  166. Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway. Bugaj LJ, Sabnis AJ, Mitchell A, Garbarino JE, Toettcher JE, Bivona TG, Lim WA. Science 361 eaao3048 (2018)
  167. Neurological complications of cardio-facio-cutaneous syndrome. Yoon G, Rosenberg J, Blaser S, Rauen KA. Dev Med Child Neurol 49 894-899 (2007)
  168. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Clin Colorectal Cancer 13 164-171 (2014)
  169. BRAF mutations in aberrant crypt foci and hyperplastic polyposis. Beach R, Chan AO, Wu TT, White JA, Morris JS, Lunagomez S, Broaddus RR, Issa JP, Hamilton SR, Rashid A. Am J Pathol 166 1069-1075 (2005)
  170. Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR. Schirosi L, Lantuejoul S, Cavazza A, Murer B, Yves Brichon P, Migaldi M, Sartori G, Sgambato A, Rossi G, Rossi G. Am J Surg Pathol 32 1627-1642 (2008)
  171. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Gaedcke J, Grade M, Jung K, Schirmer M, Jo P, Obermeyer C, Wolff HA, Herrmann MK, Beissbarth T, Becker H, Ried T, Ghadimi M. Radiother Oncol 94 76-81 (2010)
  172. Raf kinase signaling functions in sensory neuron differentiation and axon growth in vivo. Zhong J, Li X, McNamee C, Chen AP, Baccarini M, Snider WD. Nat Neurosci 10 598-607 (2007)
  173. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA, Parangi S. Oncologist 16 296-309 (2011)
  174. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Bucheit AD, Syklawer E, Jakob JA, Bassett RL, Curry JL, Gershenwald JE, Kim KB, Hwu P, Lazar AJ, Davies MA. Cancer 119 3821-3829 (2013)
  175. Formation of endothelial lumens requires a coordinated PKCepsilon-, Src-, Pak- and Raf-kinase-dependent signaling cascade downstream of Cdc42 activation. Koh W, Sachidanandam K, Stratman AN, Sacharidou A, Mayo AM, Murphy EA, Cheresh DA, Davis GE. J Cell Sci 122 1812-1822 (2009)
  176. Kinase regulation by hydrophobic spine assembly in cancer. Hu J, Ahuja LG, Meharena HS, Kannan N, Kornev AP, Taylor SS, Shaw AS. Mol Cell Biol 35 264-276 (2015)
  177. Mutation analysis of B-RAF gene in human gliomas. Basto D, Trovisco V, Lopes JM, Martins A, Pardal F, Soares P, Reis RM. Acta Neuropathol 109 207-210 (2005)
  178. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Reid AL, Freeman JB, Millward M, Ziman M, Gray ES. Clin Biochem 48 999-1002 (2015)
  179. ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. Marquette A, André J, Bagot M, Bensussan A, Dumaz N. Nat Struct Mol Biol 18 584-591 (2011)
  180. Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing. Salton M, Kasprzak WK, Voss T, Shapiro BA, Poulikakos PI, Misteli T. Nat Commun 6 7103 (2015)
  181. BRAF and KRAS mutations in prostatic adenocarcinoma. Cho NY, Choi M, Kim BH, Cho YM, Moon KC, Kang GH. Int J Cancer 119 1858-1862 (2006)
  182. Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. Litvak AM, Paik PK, Woo KM, Sima CS, Hellmann MD, Arcila ME, Ladanyi M, Rudin CM, Kris MG, Riely GJ. J Thorac Oncol 9 1669-1674 (2014)
  183. Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. Zheng G, Tseng LH, Chen G, Haley L, Illei P, Gocke CD, Eshleman JR, Lin MT. BMC Cancer 15 779 (2015)
  184. RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling. McKay MM, Ritt DA, Morrison DK. Curr Biol 21 563-568 (2011)
  185. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas. Li Y, Cheng HS, Chng WJ, Tergaonkar V. Proc Natl Acad Sci U S A 113 14402-14407 (2016)
  186. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA. Pediatr Blood Cancer 55 668-677 (2010)
  187. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, Fukumoto M, Miyazaki K. Br J Cancer 99 2020-2028 (2008)
  188. Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Anastasaki C, Estep AL, Marais R, Rauen KA, Patton EE. Hum Mol Genet 18 2543-2554 (2009)
  189. Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor design. Han S, Mistry A, Chang JS, Cunningham D, Griffor M, Bonnette PC, Wang H, Chrunyk BA, Aspnes GE, Walker DP, Brosius AD, Buckbinder L. J Biol Chem 284 13193-13201 (2009)
  190. A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Trovisco V, Soares P, Soares R, Magalhães J, Sá-Couto P, Sobrinho-Simões M. Hum Pathol 36 694-697 (2005)
  191. CanDrA: cancer-specific driver missense mutation annotation with optimized features. Mao Y, Chen H, Liang H, Meric-Bernstam F, Mills GB, Chen K. PLoS One 8 e77945 (2013)
  192. Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design. Dodson CA, Kosmopoulou M, Richards MW, Atrash B, Bavetsias V, Blagg J, Bayliss R. Biochem J 427 19-28 (2010)
  193. Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Eisenhardt AE, Olbrich H, Röring M, Janzarik W, Anh TN, Cin H, Remke M, Witt H, Korshunov A, Pfister SM, Omran H, Brummer T. Int J Cancer 129 2297-2303 (2011)
  194. Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase. Balan V, Leicht DT, Zhu J, Balan K, Kaplun A, Singh-Gupta V, Qin J, Ruan H, Comb MJ, Tzivion G. Mol Biol Cell 17 1141-1153 (2006)
  195. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Tanami H, Imoto I, Hirasawa A, Yuki Y, Sonoda I, Inoue J, Yasui K, Misawa-Furihata A, Kawakami Y, Inazawa J. Oncogene 23 8796-8804 (2004)
  196. Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. Estep AL, Palmer C, McCormick F, Rauen KA. PLoS One 2 e1279 (2007)
  197. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. Yoon HH, Shi Q, Alberts SR, Goldberg RM, Thibodeau SN, Sargent DJ, Sinicrope FA, Alliance for Clinical Trials in Oncology. J Natl Cancer Inst 107 djv186 (2015)
  198. Ras binding opens c-Raf to expose the docking site for mitogen-activated protein kinase kinase. Terai K, Matsuda M. EMBO Rep 6 251-255 (2005)
  199. Small molecule recognition of c-Src via the Imatinib-binding conformation. Dar AC, Lopez MS, Shokat KM. Chem Biol 15 1015-1022 (2008)
  200. BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Willmore-Payne C, Holden JA, Hirschowitz S, Layfield LJ. Hum Pathol 37 520-527 (2006)
  201. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Ross JS, Ali SM, Wang K, Palmer G, Yelensky R, Lipson D, Miller VA, Zajchowski D, Shawver LK, Stephens PJ. Gynecol Oncol 130 554-559 (2013)
  202. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. Liu S, Wang H, Currie BM, Molinolo A, Leung HJ, Moayeri M, Basile JR, Alfano RW, Gutkind JS, Frankel AE, Bugge TH, Leppla SH. J Biol Chem 283 529-540 (2008)
  203. Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization. Karbowniczek M, Robertson GP, Henske EP. J Biol Chem 281 25447-25456 (2006)
  204. Suppression of dual-specificity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells. Lin SC, Chien CW, Lee JC, Yeh YC, Hsu KF, Lai YY, Lin SC, Tsai SJ. J Clin Invest 121 1905-1916 (2011)
  205. CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Noble C, Mercer K, Hussain J, Carragher L, Giblett S, Hayward R, Patterson C, Marais R, Pritchard CA. Mol Cell 31 862-872 (2008)
  206. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. Houben R, Vetter-Kauczok CS, Ortmann S, Rapp UR, Broecker EB, Becker JC. J Invest Dermatol 128 2003-2012 (2008)
  207. Regulation of RAF activity by 14-3-3 proteins: RAF kinases associate functionally with both homo- and heterodimeric forms of 14-3-3 proteins. Fischer A, Baljuls A, Reinders J, Nekhoroshkova E, Sibilski C, Metz R, Albert S, Rajalingam K, Hekman M, Rapp UR. J Biol Chem 284 3183-3194 (2009)
  208. "RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway. Cseh B, Doma E, Baccarini M. FEBS Lett 588 2398-2406 (2014)
  209. A new screening assay for allosteric inhibitors of cSrc. Simard JR, Klüter S, Grütter C, Getlik M, Rabiller M, Rode HB, Rauh D. Nat Chem Biol 5 394-396 (2009)
  210. Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs. Mastio J, Condamine T, Dominguez G, Kossenkov AV, Donthireddy L, Veglia F, Lin C, Wang F, Fu S, Zhou J, Viatour P, Lavilla-Alonso S, Polo AT, Tcyganov EN, Mulligan C, Nam B, Bennett J, Masters G, Guarino M, Kumar A, Nefedova Y, Vonderheide RH, Languino LR, Abrams SI, Gabrilovich DI. J Exp Med 216 2150-2169 (2019)
  211. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Kim J, Giuliano AE, Turner RR, Gaffney RE, Umetani N, Kitago M, Elashoff D, Hoon DS. Ann Surg 244 799-804 (2006)
  212. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Akslen LA, Puntervoll H, Bachmann IM, Straume O, Vuhahula E, Kumar R, Molven A. Melanoma Res 18 29-35 (2008)
  213. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. Gowrishankar K, Snoyman S, Pupo GM, Becker TM, Kefford RF, Rizos H. J Invest Dermatol 132 1850-1859 (2012)
  214. Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Barroeta JE, Baloch ZW, Lal P, Pasha TL, Zhang PJ, LiVolsi VA. Endocr Pathol 17 225-234 (2006)
  215. Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations. Gilsbach BK, Ho FY, Vetter IR, van Haastert PJ, Wittinghofer A, Kortholt A. Proc Natl Acad Sci U S A 109 10322-10327 (2012)
  216. The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma. McCain J. P T 38 96-108 (2013)
  217. The importance of Raf dimerization in cell signaling. Freeman AK, Ritt DA, Morrison DK. Small GTPases 4 180-185 (2013)
  218. A catalogue of somatic NRF2 gain-of-function mutations in cancer. Kerins MJ, Ooi A. Sci Rep 8 12846 (2018)
  219. A mutated EGFR is sufficient to induce malignant melanoma with genetic background-dependent histopathologies. Schartl M, Wilde B, Laisney JA, Taniguchi Y, Takeda S, Meierjohann S. J Invest Dermatol 130 249-258 (2010)
  220. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Karreth FA, DeNicola GM, Winter SP, Tuveson DA. Mol Cell 36 477-486 (2009)
  221. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Pizzolanti G, Russo L, Richiusa P, Bronte V, Nuara RB, Rodolico V, Amato MC, Smeraldi L, Sisto PS, Nucera M, Bommarito A, Citarrella R, Lo Coco R, Cabibi D, Lo Coco A, Frasca F, Gulotta G, Latteri MA, Modica G, Galluzzo A, Giordano C. Thyroid 17 1109-1115 (2007)
  222. Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. Liu JY, Park SH, Morisseau C, Hwang SH, Hammock BD, Weiss RH. Mol Cancer Ther 8 2193-2203 (2009)
  223. B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis. Boisvert-Adamo K, Aplin AE. Oncogene 25 4848-4856 (2006)
  224. Constitutive activation of Raf-1 induces glioma formation in mice. Lyustikman Y, Momota H, Pao W, Holland EC. Neoplasia 10 501-510 (2008)
  225. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. Behling F, Barrantes-Freer A, Skardelly M, Nieser M, Christians A, Stockhammer F, Rohde V, Tatagiba M, Hartmann C, Stadelmann C, Schittenhelm J. Diagn Pathol 11 55 (2016)
  226. Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Packer LM, East P, Reis-Filho JS, Marais R. Pigment Cell Melanoma Res 22 785-798 (2009)
  227. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. Zebary A, Omholt K, Vassilaki I, Höiom V, Lindén D, Viberg L, Kanter-Lewensohn L, Johansson CH, Hansson J. J Dermatol Sci 72 284-289 (2013)
  228. Sequence and structure signatures of cancer mutation hotspots in protein kinases. Dixit A, Yi L, Gowthaman R, Torkamani A, Schork NJ, Verkhivker GM. PLoS One 4 e7485 (2009)
  229. B- and C-RAF display essential differences in their binding to Ras: the isotype-specific N terminus of B-RAF facilitates Ras binding. Fischer A, Hekman M, Kuhlmann J, Rubio I, Wiese S, Rapp UR. J Biol Chem 282 26503-26516 (2007)
  230. High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies. Boyd EM, Bench AJ, van 't Veer MB, Wright P, Bloxham DM, Follows GA, Scott MA. Br J Haematol 155 609-612 (2011)
  231. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sen B, Peng S, Tang X, Erickson HS, Galindo H, Mazumdar T, Stewart DJ, Wistuba I, Johnson FM. Sci Transl Med 4 136ra70 (2012)
  232. The genomics of lung adenocarcinoma: opportunities for targeted therapies. Greulich H. Genes Cancer 1 1200-1210 (2010)
  233. Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein. Brummer T, Martin P, Herzog S, Misawa Y, Daly RJ, Reth M. Oncogene 25 6262-6276 (2006)
  234. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. Uribe P, Andrade L, Gonzalez S. J Invest Dermatol 126 161-166 (2006)
  235. Menin determines K-RAS proliferative outputs in endocrine cells. Chamberlain CE, Scheel DW, McGlynn K, Kim H, Miyatsuka T, Wang J, Nguyen V, Zhao S, Mavropoulos A, Abraham AG, O'Neill E, Ku GM, Cobb MH, Martin GR, German MS. J Clin Invest 124 4093-4101 (2014)
  236. Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication. Bürckstümmer T, Kriegs M, Lupberger J, Pauli EK, Schmittel S, Hildt E. FEBS Lett 580 575-580 (2006)
  237. Transformation potential of Ras isoforms correlates with activation of phosphatidylinositol 3-kinase but not ERK. Li W, Zhu T, Guan KL. J Biol Chem 279 37398-37406 (2004)
  238. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. Volckmar AL, Leichsenring J, Kirchner M, Christopoulos P, Neumann O, Budczies J, Budczies J, Morais de Oliveira CM, Rempel E, Buchhalter I, Brandt R, Allgäuer M, Talla SB, von Winterfeld M, Herpel E, Goeppert B, Lier A, Winter H, Brummer T, Fröhling S, Faehling M, Fischer JR, Heußel CP, Herth F, Lasitschka F, Schirmacher P, Thomas M, Endris V, Penzel R, Stenzinger A. Int J Cancer 145 649-661 (2019)
  239. Cutaneous effects of BRAF inhibitor therapy: a case series. Mattei PL, Alora-Palli MB, Kraft S, Lawrence DP, Flaherty KT, Kimball AB. Ann Oncol 24 530-537 (2013)
  240. NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma. Flockhart RJ, Armstrong JL, Reynolds NJ, Lovat PE. Br J Cancer 101 1448-1455 (2009)
  241. Sequence determinants of a specific inactive protein kinase conformation. Hari SB, Merritt EA, Maly DJ. Chem Biol 20 806-815 (2013)
  242. Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Huber S, Oelsner M, Decker T, zum Büschenfelde CM, Wagner M, Lutzny G, Kuhnt T, Schmidt B, Oostendorp RA, Peschel C, Ringshausen I. Leukemia 25 838-847 (2011)
  243. Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. McCubrey JA, Steelman LS, Franklin RA, Abrams SL, Chappell WH, Wong EW, Lehmann BD, Terrian DM, Basecke J, Stivala F, Libra M, Evangelisti C, Martelli AM. Adv Enzyme Regul 47 64-103 (2007)
  244. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy. Bommarito A, Richiusa P, Carissimi E, Pizzolanti G, Rodolico V, Zito G, Criscimanna A, Di Blasi F, Pitrone M, Zerilli M, Amato MC, Spinelli G, Carina V, Modica G, Latteri MA, Galluzzo A, Giordano C. Endocr Relat Cancer 18 669-685 (2011)
  245. CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers. Tokheim C, Karchin R. Cell Syst 9 9-23.e8 (2019)
  246. Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma. Chen JH, Faquin WC, Lloyd RV, Nosé V. Mod Pathol 24 739-749 (2011)
  247. Crystal structure of the TAO2 kinase domain: activation and specificity of a Ste20p MAP3K. Zhou T, Raman M, Gao Y, Earnest S, Chen Z, Machius M, Cobb MH, Goldsmith EJ. Structure 12 1891-1900 (2004)
  248. Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors. Marusiak AA, Edwards ZC, Hugo W, Trotter EW, Girotti MR, Stephenson NL, Kong X, Gartside MG, Fawdar S, Hudson A, Breitwieser W, Hayward NK, Marais R, Lo RS, Brognard J. Nat Commun 5 3901 (2014)
  249. A mouse model of melanoma driven by oncogenic KRAS. Milagre C, Dhomen N, Geyer FC, Hayward R, Lambros M, Reis-Filho JS, Marais R. Cancer Res 70 5549-5557 (2010)
  250. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Gonzalez-Cao M, Mayo-de-Las-Casas C, Molina-Vila MA, De Mattos-Arruda L, Muñoz-Couselo E, Manzano JL, Cortes J, Berros JP, Drozdowskyj A, Sanmamed M, Gonzalez A, Alvarez C, Viteri S, Karachaliou N, Martin Algarra S, Bertran-Alamillo J, Jordana-Ariza N, Rosell R. Melanoma Res 25 486-495 (2015)
  251. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Liu CY, Tseng LM, Su JC, Chang KC, Chu PY, Tai WT, Shiau CW, Chen KF. Breast Cancer Res 15 R63 (2013)
  252. AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. Hu W, Jin L, Jiang CC, Long GV, Scolyer RA, Wu Q, Zhang XD, Mei Y, Wu M. Cell Death Dis 4 e914 (2013)
  253. Molecular recognition of RAS/RAF complex at the membrane: Role of RAF cysteine-rich domain. Travers T, López CA, Van QN, Neale C, Tonelli M, Stephen AG, Gnanakaran S. Sci Rep 8 8461 (2018)
  254. New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging. Brighton HE, Angus SP, Bo T, Roques J, Tagliatela AC, Darr DB, Karagoz K, Sciaky N, Gatza ML, Sharpless NE, Johnson GL, Bear JE. Cancer Res 78 542-557 (2018)
  255. Polyclonality of BRAF mutations in acquired melanocytic nevi. Lin J, Takata M, Murata H, Goto Y, Kido K, Ferrone S, Saida T. J Natl Cancer Inst 101 1423-1427 (2009)
  256. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Tiacci E, Schiavoni G, Martelli MP, Boveri E, Pacini R, Tabarrini A, Zibellini S, Santi A, Pettirossi V, Fortini E, Ascani S, Arcaini L, Inghirami G, Paulli M, Falini B. Haematologica 98 635-639 (2013)
  257. Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation. Lietha D, Eck MJ. PLoS One 3 e3800 (2008)
  258. Cutting Edge: IL-1 receptor-associated kinase 4 structures reveal novel features and multiple conformations. Kuglstatter A, Villaseñor AG, Shaw D, Lee SW, Tsing S, Niu L, Song KW, Barnett JW, Browner MF. J Immunol 178 2641-2645 (2007)
  259. Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform. Lebakken CS, Riddle SM, Singh U, Frazee WJ, Eliason HC, Gao Y, Reichling LJ, Marks BD, Vogel KW. J Biomol Screen 14 924-935 (2009)
  260. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. Lionetti M, Barbieri M, Todoerti K, Agnelli L, Marzorati S, Fabris S, Ciceri G, Galletti S, Milesi G, Manzoni M, Mazzoni M, Greco A, Tonon G, Musto P, Baldini L, Neri A. Oncotarget 6 24205-24217 (2015)
  261. Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, de Groot JWB, van der Veldt AAM, Johnson DB, Meiss F, Schlaak M, Schilling B, Westgeest HM, Gutzmer R, Pföhler C, Meier F, Zimmer L, Suijkerbuijk KPM, Haalck T, Thoms KM, Herbschleb K, Leichsenring J, Menzer A, Kopp-Schneider A, Long GV, Kefford R, Enk A, Blank CU, Hassel JC. J Clin Oncol 37 3142-3151 (2019)
  262. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Lubomierski N, Plotz G, Wormek M, Engels K, Kriener S, Trojan J, Jungling B, Zeuzem S, Raedle J. Cancer 104 952-961 (2005)
  263. Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome. Urosevic J, Sauzeau V, Soto-Montenegro ML, Reig S, Desco M, Wright EM, Cañamero M, Mulero F, Ortega S, Bustelo XR, Barbacid M. Proc Natl Acad Sci U S A 108 5015-5020 (2011)
  264. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, Kamranpour N, Pitts S, Desai A, Elashoff D, French T, Smith P, Slamon DJ. Mol Cancer Ther 9 1985-1994 (2010)
  265. Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib. Noeparast A, Teugels E, Giron P, Verschelden G, De Brakeleer S, Decoster L, De Grève J. Oncotarget 8 60094-60108 (2017)
  266. Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells. Argast GM, Croy CH, Couts KL, Zhang Z, Litman E, Chan DC, Ahn NG. Oncogene 28 2697-2709 (2009)
  267. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Le K, Blomain ES, Rodeck U, Aplin AE. Pigment Cell Melanoma Res 26 509-517 (2013)
  268. B-Raf Inhibition in the Clinic: Present and Future. Fiskus W, Mitsiades N. Annu Rev Med 67 29-43 (2016)
  269. Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf heterodimerization. Yasuda S, Kai M, Imai S, Takeishi K, Taketomi A, Toyota M, Kanoh H, Sakane F. J Biol Chem 284 29559-29570 (2009)
  270. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, Morton CL, Reynolds CP, Kang MH, Watkins A, Houghton PJ, Smith MA. Pediatr Blood Cancer 55 1126-1133 (2010)
  271. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. Phillips JJ, Gong H, Chen K, Joseph NM, van Ziffle J, Bastian BC, Grenert JP, Kline CN, Mueller S, Banerjee A, Nicolaides T, Gupta N, Berger MS, Lee HS, Pekmezci M, Tihan T, Bollen AW, Perry A, Shieh JTC, Solomon DA. Brain Pathol 29 85-96 (2019)
  272. The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. Andreadi C, Cheung LK, Giblett S, Patel B, Jin H, Mercer K, Kamata T, Lee P, Williams A, McMahon M, Marais R, Pritchard C. Genes Dev 26 1945-1958 (2012)
  273. A KSR/CNK complex mediated by HYP, a novel SAM domain-containing protein, regulates RAS-dependent RAF activation in Drosophila. Douziech M, Sahmi M, Laberge G, Therrien M. Genes Dev 20 807-819 (2006)
  274. A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Chiosea S, Nikiforova M, Zuo H, Ogilvie J, Gandhi M, Seethala RR, Ohori NP, Nikiforov Y. Endocr Pathol 20 122-126 (2009)
  275. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Macerola E, Loggini B, Giannini R, Garavello G, Giordano M, Proietti A, Niccoli C, Basolo F, Fontanini G. Virchows Arch 467 177-184 (2015)
  276. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Pappa KI, Choleza M, Markaki S, Giannikaki E, Kyroudi A, Vlachos G, Voulgaris Z, Anagnou NP. Gynecol Oncol 100 596-600 (2006)
  277. Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression. Henderson V, Smith B, Burton LJ, Randle D, Morris M, Odero-Marah VA. Cell Adh Migr 9 255-264 (2015)
  278. Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury. Martens S, Jeong M, Tonnus W, Feldmann F, Hofmans S, Goossens V, Takahashi N, Bräsen JH, Lee EW, Van der Veken P, Joossens J, Augustyns K, Fulda S, Linkermann A, Song J, Vandenabeele P. Cell Death Dis 8 e2904 (2017)
  279. The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf. Terai K, Matsuda M. EMBO J 25 3556-3564 (2006)
  280. mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Kitago M, Koyanagi K, Nakamura T, Goto Y, Faries M, O'Day SJ, Morton DL, Ferrone S, Hoon DS. Clin Chem 55 757-764 (2009)
  281. BRAF-mutations in non-small cell lung cancer. Brustugun OT, Khattak AM, Trømborg AK, Beigi M, Beiske K, Lund-Iversen M, Helland Å. Lung Cancer 84 36-38 (2014)
  282. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. Ilie MI, Lassalle S, Long-Mira E, Bonnetaud C, Bordone O, Lespinet V, Lamy A, Sabourin JC, Haudebourg J, Butori C, Guevara N, Peyrottes I, Sadoul JL, Bozec A, Santini J, Capper D, von Deimling A, Emile JF, Hofman V, Hofman P. Thyroid 24 858-866 (2014)
  283. Genetics of uveal melanoma and cutaneous melanoma: two of a kind? van den Bosch T, Kilic E, Paridaens D, de Klein A. Dermatol Res Pract 2010 360136 (2010)
  284. Raf-1 serine 338 phosphorylation plays a key role in adhesion-dependent activation of extracellular signal-regulated kinase by epidermal growth factor. Edin ML, Juliano RL. Mol Cell Biol 25 4466-4475 (2005)
  285. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor. Kaplan FM, Kugel CH, Dadpey N, Shao Y, Abel EV, Aplin AE. J Biol Chem 287 41797-41807 (2012)
  286. Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations. Kiel C, Serrano L. Mol Syst Biol 10 727 (2014)
  287. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers. Rebocho AP, Marais R. Oncogene 32 3207-3212 (2013)
  288. Down-Regulation of miR-129-5p and the let-7 Family in Neuroendocrine Tumors and Metastases Leads to Up-Regulation of Their Targets Egr1, G3bp1, Hmga2 and Bach1. Døssing KB, Binderup T, Kaczkowski B, Jacobsen A, Rossing M, Winther O, Federspiel B, Knigge U, Kjær A, Friis-Hansen L. Genes (Basel) 6 1-21 (2014)
  289. HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL. Carson R, Celtikci B, Fenning C, Javadi A, Crawford N, Carbonell LP, Lawler M, Longley DB, Johnston PG, Van Schaeybroeck S. Clin Cancer Res 21 3230-3240 (2015)
  290. Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma. Jung CK, Im SY, Kang YJ, Lee H, Jung ES, Kang CS, Bae JS, Choi YJ. Thyroid 22 791-797 (2012)
  291. Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro. Eskandarpour M, Huang F, Reeves KA, Clark E, Hansson J. Int J Cancer 124 16-26 (2009)
  292. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Yadav A, Kumar B, Teknos TN, Kumar P. Mol Cancer Ther 10 1241-1251 (2011)
  293. Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer. Fawdar S, Trotter EW, Li Y, Stephenson NL, Hanke F, Marusiak AA, Edwards ZC, Ientile S, Waszkowycz B, Miller CJ, Brognard J. Proc Natl Acad Sci U S A 110 12426-12431 (2013)
  294. BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma. Rusinek D, Swierniak M, Chmielik E, Kowal M, Kowalska M, Cyplinska R, Czarniecka A, Piglowski W, Korfanty J, Chekan M, Krajewska J, Szpak-Ulczok S, Jarzab M, Widlak W, Jarzab B. PLoS One 10 e0143688 (2015)
  295. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. Hsieh LL, Er TK, Chen CC, Hsieh JS, Chang JG, Liu TC. Clin Chim Acta 413 1605-1611 (2012)
  296. Exome-wide somatic mutation characterization of small bowel adenocarcinoma. Hänninen UA, Katainen R, Tanskanen T, Plaketti RM, Laine R, Hamberg J, Ristimäki A, Pukkala E, Taipale M, Mecklin JP, Forsström LM, Pitkänen E, Palin K, Välimäki N, Mäkinen N, Aaltonen LA. PLoS Genet 14 e1007200 (2018)
  297. Flotillins in receptor tyrosine kinase signaling and cancer. Banning A, Kurrle N, Meister M, Tikkanen R. Cells 3 129-149 (2014)
  298. Mitogen-activated protein kinase signaling pathway in oral cancer. Peng Q, Deng Z, Pan H, Gu L, Liu O, Tang Z. Oncol Lett 15 1379-1388 (2018)
  299. Mutant-selective degradation by BRAF-targeting PROTACs. Alabi S, Jaime-Figueroa S, Yao Z, Gao Y, Hines J, Samarasinghe KTG, Vogt L, Rosen N, Crews CM. Nat Commun 12 920 (2021)
  300. Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization. Liau NPD, Wendorff TJ, Quinn JG, Steffek M, Phung W, Liu P, Tang J, Irudayanathan FJ, Izadi S, Shaw AS, Malek S, Hymowitz SG, Sudhamsu J. Nat Struct Mol Biol 27 134-141 (2020)
  301. Protein domain-level landscape of cancer-type-specific somatic mutations. Yang F, Petsalaki E, Rolland T, Hill DE, Vidal M, Roth FP. PLoS Comput Biol 11 e1004147 (2015)
  302. Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer. Yaeger R, Kotani D, Mondaca S, Parikh AR, Bando H, Van Seventer EE, Taniguchi H, Zhao H, Thant CN, de Stanchina E, Rosen N, Corcoran RB, Yoshino T, Yao Z, Ebi H. Clin Cancer Res 25 7089-7097 (2019)
  303. A basis for reduced chemical library inhibition of firefly luciferase obtained from directed evolution. Auld DS, Zhang YQ, Southall NT, Rai G, Landsman M, MacLure J, Langevin D, Thomas CJ, Austin CP, Inglese J. J Med Chem 52 1450-1458 (2009)
  304. Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex. Jacobs MD, Caron PR, Hare BJ. Proteins 70 1451-1460 (2008)
  305. Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Daniotti M, Vallacchi V, Rivoltini L, Patuzzo R, Santinami M, Arienti F, Cutolo G, Pierotti MA, Parmiani G, Rodolfo M. Int J Cancer 120 2439-2444 (2007)
  306. Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models. Albaugh P, Fan Y, Mi Y, Sun F, Adrian F, Li N, Jia Y, Sarkisova Y, Kreusch A, Hood T, Lu M, Liu G, Huang S, Liu Z, Loren J, Tuntland T, Karanewsky DS, Seidel HM, Molteni V. ACS Med Chem Lett 3 140-145 (2012)
  307. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. Yeh AH, Bohula EA, Macaulay VM. Oncogene 25 6574-6581 (2006)
  308. Letter Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. Gustafsson B, Angelini S, Sander B, Christensson B, Hemminki K, Kumar R. Leukemia 19 310-312 (2005)
  309. PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Sabbatino F, Wang Y, Wang X, Flaherty KT, Yu L, Pepin D, Scognamiglio G, Pepe S, Kirkwood JM, Cooper ZA, Frederick DT, Wargo JA, Ferrone S, Ferrone CR. Oncotarget 5 1926-1941 (2014)
  310. Raf-1 Cysteine-Rich Domain Increases the Affinity of K-Ras/Raf at the Membrane, Promoting MAPK Signaling. Li S, Jang H, Zhang J, Nussinov R. Structure 26 513-525.e2 (2018)
  311. The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. Wan L, Chen M, Cao J, Dai X, Yin Q, Zhang J, Song SJ, Lu Y, Liu J, Inuzuka H, Katon JM, Berry K, Fung J, Ng C, Liu P, Song MS, Xue L, Bronson RT, Kirschner MW, Cui R, Pandolfi PP, Wei W. Cancer Discov 7 424-441 (2017)
  312. BRAF inactivation drives aneuploidy by deregulating CRAF. Kamata T, Hussain J, Giblett S, Hayward R, Marais R, Pritchard C. Cancer Res 70 8475-8486 (2010)
  313. Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma. Pires da Silva I, Wang KYX, Wilmott JS, Holst J, Carlino MS, Park JJ, Quek C, Wongchenko M, Yan Y, Mann G, Johnson DB, McQuade JL, Rai R, Kefford RF, Rizos H, Scolyer RA, Yang JYH, Long GV, Menzies AM. Clin Cancer Res 25 1272-1279 (2019)
  314. Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis. Jian C, Fu J, Cheng X, Shen LJ, Ji YX, Wang X, Pan S, Tian H, Tian S, Liao R, Song K, Wang HP, Zhang X, Wang Y, Huang Z, She ZG, Zhang XJ, Zhu L, Li H. Cell Metab 31 892-908.e11 (2020)
  315. Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma. Bahadoran P, Allegra M, Le Duff F, Long-Mira E, Hofman P, Giacchero D, Passeron T, Lacour JP, Ballotti R. J Clin Oncol 31 e324-6 (2013)
  316. Oncogenic activation of MAP kinase by BRAF pseudogene in thyroid tumors. Zou M, Baitei EY, Alzahrani AS, Al-Mohanna F, Farid NR, Meyer B, Shi Y. Neoplasia 11 57-65 (2009)
  317. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Wu CP, Sim HM, Huang YH, Liu YC, Hsiao SH, Cheng HW, Li YQ, Ambudkar SV, Hsu SC. Biochem Pharmacol 85 325-334 (2013)
  318. Potent and selective pyrazole-based inhibitors of B-Raf kinase. Hansen JD, Grina J, Newhouse B, Welch M, Topalov G, Littman N, Callejo M, Gloor S, Martinson M, Laird E, Brandhuber BJ, Vigers G, Morales T, Woessner R, Randolph N, Lyssikatos J, Olivero A. Bioorg Med Chem Lett 18 4692-4695 (2008)
  319. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. Chen SH, Gong X, Zhang Y, Van Horn RD, Yin T, Huber L, Burke TF, Manro J, Iversen PW, Wu W, Bhagwat SV, Beckmann RP, Tiu RV, Buchanan SG, Peng SB. Oncogene 37 821-832 (2018)
  320. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Bottos A, Martini M, Di Nicolantonio F, Comunanza V, Maione F, Minassi A, Appendino G, Bussolino F, Bardelli A. Proc Natl Acad Sci U S A 109 E353-9 (2012)
  321. Computational study of the "DFG-flip" conformational transition in c-Abl and c-Src tyrosine kinases. Meng Y, Lin YL, Roux B. J Phys Chem B 119 1443-1456 (2015)
  322. Correlation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer. Brait M, Loyo M, Rosenbaum E, Ostrow KL, Markova A, Papagerakis S, Zahurak M, Goodman SM, Zeiger M, Sidransky D, Umbricht CB, Hoque MO. Epigenetics 7 710-719 (2012)
  323. Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells. Calipel A, Mouriaux F, Glotin AL, Malecaze F, Faussat AM, Mascarelli F. J Biol Chem 281 9238-9250 (2006)
  324. Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma. Feller JK, Yang S, Mahalingam M. Mod Pathol 26 414-420 (2013)
  325. New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome. Inoue S, Moriya M, Watanabe Y, Miyagawa-Tomita S, Niihori T, Oba D, Ono M, Kure S, Ogura T, Matsubara Y, Aoki Y. Hum Mol Genet 23 6553-6566 (2014)
  326. Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations. Barollo S, Pezzani R, Cristiani A, Redaelli M, Zambonin L, Rubin B, Bertazza L, Zane M, Mucignat-Caretta C, Bulfone A, Pennelli G, Casal Ide E, Pelizzo MR, Mantero F, Moro S, Mian C. Thyroid 24 809-819 (2014)
  327. Proteomic patterns of cervical cancer cell lines, a network perspective. Higareda-Almaraz JC, Enríquez-Gasca Mdel R, Hernández-Ortiz M, Resendis-Antonio O, Encarnación-Guevara S. BMC Syst Biol 5 96 (2011)
  328. Revealing the favorable dissociation pathway of type II kinase inhibitors via enhanced sampling simulations and two-end-state calculations. Sun H, Tian S, Zhou S, Li Y, Li D, Xu L, Shen M, Pan P, Hou T. Sci Rep 5 8457 (2015)
  329. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma. Givens DJ, Buchmann LO, Agarwal AM, Grimmer JF, Hunt JP. Laryngoscope 124 E389-93 (2014)
  330. CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis. Fu T, Pappou EP, Guzzetta AA, Jeschke J, Kwak R, Dave P, Hooker CM, Morgan R, Baylin SB, Iacobuzio-Donahue CA, Wolfgang CL, Ahuja N. Clin Cancer Res 18 4743-4752 (2012)
  331. Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling. Rukhlenko OS, Khorsand F, Krstic A, Rozanc J, Alexopoulos LG, Rauch N, Erickson KE, Hlavacek WS, Posner RG, Gómez-Coca S, Rosta E, Fitzgibbon C, Matallanas D, Rauch J, Kolch W, Kholodenko BN. Cell Syst 7 161-179.e14 (2018)
  332. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction. Manov I, Pollak Y, Broneshter R, Iancu TC. FEBS J 278 3494-3507 (2011)
  333. Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool. Carter J, Tseng LH, Zheng G, Dudley J, Illei P, Gocke CD, Eshleman JR, Lin MT. Am J Clin Pathol 144 620-628 (2015)
  334. Editorial Oncogenic B-Raf mutations: crystal clear at last. Dhillon AS, Kolch W. Cancer Cell 5 303-304 (2004)
  335. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. Haley L, Tseng LH, Zheng G, Dudley J, Anderson DA, Azad NS, Gocke CD, Eshleman JR, Lin MT. Mod Pathol 28 1390-1399 (2015)
  336. Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. Hwang SH, Wecksler AT, Zhang G, Morisseau C, Nguyen LV, Fu SH, Hammock BD. Bioorg Med Chem Lett 23 3732-3737 (2013)
  337. 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Solit DB, Santos E, Pratilas CA, Lobo J, Moroz M, Cai S, Blasberg R, Sebolt-Leopold J, Larson S, Rosen N. Cancer Res 67 11463-11469 (2007)
  338. A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation. Lee NV, Lira ME, Pavlicek A, Ye J, Buckman D, Bagrodia S, Srinivasa SP, Zhao Y, Aparicio S, Rejto PA, Christensen JG, Ching KA. PLoS One 7 e39653 (2012)
  339. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma. Baitei EY, Zou M, Al-Mohanna F, Collison K, Alzahrani AS, Farid NR, Meyer B, Shi Y. J Pathol 217 707-715 (2009)
  340. Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. Gatalica Z, Millis SZ, Vranic S, Bender R, Basu GD, Voss A, Von Hoff DD. Oncotarget 5 12440-12447 (2014)
  341. Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition. Diedrich B, Rigbolt KT, Röring M, Herr R, Kaeser-Pebernard S, Gretzmeier C, Murphy RF, Brummer T, Dengjel J. EMBO J 36 646-663 (2017)
  342. New targeted therapies for thyroid cancer. Antonelli A, Fallahi P, Ferrari SM, Ruffilli I, Santini F, Minuto M, Galleri D, Miccoli P. Curr Genomics 12 626-631 (2011)
  343. Oleuropein, the Main Polyphenol of Olea europaea Leaf Extract, Has an Anti-Cancer Effect on Human BRAF Melanoma Cells and Potentiates the Cytotoxicity of Current Chemotherapies. Ruzzolini J, Peppicelli S, Andreucci E, Bianchini F, Scardigli A, Romani A, la Marca G, Nediani C, Calorini L. Nutrients 10 E1950 (2018)
  344. Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors. Wenglowsky S, Ren L, Ahrendt KA, Laird ER, Aliagas I, Alicke B, Buckmelter AJ, Choo EF, Dinkel V, Feng B, Gloor SL, Gould SE, Gross S, Gunzner-Toste J, Hansen JD, Hatzivassiliou G, Liu B, Malesky K, Mathieu S, Newhouse B, Raddatz NJ, Ran Y, Rana S, Randolph N, Risom T, Rudolph J, Savage S, Selby LT, Shrag M, Song K, Sturgis HL, Voegtli WC, Wen Z, Willis BS, Woessner RD, Wu WI, Young WB, Grina J. ACS Med Chem Lett 2 342-347 (2011)
  345. Retinol induces the ERK1/2-dependent phosphorylation of CREB through a pathway involving the generation of reactive oxygen species in cultured Sertoli cells. Gelain DP, Cammarota M, Zanotto-Filho A, de Oliveira RB, Dal-Pizzol F, Izquierdo I, Bevilaqua LR, Moreira JC. Cell Signal 18 1685-1694 (2006)
  346. Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer. Liu Y, Gunda V, Zhu X, Xu X, Wu J, Askhatova D, Farokhzad OC, Parangi S, Shi J. Proc Natl Acad Sci U S A 113 7750-7755 (2016)
  347. BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer. Zerilli M, Zito G, Martorana A, Pitrone M, Cabibi D, Cappello F, Giordano C, Rodolico V. Mod Pathol 23 1052-1060 (2010)
  348. Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor. Nagashima K, Shumway SD, Sathyanarayanan S, Chen AH, Dolinski B, Xu Y, Keilhack H, Nguyen T, Wiznerowicz M, Li L, Lutterbach BA, Chi A, Paweletz C, Allison T, Yan Y, Munshi SK, Klippel A, Kraus M, Bobkova EV, Deshmukh S, Xu Z, Mueller U, Szewczak AA, Pan BS, Richon V, Pollock R, Blume-Jensen P, Northrup A, Andersen JN. J Biol Chem 286 6433-6448 (2011)
  349. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs. Martinho O, Gouveia A, Viana-Pereira M, Silva P, Pimenta A, Reis RM, Lopes JM. Histopathology 55 53-62 (2009)
  350. Panax notoginseng saponins attenuate lung cancer growth in part through modulating the level of Met/miR-222 axis. Yang Q, Wang P, Cui J, Wang W, Chen Y, Zhang T. J Ethnopharmacol 193 255-265 (2016)
  351. Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients. Launay-Vacher V, Zimner-Rapuch S, Poulalhon N, Fraisse T, Garrigue V, Gosselin M, Amet S, Janus N, Deray G. Cancer 120 2158-2163 (2014)
  352. Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias. Tschernitz S, Flossbach L, Bonengel M, Roth S, Rosenwald A, Geissinger E. Br J Haematol 165 529-533 (2014)
  353. BRAF mutations in thyroid tumors from an ethnically diverse group. Schulten HJ, Salama S, Al-Mansouri Z, Alotibi R, Al-Ghamdi K, Al-Hamour OA, Sayadi H, Al-Aradati H, Al-Johari A, Huwait E, Gari M, Al-Qahtani MH, Al-Maghrabi J. Hered Cancer Clin Pract 10 10 (2012)
  354. BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic. Sykorova V, Dvorakova S, Ryska A, Vcelak J, Vaclavikova E, Laco J, Kodetova D, Kodet R, Cibula A, Duskova J, Hlobilkova A, Astl J, Vesely D, Betka J, Hoch J, Smutny S, Cap J, Vlcek P, Novak Z, Bendlova B. J Endocrinol Invest 33 318-324 (2010)
  355. Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways. Gunda V, Bucur O, Varnau J, Vanden Borre P, Bernasconi MJ, Khosravi-Far R, Parangi S. Cell Death Dis 5 e1104 (2014)
  356. PKR and GCN2 stress kinases promote an ER stress-independent eIF2α phosphorylation responsible for calreticulin exposure in melanoma cells. Giglio P, Gagliardi M, Tumino N, Antunes F, Smaili S, Cotella D, Santoro C, Bernardini R, Mattei M, Piacentini M, Corazzari M. Oncoimmunology 7 e1466765 (2018)
  357. Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms. Le P, Kunold E, Macsics R, Rox K, Jennings MC, Ugur I, Reinecke M, Chaves-Moreno D, Hackl MW, Fetzer C, Mandl FAM, Lehmann J, Korotkov VS, Hacker SM, Kuster B, Antes I, Pieper DH, Rohde M, Wuest WM, Medina E, Sieber SA. Nat Chem 12 145-158 (2020)
  358. Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. Moretti S, Macchiarulo A, De Falco V, Avenia N, Barbi F, Carta C, Cavaliere A, Melillo RM, Passeri L, Santeusanio F, Tartaglia M, Santoro M, Puxeddu E. Oncogene 25 4235-4240 (2006)
  359. Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF. Christensen C, Guldberg P. Oncogene 24 6292-6302 (2005)
  360. Oncogenic BRAF-Mediated Melanoma Cell Invasion. Lu H, Liu S, Zhang G, Kwong LN, Zhu Y, Miller JP, Hu Y, Zhong W, Zeng J, Wu L, Krepler C, Sproesser K, Xiao M, Xu W, Karakousis GC, Schuchter LM, Field J, Zhang PJ, Herlyn M, Xu X, Guo W. Cell Rep 15 2012-2024 (2016)
  361. Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states. Lake EW, Muretta JM, Thompson AR, Rasmussen DM, Majumdar A, Faber EB, Ruff EF, Thomas DD, Levinson NM. Proc Natl Acad Sci U S A 115 E11894-E11903 (2018)
  362. RIG1 inhibits the Ras/mitogen-activated protein kinase pathway by suppressing the activation of Ras. Tsai FM, Shyu RY, Jiang SY. Cell Signal 18 349-358 (2006)
  363. p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors. Gallagher SJ, Thompson JF, Indsto J, Scurr LL, Lett M, Gao BF, Dunleavey R, Mann GJ, Kefford RF, Rizos H. Neoplasia 10 1231-1239 (2008)
  364. BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization. Ciampi R, Zhu Z, Nikiforov YE. Endocr Pathol 16 99-105 (2005)
  365. Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis. Kansal R, Quintanilla-Martinez L, Datta V, Lopategui J, Garshfield G, Nathwani BN. Genes Chromosomes Cancer 52 99-106 (2013)
  366. Role of phosphatidic acid in the coupling of the ERK cascade. Kraft CA, Garrido JL, Fluharty E, Leiva-Vega L, Romero G. J Biol Chem 283 36636-36645 (2008)
  367. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. Simbulan-Rosenthal CM, Dakshanamurthy S, Gaur A, Chen YS, Fang HB, Abdussamad M, Zhou H, Zapas J, Calvert V, Petricoin EF, Atkins MB, Byers SW, Rosenthal DS. Oncotarget 8 12576-12595 (2017)
  368. Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry. Ghosh AK, Brindisi M. J Med Chem 63 2751-2788 (2020)
  369. Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Fisher R, Larkin J. Cancer Manag Res 4 243-252 (2012)
  370. Activating mutations in MEK1 enhance homodimerization and promote tumorigenesis. Yuan J, Ng WH, Tian Z, Yap J, Baccarini M, Chen Z, Hu J. Sci Signal 11 eaar6795 (2018)
  371. BRAF mutation in papillary thyroid carcinoma. Li X, Abdel-Mageed AB, Kandil E. Int J Clin Exp Med 5 310-315 (2012)
  372. Chaperone over-expression in Escherichia coli: apparent increased yields of soluble recombinant protein kinases are due mainly to soluble aggregates. Haacke A, Fendrich G, Ramage P, Geiser M. Protein Expr Purif 64 185-193 (2009)
  373. Cyanidin suppresses ultraviolet B-induced COX-2 expression in epidermal cells by targeting MKK4, MEK1, and Raf-1. Kim JE, Kwon JY, Seo SK, Son JE, Jung SK, Min SY, Hwang MK, Heo YS, Lee KW, Lee HJ. Biochem Pharmacol 79 1473-1482 (2010)
  374. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. Guedes JG, Veiga I, Rocha P, Pinto P, Pinto C, Pinheiro M, Peixoto A, Fragoso M, Raimundo A, Ferreira P, Machado M, Sousa N, Lopes P, Araújo A, Macedo J, Alves F, Coutinho C, Henrique R, Santos LL, Teixeira MR, Teixeira MR. BMC Cancer 13 169 (2013)
  375. Inhibitors of BRAF dimers using an allosteric site. Cotto-Rios XM, Agianian B, Gitego N, Zacharioudakis E, Giricz O, Wu Y, Zou Y, Verma A, Poulikakos PI, Gavathiotis E. Nat Commun 11 4370 (2020)
  376. PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events. Agell L, Hernández S, Salido M, de Muga S, Juanpere N, Arumí-Uria M, Menendez S, Lorenzo M, Lorente JA, Serrano S, Lloreta J. Mod Pathol 24 443-452 (2011)
  377. Pathogenic mechanisms of deregulated microRNA expression in thyroid carcinomas of follicular origin. Braun J, Hüttelmaier S. Thyroid Res 4 Suppl 1 S1 (2011)
  378. Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. Backes A, Zech B, Felber B, Klebl B, Müller G. Expert Opin Drug Discov 3 1427-1449 (2008)
  379. Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo. Robinson JP, Robinson JP, Vanbrocklin MW, Lastwika KJ, McKinney AJ, Brandner S, Holmen SL. Oncogene 30 1341-1350 (2011)
  380. BRAF mutations in chronic lymphocytic leukemia. Jebaraj BM, Kienle D, Bühler A, Winkler D, Döhner H, Stilgenbauer S, Zenz T. Leuk Lymphoma 54 1177-1182 (2013)
  381. BRAF mutations in non-small cell lung cancer. Luk PP, Yu B, Ng CC, Mercorella B, Selinger C, Lum T, Kao S, O'Toole SA, Cooper WA. Transl Lung Cancer Res 4 142-148 (2015)
  382. Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity. Adelmann CH, Ching G, Du L, Saporito RC, Bansal V, Pence LJ, Liang R, Lee W, Tsai KY. Oncotarget 7 30453-30460 (2016)
  383. Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas. Shelly S, Chien MB, Yip B, Kent MS, Theon AP, McCallan JL, London CA. Mamm Genome 16 211-217 (2005)
  384. Identification of Raf-1 S471 as a novel phosphorylation site critical for Raf-1 and B-Raf kinase activities and for MEK binding. Zhu J, Balan V, Bronisz A, Balan K, Sun H, Leicht DT, Luo Z, Qin J, Avruch J, Tzivion G. Mol Biol Cell 16 4733-4744 (2005)
  385. MAPK signaling determines anxiety in the juvenile mouse brain but depression-like behavior in adults. Wefers B, Hitz C, Hölter SM, Trümbach D, Hansen J, Weber P, Pütz B, Deussing JM, de Angelis MH, Roenneberg T, Zheng F, Alzheimer C, Silva A, Wurst W, Kühn R. PLoS One 7 e35035 (2012)
  386. Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands. Tetsu O, Phuchareon J, Chou A, Cox DP, Eisele DW, Jordan RC. Neoplasia 12 708-717 (2010)
  387. PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways. Naidu S, Shi L, Magee P, Middleton JD, Laganá A, Sahoo S, Leong HS, Galvin M, Frese K, Dive C, Guzzardo V, Fassan M, Garofalo M. Sci Rep 7 15441 (2017)
  388. Phosphorylation of Mps1 by BRAFV600E prevents Mps1 degradation and contributes to chromosome instability in melanoma. Liu J, Cheng X, Zhang Y, Li S, Cui H, Zhang L, Shi R, Zhao Z, He C, Wang C, Zhao H, Zhang C, Fisk HA, Guadagno TM, Cui Y. Oncogene 32 713-723 (2013)
  389. Selfish mutations dysregulating RAS-MAPK signaling are pervasive in aged human testes. Maher GJ, Ralph HK, Ding Z, Koelling N, Mlcochova H, Giannoulatou E, Dhami P, Paul DS, Stricker SH, Beck S, McVean G, Wilkie AOM, Goriely A. Genome Res 28 1779-1790 (2018)
  390. Squamoproliferative lesions arising in the setting of BRAF inhibition. Harvey NT, Millward M, Wood BA. Am J Dermatopathol 34 822-826 (2012)
  391. The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose. Takahashi K, Eguchi H, Arihiro K, Ito R, Koyama K, Soda M, Cologne J, Hayashi Y, Nakata Y, Nakachi K, Hamatani K. Mol Carcinog 46 242-248 (2007)
  392. Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). Johnson DB, Zhao F, Noel M, Riely GJ, Mitchell EP, Wright JJ, Chen HX, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Clin Cancer Res 26 1812-1819 (2020)
  393. Comment Where does the combination of sorafenib and interferon in renal cell carcinoma stand? Flaherty KT. Cancer 116 4-7 (2010)
  394. Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatment. Anvekar RA, Asciolla JJ, Missert DJ, Chipuk JE. Front Oncol 1 fonc.2011.00034 (2011)
  395. Letter Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations. Jovanovic B, Egyhazi S, Eskandarpour M, Ghiorzo P, Palmer JM, Bianchi Scarrà G, Hayward NK, Hansson J. J Invest Dermatol 130 618-620 (2010)
  396. Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. Kordes M, Röring M, Heining C, Braun S, Hutter B, Richter D, Geörg C, Scholl C, Gröschel S, Roth W, Rosenwald A, Geissinger E, von Kalle C, Jäger D, Brors B, Weichert W, Grüllich C, Glimm H, Brummer T, Fröhling S. Leukemia 30 937-946 (2016)
  397. Genetics of papillary thyroid cancer initiation: implications for therapy. Fagin JA. Trans Am Clin Climatol Assoc 116 259-69; discussion 269-71 (2005)
  398. Positive regulation of A-RAF by phosphorylation of isoform-specific hinge segment and identification of novel phosphorylation sites. Baljuls A, Schmitz W, Mueller T, Zahedi RP, Sickmann A, Hekman M, Rapp UR. J Biol Chem 283 27239-27254 (2008)
  399. The normalization of gene expression data in melanoma: investigating the use of glyceraldehyde 3-phosphate dehydrogenase and 18S ribosomal RNA as internal reference genes for quantitative real-time PCR. Giricz O, Lauer-Fields JL, Fields GB. Anal Biochem 380 137-139 (2008)
  400. Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by β-catenin activity. Riemer P, Sreekumar A, Reinke S, Rad R, Schäfer R, Sers C, Bläker H, Herrmann BG, Morkel M. Oncogene 34 3164-3175 (2015)
  401. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma. Sasaki H, Shimizu S, Tani Y, Shitara M, Okuda K, Hikosaka Y, Moriyama S, Yano M, Fujii Y. Lung Cancer 82 51-54 (2013)
  402. Viral oncolysis that targets Raf-1 signaling control of nuclear transport. Riolobos L, Valle N, Hernando E, Maroto B, Kann M, Almendral JM. J Virol 84 2090-2099 (2010)
  403. Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing. Lokhandwala PM, Tseng LH, Rodriguez E, Zheng G, Pallavajjalla A, Gocke CD, Eshleman JR, Lin MT. BMC Cancer 19 665 (2019)
  404. Case Reports Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma. Matsumura N, Nakajima N, Yamazaki T, Nagano T, Kagoshima K, Nobusawa S, Ikota H, Yokoo H. Neuropathology 37 58-63 (2017)
  405. Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants. Wu X, Yin J, Simpson J, Kim KH, Gu S, Hong JH, Bayliss P, Backx PH, Neel BG, Araki T. Mol Cell Biol 32 3872-3890 (2012)
  406. Interleukin 6 mediates production of interleukin 10 in metastatic melanoma. Terai M, Eto M, Young GD, Berd D, Mastrangelo MJ, Tamura Y, Harigaya K, Sato T. Cancer Immunol Immunother 61 145-155 (2012)
  407. Ring finger protein 149 is an E3 ubiquitin ligase active on wild-type v-Raf murine sarcoma viral oncogene homolog B1 (BRAF). Hong SW, Jin DH, Shin JS, Moon JH, Na YS, Jung KA, Kim SM, Kim JC, Kim KP, Hong YS, Lee JL, Choi EK, Lee JS, Kim TW. J Biol Chem 287 24017-24025 (2012)
  408. Somatic mutations in histiocytic sarcoma identified by next generation sequencing. Liu Q, Tomaszewicz K, Hutchinson L, Hornick JL, Woda B, Yu H. Virchows Arch 469 233-241 (2016)
  409. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Genet Med 24 986-998 (2022)
  410. The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants. Yuan J, Ng WH, Lam PYP, Wang Y, Xia H, Yap J, Guan SP, Lee ASG, Wang M, Baccarini M, Hu J. Oncogene 37 5719-5734 (2018)
  411. Affinity reagents that target a specific inactive form of protein kinases. Ranjitkar P, Brock AM, Maly DJ. Chem Biol 17 195-206 (2010)
  412. Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: a cytohistologic institutional experience. Rossi ED, Martini M, Capodimonti S, Cenci T, Cenci T, Straccia P, Angrisani B, Ricci C, Lanza P, Lombardi CP, Pontecorvi A, Larocca LM, Fadda G. Cancer Cytopathol 122 527-535 (2014)
  413. Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms. Hmitou I, Druillennec S, Valluet A, Peyssonnaux C, Eychène A. Mol Cell Biol 27 31-43 (2007)
  414. Genome-wide analysis of miRNA signature differentially expressed in doxorubicin-resistant and parental human hepatocellular carcinoma cell lines. Zhang J, Wang Y, Zhen P, Luo X, Zhang C, Zhou L, Lu Y, Yang Y, Zhang W, Wan J. PLoS One 8 e54111 (2013)
  415. KIAA1549:BRAF fusion gene in pediatric brain tumors of various histogenesis. Antonelli M, Badiali M, Moi L, Buttarelli FR, Baldi C, Massimino M, Sanson M, Giangaspero F. Pediatr Blood Cancer 62 724-727 (2015)
  416. ORF66 protein kinase function is required for T-cell tropism of varicella-zoster virus in vivo. Schaap-Nutt A, Sommer M, Che X, Zerboni L, Arvin AM. J Virol 80 11806-11816 (2006)
  417. RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancer. Lee SE, Lee JU, Lee MH, Ryu MJ, Kim SJ, Kim YK, Choi MJ, Kim KS, Kim JM, Kim JW, Koh YW, Lim DS, Jo YS, Shong M. Oncogenesis 2 e55 (2013)
  418. RAF1/BRAF dimerization integrates the signal from RAS to ERK and ROKα. Varga A, Varga A, Ehrenreiter K, Aschenbrenner B, Kocieniewski P, Kochanczyk M, Lipniacki T, Baccarini M. Sci Signal 10 eaai8482 (2017)
  419. Targeting oncogenic BRAF in human cancer. Pratilas CA, Xing F, Solit DB. Curr Top Microbiol Immunol 355 83-98 (2012)
  420. The raf inhibitor paradox: unexpected consequences of targeted drugs. Cox AD, Der CJ. Cancer Cell 17 221-223 (2010)
  421. Letter Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients. Hofman V, Ilie M, Long-Mira E, Giacchero D, Butori C, Dadone B, Selva E, Tanga V, Passeron T, Poissonnet G, Emile JF, Lacour JP, Bahadoran P, Hofman P. J Invest Dermatol 133 1378-1381 (2013)
  422. Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification. Gierke M, Sperveslage J, Schwab D, Beschorner R, Ebinger M, Schuhmann MU, Schittenhelm J. J Cancer Res Clin Oncol 142 89-100 (2016)
  423. Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma. Sabbatino F, Wang Y, Scognamiglio G, Favoino E, Feldman SA, Villani V, Flaherty KT, Nota S, Giannarelli D, Simeone E, Anniciello AM, Palmieri G, Pepe S, Botti G, Ascierto PA, Ferrone CR, Ferrone S. J Natl Cancer Inst 108 (2016)
  424. Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Santarpia L, Sherman SI, Marabotti A, Clayman GL, El-Naggar AK. Hum Pathol 40 827-833 (2009)
  425. Distinct phenotypic changes between the superficial and deep component of giant congenital melanocytic naevi: a rationale for curettage. De Raeve LE, Claes A, Ruiter DJ, van Muijen GN, Roseeuw D, van Kempen LC. Br J Dermatol 154 485-492 (2006)
  426. Hypoxia-regulated gene network in drug resistance and cancer progression. Lin SC, Liao WL, Lee JC, Tsai SJ. Exp Biol Med (Maywood) 239 779-792 (2014)
  427. Identification of BRAF inhibitors through in silico screening. Luo C, Xie P, Marmorstein R. J Med Chem 51 6121-6127 (2008)
  428. Implication of RAF and RKIP genes in urinary bladder cancer. Zaravinos A, Chatziioannou M, Lambrou GI, Boulalas I, Delakas D, Spandidos DA. Pathol Oncol Res 17 181-190 (2011)
  429. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. Frankel TL, Vakiani E, Nathan H, DeMatteo RP, Kingham TP, Allen PJ, Jarnagin WR, Kemeny NE, Solit DB, D'Angelica MI. Cancer 123 568-575 (2017)
  430. Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. Giménez N, Martínez-Trillos A, Montraveta A, Lopez-Guerra M, Rosich L, Nadeu F, Valero JG, Aymerich M, Magnano L, Rozman M, Matutes E, Delgado J, Baumann T, Gine E, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer AR, Puente XS, López-Otín C, Lopez-Guillermo A, Campo E, Colomer D, Villamor N. Haematologica 104 576-586 (2019)
  431. Rap1 signaling prevents L-type calcium channel-dependent neurotransmitter release. Subramanian J, Dye L, Morozov A. J Neurosci 33 7245-7252 (2013)
  432. Single substitution within the RKTR motif impairs kinase activity but promotes dimerization of RAF kinase. Baljuls A, Mahr R, Schwarzenau I, Müller T, Polzien L, Hekman M, Rapp UR. J Biol Chem 286 16491-16503 (2011)
  433. Specifically targeting ERK1 or ERK2 kills melanoma cells. Qin J, Xin H, Nickoloff BJ. J Transl Med 10 15 (2012)
  434. The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer. Xing M. Clin Endocrinol (Oxf) 63 263-266 (2005)
  435. Transforming growth factor-β-stimulated clone-22 is a negative-feedback regulator of Ras / Raf signaling: Implications for tumorigenesis. Nakamura M, Kitaura J, Enomoto Y, Lu Y, Nishimura K, Isobe M, Ozaki K, Komeno Y, Nakahara F, Oki T, Kume H, Homma Y, Kitamura T. Cancer Sci 103 26-33 (2012)
  436. BRAF mutation detection and identification by cycling temperature capillary electrophoresis. Hinselwood DC, Abrahamsen TW, Ekstrøm PO. Electrophoresis 26 2553-2561 (2005)
  437. Bi-directional SIFT predicts a subset of activating mutations. Lee W, Zhang Y, Mukhyala K, Lazarus RA, Zhang Z. PLoS One 4 e8311 (2009)
  438. Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma. Bianchi G, Ghobrial IM. Curr Cancer Ther Rev 10 70-79 (2014)
  439. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. Rankin A, Klempner SJ, Erlich R, Sun JX, Grothey A, Fakih M, George TJ, Lee J, Ross JS, Stephens PJ, Miller VA, Ali SM, Schrock AB. Oncologist 21 1306-1314 (2016)
  440. C-RAF mutations confer resistance to RAF inhibitors. Antony R, Emery CM, Sawyer AM, Garraway LA. Cancer Res 73 4840-4851 (2013)
  441. C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Jilaveanu LB, Zito CR, Aziz SA, Conrad PJ, Schmitz JC, Sznol M, Camp RL, Rimm DL, Kluger HM. Clin Cancer Res 15 5704-5713 (2009)
  442. Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations. Peng S, Sen B, Mazumdar T, Byers LA, Diao L, Wang J, Tong P, Giri U, Heymach JV, Kadara HN, Johnson FM. Oncotarget 7 565-579 (2016)
  443. Differential selection for B-raf and Ha-ras mutated liver tumors in mice with high and low susceptibility to hepatocarcinogenesis. Buchmann A, Karcier Z, Schmid B, Strathmann J, Schwarz M. Mutat Res 638 66-74 (2008)
  444. FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors. Nguyen B, Williams AB, Young DJ, Ma H, Li L, Levis M, Brown P, Small D. Oncotarget 8 10931-10944 (2017)
  445. Genomics and the second golden era of cancer drug development. Workman P. Mol Biosyst 1 17-26 (2005)
  446. Monitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases. Uhrig M, Sedlmair M, Schlemmer HP, Hassel JC, Ganten M. Cancer Imaging 13 306-313 (2013)
  447. RAC1b overexpression in papillary thyroid carcinoma: a role to unravel. Silva AL, Carmo F, Bugalho MJ. Eur J Endocrinol 168 795-804 (2013)
  448. Raf and PI3K are the molecular targets for the anti-metastatic effect of luteolin. Kim HY, Jung SK, Byun S, Son JE, Oh MH, Lee J, Kang MJ, Heo YS, Lee KW, Lee HJ. Phytother Res 27 1481-1488 (2013)
  449. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. Kim HS, Heo JS, Lee J, Lee JY, Lee MY, Lim SH, Lee WY, Kim SH, Park YA, Cho YB, Yun SH, Kim ST, Park JO, Lim HY, Choi YS, Kwon WI, Kim HC, Park YS. BMC Cancer 16 120 (2016)
  450. Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. Spangler JB, Manzari MT, Rosalia EK, Chen TF, Wittrup KD. J Mol Biol 422 532-544 (2012)
  451. Unique N-region determines low basal activity and limited inducibility of A-RAF kinase: the role of N-region in the evolutionary divergence of RAF kinase function in vertebrates. Baljuls A, Mueller T, Drexler HC, Hekman M, Rapp UR. J Biol Chem 282 26575-26590 (2007)
  452. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, Broaddus RR, Williams MD, Davies MA, Routbort MJ, Lazar AJ, Woodman SE, Hwu WJ, Gershenwald JE, Prieto VG, Torres-Cabala CA, Curry JL. Hum Pathol 46 1101-1110 (2015)
  453. Virtual screening and optimization of Type II inhibitors of JAK2 from a natural product library. Ma DL, Chan DS, Wei G, Zhong HJ, Yang H, Leung LT, Gullen EA, Chiu P, Cheng YC, Leung CH. Chem Commun (Camb) 50 13885-13888 (2014)
  454. A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. Barouch-Bentov R, Che J, Lee CC, Yang Y, Herman A, Jia Y, Velentza A, Watson J, Sternberg L, Kim S, Ziaee N, Miller A, Jackson C, Fujimoto M, Young M, Batalov S, Liu Y, Warmuth M, Wiltshire T, Cooke MP, Sauer K. Mol Cell 33 43-52 (2009)
  455. BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS. Zhang L, Singh RR, Patel KP, Stingo F, Routbort M, You MJ, Miranda RN, Garcia-Manero G, Kantarjian HM, Medeiros LJ, Luthra R, Khoury JD. Am J Hematol 89 499-504 (2014)
  456. Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA. Cancer 123 1372-1381 (2017)
  457. Clinicopathological features of rare BRAF mutations in Korean thyroid cancer patients. Cho U, Oh WJ, Bae JS, Bae JS, Lee S, Lee YS, Park GS, Lee YS, Jung CK. J Korean Med Sci 29 1054-1060 (2014)
  458. Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer. Lee JU, Huang S, Lee MH, Lee SE, Ryu MJ, Kim SJ, Kim YK, Kim SY, Joung KH, Kim JM, Shong M, Jo YS. Eur J Endocrinol 167 93-101 (2012)
  459. Effects of altered expression and activity levels of CK1δ and ɛ on tumor growth and survival of colorectal cancer patients. Richter J, Ullah K, Xu P, Alscher V, Blatz A, Peifer C, Halekotte J, Leban J, Vitt D, Holzmann K, Bakulev V, Pinna LA, Henne-Bruns D, Hillenbrand A, Kornmann M, Leithäuser F, Bischof J, Knippschild U. Int J Cancer 136 2799-2810 (2015)
  460. Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib. Doudican NA, Orlow SJ. Oncogene 36 423-428 (2017)
  461. Oncogenic potential is related to activating effect of cancer single and double somatic mutations in receptor tyrosine kinases. Hashimoto K, Rogozin IB, Panchenko AR. Hum Mutat 33 1566-1575 (2012)
  462. Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships. Wenglowsky S, Ahrendt KA, Buckmelter AJ, Feng B, Gloor SL, Gradl S, Grina J, Hansen JD, Laird ER, Lunghofer P, Mathieu S, Moreno D, Newhouse B, Ren L, Risom T, Rudolph J, Seo J, Sturgis HL, Voegtli WC, Wen Z. Bioorg Med Chem Lett 21 5533-5537 (2011)
  463. Significance of allelic percentage of BRAF c.1799T > A (V600E) mutation in papillary thyroid carcinoma. Cheng SP, Hsu YC, Liu CL, Liu TP, Chien MN, Wang TY, Lee JJ. Ann Surg Oncol 21 Suppl 4 S619-26 (2014)
  464. Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Halling T, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA, Kumar S. Am J Hematol 87 277-283 (2012)
  465. Sprouty2 association with B-Raf is regulated by phosphorylation and kinase conformation. Brady SC, Coleman ML, Munro J, Feller SM, Morrice NA, Olson MF. Cancer Res 69 6773-6781 (2009)
  466. Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl. Yang LJ, Zou J, Xie HZ, Li LL, Wei YQ, Yang SY. PLoS One 4 e8470 (2009)
  467. The structure of the MAP2K MEK6 reveals an autoinhibitory dimer. Min X, Akella R, He H, Humphreys JM, Tsutakawa SE, Lee SJ, Tainer JA, Cobb MH, Goldsmith EJ. Structure 17 96-104 (2009)
  468. Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer. Noeparast A, Giron P, De Brakeleer S, Eggermont C, De Ridder U, Teugels E, De Grève J. Oncotarget 9 16110-16123 (2018)
  469. A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology. Hatae R, Hata N, Suzuki SO, Yoshimoto K, Kuga D, Murata H, Akagi Y, Sangatsuda Y, Iwaki T, Mizoguchi M, Iihara K. Neuropathology 37 191-199 (2017)
  470. A theoretical entropy score as a single value to express inhibitor selectivity. Uitdehaag JC, Zaman GJ. BMC Bioinformatics 12 94 (2011)
  471. Activation loop phosphorylation regulates B-Raf in vivo and transformation by B-Raf mutants. Köhler M, Röring M, Schorch B, Heilmann K, Stickel N, Fiala GJ, Schmitt LC, Braun S, Ehrenfeld S, Uhl FM, Kaltenbacher T, Weinberg F, Herzog S, Zeiser R, Schamel WW, Jumaa H, Brummer T. EMBO J 35 143-161 (2016)
  472. BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association. Vido MJ, Le K, Hartsough EJ, Aplin AE. Cell Rep 25 1501-1510.e3 (2018)
  473. BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells. Atay C, Kwak T, Lavilla-Alonso S, Donthireddy L, Richards A, Moberg V, Pilon-Thomas S, Schell M, Messina JL, Rebecca VW, Xiao M, Tan J, Zhang G, Weber JS, Herlyn M, Sarnaik AA, Gabrilovich DI. Clin Cancer Res 25 2783-2794 (2019)
  474. Classifying kinase conformations using a machine learning approach. McSkimming DI, Rasheed K, Kannan N. BMC Bioinformatics 18 86 (2017)
  475. Clinical mutational profiling of 1006 lung cancers by next generation sequencing. Illei PB, Belchis D, Tseng LH, Nguyen D, De Marchi F, Haley L, Riel S, Beierl K, Zheng G, Brahmer JR, Askin FB, Gocke CD, Eshleman JR, Forde PM, Lin MT. Oncotarget 8 96684-96696 (2017)
  476. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma. Safaee Ardekani G, Jafarnejad SM, Khosravi S, Martinka M, Ho V, Li G. Br J Dermatol 169 320-328 (2013)
  477. Effects of Copper Chelation on BRAFV600E Positive Colon Carcinoma Cells. Baldari S, Di Rocco G, Heffern MC, Su TA, Chang CJ, Toietta G. Cancers (Basel) 11 E659 (2019)
  478. Genetic variation associated with condensate dysregulation in disease. Banani SF, Afeyan LK, Hawken SW, Henninger JE, Dall'Agnese A, Clark VE, Platt JM, Oksuz O, Hannett NM, Sagi I, Lee TI, Young RA. Dev Cell 57 1776-1788.e8 (2022)
  479. IMP modulates KSR1-dependent multivalent complex formation to specify ERK1/2 pathway activation and response thresholds. Chen C, Lewis RE, White MA. J Biol Chem 283 12789-12796 (2008)
  480. Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. Alfano RW, Leppla SH, Liu S, Bugge TH, Ortiz JM, Lairmore TC, Duesbery NS, Duesbery NS, Mitchell IC, Nwariaku F, Frankel AE. Mol Cancer Ther 9 190-201 (2010)
  481. Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives. Fukuyo Y, Inoue M, Nakajima T, Higashikubo R, Horikoshi NT, Hunt C, Usheva A, Freeman ML, Horikoshi N. Cancer Res 68 6324-6330 (2008)
  482. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. Preto A, Gonçalves J, Rebocho AP, Figueiredo J, Meireles AM, Rocha AS, Vasconcelos HM, Seca H, Seruca R, Soares P, Sobrinho-Simões M. BMC Cancer 9 387 (2009)
  483. Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD). Bentivegna S, Zheng J, Namsaraev E, Carlton VE, Pavlicek A, Moorhead M, Siddiqui F, Wang Z, Lee L, Ireland JS, Suyenaga K, Willis TD, Faham M, Seymour AB. Hum Mutat 29 441-450 (2008)
  484. The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients. Lin Q, Zhang H, Ding H, Qian J, Lizaso A, Lin J, Han-Zhang H, Xiang J, Li Y, Zhu H. J Transl Med 17 298 (2019)
  485. ADAMTS13 and its variants promote angiogenesis via upregulation of VEGF and VEGFR2. Lee M, Keener J, Xiao J, Long Zheng X, Rodgers GM. Cell Mol Life Sci 72 349-356 (2015)
  486. Autonomous and Non-autonomous Defects Underlie Hypertrophic Cardiomyopathy in BRAF-Mutant hiPSC-Derived Cardiomyocytes. Josowitz R, Mulero-Navarro S, Rodriguez NA, Falce C, Cohen N, Ullian EM, Weiss LA, Rauen KA, Sobie EA, Gelb BD. Stem Cell Reports 7 355-369 (2016)
  487. BRAF inhibitors in clinical oncology. Morris V, Kopetz S. F1000Prime Rep 5 11 (2013)
  488. Contributions of water transfer energy to protein-ligand association and dissociation barriers: Watermap analysis of a series of p38α MAP kinase inhibitors. Pearlstein RA, Sherman W, Abel R. Proteins 81 1509-1526 (2013)
  489. Driver gene mutations of non-small-cell lung cancer are rare in primary carcinoids of the lung: NGS study by ion Torrent. Armengol G, Sarhadi VK, Rönty M, Tikkanen M, Knuuttila A, Knuutila S. Lung 193 303-308 (2015)
  490. Low frequency of BRAF mutations in adult patients with papillary thyroid cancers following childhood radiation exposure. Collins BJ, Schneider AB, Prinz RA, Xu X. Thyroid 16 61-66 (2006)
  491. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. Gautschi O, Peters S, Zoete V, Aebersold-Keller F, Strobel K, Schwizer B, Hirschmann A, Michielin O, Diebold J. Lung Cancer 82 365-367 (2013)
  492. MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor. Caenepeel S, Cooke K, Wadsworth S, Huang G, Robert L, Moreno BH, Parisi G, Cajulis E, Kendall R, Beltran P, Ribas A, Coxon A, Hughes PE. Oncotarget 8 17795-17809 (2017)
  493. Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia. Kim YH, Kim MJ, Choe SW, Sprecher D, Lee YJ, P Oh S. J Thromb Haemost 15 1095-1102 (2017)
  494. Letter Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia. Zhang X, Reis M, Khoriaty R, Li Y, Ouillette P, Samayoa J, Carter H, Karchin R, Li M, Diaz LA, Velculescu VE, Papadopoulos N, Kinzler KW, Vogelstein B, Malek SN. Leukemia 25 1908-1910 (2011)
  495. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. Won DD, Lee JI, Lee IK, Oh ST, Jung ES, Lee SH. BMC Cancer 17 403 (2017)
  496. A structural biology view of target drugability. Egner U, Hillig RC. Expert Opin Drug Discov 3 391-401 (2008)
  497. Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion. Serrano-Oviedo L, Ortega-Muelas M, García-Cano J, Valero ML, Cimas FJ, Pascual-Serra R, Fernandez-Aroca DM, Roche O, Ruiz-Hidalgo MJ, Belandia B, Giménez-Bachs JM, Salinas AS, Sanchez-Prieto R. PLoS One 13 e0200878 (2018)
  498. B-Raf autoinhibition in the presence and absence of 14-3-3. Zhang M, Jang H, Li Z, Sacks DB, Nussinov R. Structure 29 768-777.e2 (2021)
  499. BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS. Röck R, Mayrhofer JE, Torres-Quesada O, Enzler F, Raffeiner A, Raffeiner P, Feichtner A, Huber RG, Koide S, Taylor SS, Troppmair J, Stefan E. Sci Adv 5 eaav8463 (2019)
  500. Cooperation between Noncanonical Ras Network Mutations. Stites EC, Trampont PC, Haney LB, Walk SF, Ravichandran KS. Cell Rep 10 307-316 (2015)
  501. Genetic mutations in human rectal cancers detected by targeted sequencing. Bai J, Gao J, Mao Z, Wang J, Li J, Li W, Lei Y, Li S, Wu Z, Tang C, Jones L, Ye H, Lou F, Liu Z, Dong Z, Guo B, Huang XF, Chen SY, Zhang E. J Hum Genet 60 589-596 (2015)
  502. Mechanisms of aneuploidy induction by RAS and RAF oncogenes. Kamata T, Pritchard C. Am J Cancer Res 1 955-971 (2011)
  503. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits. Hao J, Fan W, Li Y, Tang R, Tian C, Yang Q, Zhu T, Diao C, Hu S, Chen M, Guo P, Long Q, Zhang C, Qin G, Yu W, Chen M, Li L, Qin L, Wang J, Zhang X, Ren Y, Zhou P, Zou L, Jiang K, Guo W, Deng W. J Exp Clin Cancer Res 38 48 (2019)
  504. Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations. Wetterskog D, Wilkerson PM, Rodrigues DN, Lambros MB, Fritchie K, Andersson MK, Natrajan R, Gauthier A, Di Palma S, Shousha S, Gatalica Z, Töpfer C, Vukovic V, A'Hern R, Weigelt B, Vincent-Salomon A, Stenman G, Rubin BP, Reis-Filho JS. Histopathology 62 543-550 (2013)
  505. Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database. Owsley J, Stein MK, Porter J, In GK, Salem M, O'Day S, Elliott A, Poorman K, Gibney G, VanderWalde A. Exp Biol Med (Maywood) 246 31-39 (2021)
  506. ProtCID: a data resource for structural information on protein interactions. Xu Q, Dunbrack RL. Nat Commun 11 711 (2020)
  507. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform. Bisschop C, Ter Elst A, Bosman LJ, Platteel I, Jalving M, van den Berg A, Diepstra A, van Hemel B, Diercks GFH, Hospers GAP, Schuuring E. Melanoma Res 28 96-104 (2018)
  508. Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways. Rosenberg L, Yoon CH, Sharma G, Bertagnolli MM, Cho NL. Carcinogenesis 39 681-688 (2018)
  509. The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways. Barollo S, Bertazza L, Baldini E, Ulisse S, Cavedon E, Boscaro M, Pezzani R, Mian C. Invest New Drugs 32 626-635 (2014)
  510. The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells. Wada M, Horinaka M, Yamazaki T, Katoh N, Sakai T. PLoS One 9 e113217 (2014)
  511. The role of molecular pathology in non-small-cell lung carcinoma-now and in the future. Brandao GD, Brega EF, Spatz A. Curr Oncol 19 S24-32 (2012)
  512. VEGFR-2 inhibitors and apoptosis inducers: synthesis and molecular design of new benzo[g]quinazolin bearing benzenesulfonamide moiety. Ghorab MM, Alsaid MS, Soliman AM, Ragab FA. J Enzyme Inhib Med Chem 32 893-907 (2017)
  513. Ablation of BRaf impairs neuronal differentiation in the postnatal hippocampus and cerebellum. Pfeiffer V, Götz R, Xiang C, Camarero G, Braun A, Zhang Y, Blum R, Heinsen H, Nieswandt B, Rapp UR. PLoS One 8 e58259 (2013)
  514. An Update on the Biology of RAS/RAF Mutations in Colorectal Cancer. Nandan MO, Yang VW. Curr Colorectal Cancer Rep 7 113-120 (2011)
  515. Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. Micel LN, Tentler JJ, Tan AC, Selby HM, Brunkow KL, Robertson KM, Davis SL, Klauck PJ, Pitts TM, Gangolli E, Fabrey R, O'Connell SM, Vincent PW, Eckhardt SG. Mol Cancer Ther 14 317-325 (2015)
  516. Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome. Champion KJ, Bunag C, Estep AL, Jones JR, Bolt CH, Rogers RC, Rauen KA, Everman DB. Clin Genet 79 468-474 (2011)
  517. Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM. Rohrbeck L, Gong JN, Lee EF, Kueh AJ, Behren A, Tai L, Lessene G, Huang DC, Fairlie WD, Strasser A, Herold MJ. Cell Death Differ 23 2054-2062 (2016)
  518. Kinase domain dimerization drives RIPK3-dependent necroptosis. Raju S, Whalen DM, Mengistu M, Swanson C, Quinn JG, Taylor SS, Webster JD, Newton K, Shaw AS. Sci Signal 11 eaar2188 (2018)
  519. Molecular changes during arsenic-induced cell transformation. Li G, Lee LS, Li M, Tsao SW, Chiu JF. J Cell Physiol 226 3225-3232 (2011)
  520. Mutation profiling of cancer drivers in Brazilian colorectal cancer. Dos Santos W, Sobanski T, de Carvalho AC, Evangelista AF, Matsushita M, Berardinelli GN, de Oliveira MA, Reis RM, Guimarães DP. Sci Rep 9 13687 (2019)
  521. Recent advances in personalized lung cancer medicine. Okimoto RA, Bivona TG. Per Med 11 309-321 (2014)
  522. Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. Chen KF, Tai WT, Huang JW, Hsu CY, Chen WL, Cheng AL, Chen PJ, Shiau CW. Eur J Med Chem 46 2845-2851 (2011)
  523. Targeting CDC7 sensitizes resistance melanoma cells to BRAFV600E-specific inhibitor by blocking the CDC7/MCM2-7 pathway. Gad SA, Ali HEA, Gaballa R, Abdelsalam RM, Zerfaoui M, Ali HI, Salama SH, Kenawy SA, Kandil E, Abd Elmageed ZY. Sci Rep 9 14197 (2019)
  524. Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma. Yuan L, Mishra R, Patel H, Abdulsalam S, Greis KD, Kadekaro AL, Merino EJ, Garrett JT. J Cancer 9 4665-4676 (2018)
  525. A framework to find the logic backbone of a biological network. Maheshwari P, Albert R. BMC Syst Biol 11 122 (2017)
  526. A novel spheroid-based co-culture model mimics loss of keratinocyte differentiation, melanoma cell invasion, and drug-induced selection of ABCB5-expressing cells. Klicks J, Maßlo C, Kluth A, Rudolf R, Hafner M. BMC Cancer 19 402 (2019)
  527. BRAF V600E Mutations Occur in a Subset of Glomus Tumors, and Are Associated With Malignant Histologic Characteristics. Karamzadeh Dashti N, Bahrami A, Lee SJ, Jenkins SM, Rodriguez FJ, Folpe AL, Boland JM. Am J Surg Pathol 41 1532-1541 (2017)
  528. Caenorhabditis elegans CNK-1 promotes Raf activation but is not essential for Ras/Raf signaling. Rocheleau CE, Rönnlund A, Tuck S, Sundaram MV. Proc Natl Acad Sci U S A 102 11757-11762 (2005)
  529. Complexity in KSR function revealed by Raf inhibitor and KSR structure studies. McKay MM, Freeman AK, Morrison DK. Small GTPases 2 276-281 (2011)
  530. Deriving a mutation index of carcinogenicity using protein structure and protein interfaces. Espinosa O, Mitsopoulos K, Hakas J, Pearl F, Zvelebil M. PLoS One 9 e84598 (2014)
  531. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Kotani H, Adachi Y, Kitai H, Tomida S, Bando H, Faber AC, Yoshino T, Voon DC, Yano S, Ebi H. Oncogene 37 1775-1787 (2018)
  532. Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Seip K, Fleten KG, Barkovskaya A, Nygaard V, Haugen MH, Engesæter BØ, Mælandsmo GM, Prasmickaite L. Oncotarget 7 19997-20015 (2016)
  533. Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma. De Falco V, Giannini R, Tamburrino A, Ugolini C, Lupi C, Puxeddu E, Santoro M, Basolo F. J Clin Endocrinol Metab 93 4398-4402 (2008)
  534. Genetics of melanoma. Wangari-Talbot J, Chen S. Front Genet 3 330 (2012)
  535. In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures. Verkhivker GM. Biopolymers 85 333-348 (2007)
  536. Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles. Eisenhardt AE, Sprenger A, Röring M, Herr R, Weinberg F, Köhler M, Braun S, Orth J, Diedrich B, Lanner U, Tscherwinski N, Schuster S, Dumaz N, Schmidt E, Baumeister R, Schlosser A, Dengjel J, Brummer T. Oncotarget 7 26628-26652 (2016)
  537. Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation. Virzì AR, Gentile A, Benvenuti S, Comoglio PM. Proc Natl Acad Sci U S A 115 10058-10063 (2018)
  538. Synthesis of pyrrolo[2,3-d]pyrimidine derivatives and their antiproliferative activity against melanoma cell line. Jung MH, Kim H, Choi WK, El-Gamal MI, Park JH, Yoo KH, Sim TB, Lee SH, Baek D, Hah JM, Cho JH, Oh CH. Bioorg Med Chem Lett 19 6538-6543 (2009)
  539. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. Patrawala S, Puzanov I. Future Oncol 8 509-523 (2012)
  540. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Dela Cruz FS, Diolaiti D, Turk AT, Rainey AR, Ambesi-Impiombato A, Andrews SJ, Mansukhani MM, Nagy PL, Alvarez MJ, Califano A, Forouhar F, Modzelewski B, Mitchell CM, Yamashiro DJ, Marks LJ, Glade Bender JL, Kung AL. Genome Med 8 116 (2016)
  541. BRAF mutation analysis in thyroid nodules with indeterminate cytology: our experience on surgical management of patients with thyroid nodules from an area of borderline iodine deficiency. Agretti P, Niccolai F, Rago T, De Marco G, Molinaro A, Scutari M, Di Cosmo C, Di Coscio G, Vitale M, Maccheroni M, Vitti P, Tonacchera M. J Endocrinol Invest 37 1009-1014 (2014)
  542. Calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylates Raf-1 at serine 338 and mediates Ras-stimulated Raf-1 activation. Salzano M, Rusciano MR, Russo E, Bifulco M, Postiglione L, Vitale M. Cell Cycle 11 2100-2106 (2012)
  543. Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2. Schmidt SH, Weng JH, Aoto PC, Boassa D, Mathea S, Silletti S, Hu J, Wallbott M, Komives EA, Knapp S, Herberg FW, Taylor SS. Proc Natl Acad Sci U S A 118 e2100844118 (2021)
  544. Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition. El Zaoui I, Bucher M, Rimoldi D, Nicolas M, Kaya G, Pescini Gobert R, Bedoni N, Schalenbourg A, Sakina E, Zografos L, Leyvraz S, Riggi N, Rivolta C, Moulin AP. Invest Ophthalmol Vis Sci 60 2764-2772 (2019)
  545. Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma. Schreck KC, Morin A, Zhao G, Allen AN, Flannery P, Glantz M, Green AL, Jones C, Jones KL, Kilburn LB, Nazemi KJ, Samuel D, Sanford B, Solomon DA, Wang J, Pratilas CA, Nicolaides T, Mulcahy Levy JM. Clin Cancer Res 27 6197-6208 (2021)
  546. Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors. Jasek K, Buzalkova V, Minarik G, Stanclova A, Szepe P, Plank L, Lasabova Z. Virchows Arch 470 29-36 (2017)
  547. Differential gene expression in melanocytic nevi with the V600E BRAF mutation. Bloethner S, Snellman E, Bermejo JL, Hiripi E, Gast A, Thirumaran RK, Wellenreuther R, Hemminki K, Kumar R. Genes Chromosomes Cancer 46 1019-1027 (2007)
  548. Functional divergence caused by mutations in an energetic hotspot in ERK2. Taylor CA, Cormier KW, Keenan SE, Earnest S, Stippec S, Wichaidit C, Juang YC, Wang J, Shvartsman SY, Goldsmith EJ, Cobb MH. Proc Natl Acad Sci U S A 116 15514-15523 (2019)
  549. Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis. Peng L, Wang Y, Hong Y, Ye X, Shi P, Zhang J, Zhao Q. Oncotarget 8 83280-83291 (2017)
  550. Multiplex Real-Time PCR Assays that Measure the Abundance of Extremely Rare Mutations Associated with Cancer. Vargas DY, Kramer FR, Tyagi S, Marras SA. PLoS One 11 e0156546 (2016)
  551. Oncogenic B-Raf(V600E) abrogates the AKT/B-Raf/Mps1 interaction in melanoma cells. Zhang L, Shi R, He C, Cheng C, Song B, Cui H, Zhang Y, Zhao Z, Bi Y, Yang X, Miao X, Guo J, Chen X, Wang J, Li Y, Cheng X, Liu J, Cui Y. Cancer Lett 337 125-132 (2013)
  552. Pediatric posterior fossa ganglioglioma: unique MRI features and correlation with BRAF V600E mutation status. Lindsay AJ, Rush SZ, Fenton LZ. J Neurooncol 118 395-404 (2014)
  553. Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens. Løes IM, Immervoll H, Angelsen JH, Horn A, Geisler J, Busch C, Lønning PE, Knappskog S. Tumour Biol 36 1003-1013 (2015)
  554. Regulation of BRAF protein stability by a negative feedback loop involving the MEK-ERK pathway but not the FBXW7 tumour suppressor. Hernandez MA, Patel B, Hey F, Giblett S, Davis H, Pritchard C. Cell Signal 28 561-571 (2016)
  555. Scaffold mining of kinase hinge binders in crystal structure database. Xing L, Rai B, Lunney EA. J Comput Aided Mol Des 28 13-23 (2014)
  556. Synthesis and antiproliferative activity of pyrrolo[3,2-b]pyridine derivatives against melanoma. Kim HJ, Jung MH, Kim H, El-Gamal MI, Sim TB, Lee SH, Hong JH, Hah JM, Cho JH, Choi JH, Yoo KH, Oh CH. Bioorg Med Chem Lett 20 413-417 (2010)
  557. Time-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK. Kubiniok P, Lavoie H, Therrien M, Thibault P. Mol Cell Proteomics 16 663-679 (2017)
  558. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Salemi S, Yousefi S, Simon D, Schmid I, Moretti L, Scapozza L, Simon HU. Allergy 64 913-918 (2009)
  559. Bone mesenchymal stem cells are recruited via CXCL8-CXCR2 and promote EMT through TGF-β signal pathways in oral squamous carcinoma. Meng L, Zhao Y, Bu W, Li X, Liu X, Zhou D, Chen Y, Zheng S, Lin Q, Liu Q, Sun H. Cell Prolif 53 e12859 (2020)
  560. CCAAT displacement protein regulates nuclear factor-kappa beta-mediated chemokine transcription in melanoma cells. Ueda Y, Su Y, Richmond A. Melanoma Res 17 91-103 (2007)
  561. Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer. Murugan AK, Qasem E, Al-Hindi H, Shi Y, Alzahrani AS. J Transl Med 14 204 (2016)
  562. CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer. Wu C, Bekaii-Saab T. Chemother Res Pract 2012 359041 (2012)
  563. Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics. Oguro Y, Cary DR, Miyamoto N, Tawada M, Iwata H, Miki H, Hori A, Imamura S. Bioorg Med Chem 21 4714-4729 (2013)
  564. Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives. El-Damasy AK, Seo SH, Cho NC, Kang SB, Pae AN, Kim KS, Keum G. Eur J Med Chem 101 754-768 (2015)
  565. Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. Vaidhyanathan S, Wilken-Resman B, Ma DJ, Parrish KE, Mittapalli RK, Carlson BL, Sarkaria JN, Elmquist WF. J Pharmacol Exp Ther 356 251-259 (2016)
  566. Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAFV600E-Driven Melanoma. Kim YJ, Tsang T, Anderson GR, Posimo JM, Brady DC. Cancer Res 80 1387-1400 (2020)
  567. Kinase inhibitors in cancer therapy. London C. Vet Comp Oncol 2 177-193 (2004)
  568. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L, de Wijn R, Hilhorst R, Ruijtenbeek R, Sabbah M, Kerger J, Awada A, Journe F, Ghanem GE. Cancers (Basel) 12 E512 (2020)
  569. Lack of BRAF activating mutations in prostate adenocarcinoma: a study of 93 cases. Liu T, Willmore-Payne C, Layfield LJ, Holden JA. Appl Immunohistochem Mol Morphol 17 121-125 (2009)
  570. Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. Birkeland E, Busch C, Berge EO, Geisler J, Jönsson G, Lillehaug JR, Knappskog S, Lønning PE. Clin Exp Metastasis 30 867-876 (2013)
  571. Molecular dynamics simulations and modelling of the residue interaction networks in the BRAF kinase complexes with small molecule inhibitors: probing the allosteric effects of ligand-induced kinase dimerization and paradoxical activation. Verkhivker GM. Mol Biosyst 12 3146-3165 (2016)
  572. Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma. Wu X, Yan J, Dai J, Ma M, Tang H, Yu J, Xu T, Yu H, Si L, Chi Z, Sheng X, Cui C, Kong Y, Guo J. Oncol Lett 14 3601-3605 (2017)
  573. Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line. Peng W, Hu J, Zhu XD, Liu X, Wang CC, Li WH, Chen ZY. Tumour Biol 35 2983-2988 (2014)
  574. Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma. Li Y, Umbach DM, Li L. Melanoma Res 27 527-535 (2017)
  575. Rapid synthesis of Abelson tyrosine kinase inhibitors using click chemistry. Kalesh KA, Liu K, Yao SQ. Org Biomol Chem 7 5129-5136 (2009)
  576. SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib. Karwaciak I, Sałkowska A, Karaś K, Sobalska-Kwapis M, Walczak-Drzewiecka A, Pułaski Ł, Strapagiel D, Dastych J, Ratajewski M. Cancers (Basel) 11 E673 (2019)
  577. The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma. Trudel S, Odolczyk N, Dremaux J, Toffin J, Regnier A, Sevestre H, Zielenkiewicz P, Arnault JP, Gubler B. BMC Cancer 14 727 (2014)
  578. A Systematic Literature Review and Meta-Analysis Describing the Prevalence of KRAS, NRAS, and BRAF Gene Mutations in Metastatic Colorectal Cancer. Levin-Sparenberg E, Bylsma LC, Lowe K, Sangare L, Fryzek JP, Alexander DD. Gastroenterology Res 13 184-198 (2020)
  579. Aberrant expression of the COX2/PGE2 axis is induced by activation of the RAF/MEK/ERK pathway in BRAFV595E canine urothelial carcinoma. Yoshitake R, Saeki K, Eto S, Shinada M, Nakano R, Sugiya H, Endo Y, Fujita N, Nishimura R, Nakagawa T. Sci Rep 10 7826 (2020)
  580. Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients. Köllermann J, Albrecht H, Schlomm T, Huland H, Graefen M, Bokemeyer C, Simon R, Sauter G, Wilczak W. Oncol Lett 1 729-732 (2010)
  581. Analyses of the oncogenic BRAFD594G variant reveal a kinase-independent function of BRAF in activating MAPK signaling. Cope NJ, Novak B, Liu Z, Cavallo M, Gunderwala AY, Connolly M, Wang Z. J Biol Chem 295 2407-2420 (2020)
  582. Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines. Tochizawa S, Masumori N, Yanai Y, Ohmoto Y, Yabuuchi Y, Tsukamoto T. Biomed Res 29 271-278 (2008)
  583. BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study. Mas L, Bachet JB, Taly V, Bouché O, Taieb J, Cohen R, Cohen R, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Blons H, Vernerey D, Laurent-Puig P. Cancers (Basel) 11 E998 (2019)
  584. Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo. Tsumagari K, Abd Elmageed ZY, Sholl AB, Green EA, Sobti S, Khan AR, Kandil A, Murad F, Friedlander P, Boulares AH, Kandil E. Endocr Relat Cancer 25 99-109 (2018)
  585. Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression. Piérard GE. ISRN Dermatol 2012 828146 (2012)
  586. Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer. Mu Y, Yang K, Hao X, Wang Y, Wang L, Liu Y, Lin L, Li J, Xing P. Front Oncol 10 603 (2020)
  587. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors. Rossi S, Sbaraglia M, Dell'Orto MC, Gasparotto D, Cacciatore M, Boscato E, Carraro V, Toffolatti L, Gallina G, Niero M, Pilozzi E, Mandolesi A, Sessa F, Sonzogni A, Mancini C, Mazzoleni G, Romeo S, Maestro R, Dei Tos AP. Oncotarget 7 30109-30118 (2016)
  588. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. Grossauer S, Koeck K, Murphy NE, Meyers ID, Daynac M, Truffaux N, Truong AY, Nicolaides TP, McMahon M, Berger MS, Phillips JJ, James CD, Petritsch CK. Oncotarget 7 75839-75853 (2016)
  589. Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas. Helbig D, Quaas A, Mauch C, Merkelbach-Bruse S, Büttner R, Emberger M, Wobser M, Rüsseler V, Pütz K, Binot E, Rehker J, Budczies J, Ihle MA. Oncotarget 8 109457-109467 (2017)
  590. Cortical migration defects in mice expressing A-RAF from the B-RAF locus. Camarero G, Tyrsin OY, Xiang C, Pfeiffer V, Pleiser S, Wiese S, Götz R, Rapp UR. Mol Cell Biol 26 7103-7115 (2006)
  591. Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma. Matsuse M, Mitsutake N, Tanimura S, Ogi T, Nishihara E, Hirokawa M, Fuziwara CS, Saenko VA, Suzuki K, Miyauchi A, Yamashita S. Int J Cancer 132 738-743 (2013)
  592. Histogram analysis of iodine maps from dual energy computed tomography for monitoring targeted therapy of melanoma patients. Uhrig M, Simons D, Ganten MK, Hassel JC, Schlemmer HP. Future Oncol 11 591-606 (2015)
  593. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations. Burger M, Denzinger S, Hammerschmied C, Tannapfel A, Maderstorfer A, Wieland WF, Hartmann A, Stoehr R. Eur Urol 50 1102-9; discussion 1109-10 (2006)
  594. Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance. Lyczek A, Berger BT, Rangwala AM, Paung Y, Tom J, Philipose H, Guo J, Albanese SK, Robers MB, Knapp S, Chodera JD, Seeliger MA. Proc Natl Acad Sci U S A 118 e2111451118 (2021)
  595. Phosphorylation of the C-Raf N Region Promotes Raf Dimerization. Takahashi M, Li Y, Dillon TJ, Kariya Y, Stork PJS. Mol Cell Biol 37 e00132-17 (2017)
  596. Plasmacytoid Dendritic Cell Impairment in Metastatic Melanoma by Lactic Acidosis. Monti M, Vescovi R, Consoli F, Farina D, Moratto D, Berruti A, Specchia C, Vermi W. Cancers (Basel) 12 E2085 (2020)
  597. Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents. Niculescu-Duvaz D, Niculescu-Duvaz I, Suijkerbuijk BM, Ménard D, Zambon A, Davies L, Pons JF, Whittaker S, Marais R, Springer CJ. Bioorg Med Chem 21 1284-1304 (2013)
  598. Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways. García-Echeverría C. Purinergic Signal 5 117-125 (2009)
  599. Targeting the unactivated conformations of protein kinases for small molecule drug discovery. Alton GR, Lunney EA. Expert Opin Drug Discov 3 595-605 (2008)
  600. Thyroid cancer: current molecular perspectives. Giusti F, Falchetti A, Franceschelli F, Marini F, Tanini A, Brandi ML. J Oncol 2010 351679 (2010)
  601. Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics. Kundu S, Fan K, Cao M, Lindner DJ, Tuthill R, Liu L, Gerson S, Borden E, Yi T. Mol Cancer Ther 9 2287-2296 (2010)
  602. Alternative splicing of BRAF transcripts and characterization of C-terminally truncated B-Raf isoforms in colorectal cancer. Hirschi B, Kolligs FT. Int J Cancer 133 590-596 (2013)
  603. Challenges in the delivery of therapies to melanoma brain metastases. Gampa G, Vaidhyanathan S, Resman BW, Parrish KE, Markovic SN, Sarkaria JN, Elmquist WF. Curr Pharmacol Rep 2 309-325 (2016)
  604. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene. Lin JD, Fu SS, Chen JY, Lee CH, Chau WK, Cheng CW, Wang YH, Lin YF, Fang WF, Tang KT. Thyroid 26 691-704 (2016)
  605. Clinicopathological characteristics associated with BRAF(K601E) and BRAF(L597) mutations in melanoma. Voskoboynik M, Mar V, Mailer S, Colebatch A, Fennessy A, Logan A, Hewitt C, Cebon J, Kelly J, McArthur G. Pigment Cell Melanoma Res 29 222-228 (2016)
  606. Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. Smalley KS, Flaherty KT. Future Oncol 5 775-778 (2009)
  607. Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization. Kong X, Qin J, Li Z, Vultur A, Tong L, Feng E, Rajan G, Liu S, Lu J, Liang Z, Zheng M, Zhu W, Jiang H, Herlyn M, Liu H, Marmorstein R, Luo C. Org Biomol Chem 10 7402-7417 (2012)
  608. Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Marchoudi N, Amrani Hassani Joutei H, Jouali F, Fekkak J, Rhaissi H. Pathol Biol (Paris) 61 273-276 (2013)
  609. Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data. Abdel-Rahman O, ElHalawani H, Ahmed H. Clin Transl Oncol 18 848-858 (2016)
  610. Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study. Nebhan CA, Johnson DB, Sullivan RJ, Amaria RN, Flaherty KT, Sosman JA, Davies MA. Oncologist 26 731-e1498 (2021)
  611. Guanidinium-based derivatives: searching for new kinase inhibitors. Diez-Cecilia E, Kelly B, Perez C, Zisterer DM, Nevin DK, Lloyd DG, Rozas I. Eur J Med Chem 81 427-441 (2014)
  612. Hexokinase 2 Promotes Cell Growth and Tumor Formation Through the Raf/MEK/ERK Signaling Pathway in Cervical Cancer. Cui N, Li L, Feng Q, Ma HM, Lei D, Zheng PS. Front Oncol 10 581208 (2020)
  613. High-Throughput Characterization of Viral and Cellular Protein Expression Patterns During JC Polyomavirus Infection. DuShane JK, Wilczek MP, Crocker MA, Maginnis MS. Front Microbiol 10 783 (2019)
  614. KIT Suppresses BRAFV600E-Mutant Melanoma by Attenuating Oncogenic RAS/MAPK Signaling. Neiswender JV, Kortum RL, Bourque C, Kasheta M, Zon LI, Morrison DK, Ceol CJ. Cancer Res 77 5820-5830 (2017)
  615. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia. Xu B, Zhao Y, Wang X, Gong P, Ge W. Leukemia 31 913-921 (2017)
  616. Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of C-Raf and B-Raf isoforms by FGFR and MC1R. Muller M, Obeyesekere M, Mills GB, Ram PT. FASEB J 22 1393-1403 (2008)
  617. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties. Ren L, Laird ER, Buckmelter AJ, Dinkel V, Gloor SL, Grina J, Newhouse B, Rasor K, Hastings G, Gradl SN, Rudolph J. Bioorg Med Chem Lett 22 1165-1168 (2012)
  618. Prediction of sorafenib treatment-related gene expression for hepatocellular carcinoma: preoperative MRI and histopathological correlation. Dong Z, Huang K, Liao B, Cai H, Dong Y, Huang M, Zhou X, Jia Y, Xu L, Luo Y, Li ZP, Feng ST. Eur Radiol 29 2272-2282 (2019)
  619. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors. Wenglowsky S, Moreno D, Laird ER, Gloor SL, Ren L, Risom T, Rudolph J, Sturgis HL, Voegtli WC. Bioorg Med Chem Lett 22 6237-6241 (2012)
  620. Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies. Batist G, Wu JH, Spatz A, Miller WH, Cocolakis E, Rousseau C, Diaz Z, Ferrario C, Basik M. Front Pharmacol 2 59 (2011)
  621. The p21-activated kinase PAK3 forms heterodimers with PAK1 in brain implementing trans-regulation of PAK3 activity. Combeau G, Kreis P, Domenichini F, Amar M, Fossier P, Rousseau V, Barnier JV. J Biol Chem 287 30084-30096 (2012)
  622. The rare BRAF VK600-601E mutation as a possible indicator of poor prognosis in rectal carcinoma – a report of a case. Mori Y, Nagasaka T, Mishima H, Umeda Y, Inada R, Kishimoto H, Goel A, Fujiwara T. BMC Med Genet 16 1 (2015)
  623. Thyrotropin signaling confers more aggressive features with higher genomic instability on BRAF(V600E)-induced thyroid tumors in a mouse model. Orim F, Bychkov A, Shimamura M, Nakashima M, Ito M, Matsuse M, Kurashige T, Suzuki K, Saenko V, Nagayama Y, Yamashita S, Mitsutake N. Thyroid 24 502-510 (2014)
  624. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. Ofir Dovrat T, Sokol E, Frampton G, Shachar E, Pelles S, Geva R, Wolf I. Cancer Biol Ther 19 871-874 (2018)
  625. VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations. Na JI, Kim JH, Kim HJ, Kim HK, Moon KS, Lee JS, Lee JH, Lee KH, Park JT. Virchows Arch 467 155-168 (2015)
  626. A hexylchloride-based catch-and-release system for chemical proteomic applications. Brigham JL, Perera BG, Maly DJ. ACS Chem Biol 8 691-699 (2013)
  627. A novel somatic mutation in ACD induces telomere lengthening and apoptosis resistance in leukemia cells. Spinella JF, Cassart P, Garnier N, Rousseau P, Drullion C, Richer C, Ouimet M, Saillour V, Healy J, Autexier C, Sinnett D. BMC Cancer 15 621 (2015)
  628. A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF. Whittaker S, Ménard D, Kirk R, Ogilvie L, Hedley D, Zambon A, Lopes F, Preece N, Manne H, Rana S, Lambros M, Reis-Filho JS, Marais R, Springer CJ. Cancer Res 70 8036-8044 (2010)
  629. BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells. Wu Z, Huang M, Gong Y, Lin C, Guo W. Acta Biochim Biophys Sin (Shanghai) 50 355-361 (2018)
  630. BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis. Maxwell R, Garzon-Muvdi T, Lipson EJ, Sharfman WH, Bettegowda C, Redmond KJ, Kleinberg LR, Ye X, Lim M. Int J Cancer 140 2716-2727 (2017)
  631. Characterization of a novel complex BRAF mutation in a follicular variant papillary thyroid carcinoma. Barzon L, Masi G, Boschin IM, Lavezzo E, Pacenti M, Casal Ide E, Toniato A, Toppo S, Palù G, Pelizzo MR. Eur J Endocrinol 159 77-80 (2008)
  632. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy. Saroufim M, Habib RH, Gerges R, Saab J, Loya A, Amr SS, Sheikh S, Satti M, Oberkanins C, Khalifeh I. Exp Mol Pathol 97 315-320 (2014)
  633. Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of the BRAF(V600E) Mutation in Thyroid Neoplasm. Oh HS, Kwon H, Park S, Kim M, Jeon MJ, Kim TY, Shong YK, Kim WB, Choi J, Kim WG, Song DE. Endocrinol Metab (Seoul) 33 62-69 (2018)
  634. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity. Verkhivker GM. Proteins 66 912-929 (2007)
  635. Dual Inhibition of MAPK and JAK2/STAT3 Pathways Is Critical for the Treatment of BRAF Mutant Melanoma. Zhao K, Lu Y, Chen Y, Cheng J, Zhang W. Mol Ther Oncolytics 18 100-108 (2020)
  636. Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma. Gupta A, Towers C, Willenbrock F, Brant R, Hodgson DR, Sharpe A, Smith P, Cutts A, Schuh A, Asher R, Myers K, Love S, Collins L, Wise A, Middleton MR, Macaulay VM. Br J Cancer 122 506-516 (2020)
  637. Engineering allosteric regulation in protein kinases. Pincus D, Pandey JP, Feder ZA, Creixell P, Resnekov O, Reynolds KA. Sci Signal 11 eaar3250 (2018)
  638. Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers. Ikenoue T, Kanai F, Hikiba Y, Tanaka Y, Imamura J, Ohta M, Jazag A, Guleng B, Asaoka Y, Tateishi K, Kawakami T, Matsumura M, Kawabe T, Omata M. Mol Carcinog 43 59-63 (2005)
  639. Gene Expression Profiling Reveals Regulation of ERK Phosphorylation by Androgen-Induced Tumor Suppressor U19/EAF2 in the Mouse Prostate. Su F, Correa BR, Luo J, Vencio RZ, Pascal LE, Wang Z. Cancer Microenviron 6 247-261 (2013)
  640. Genotyping of cutaneous melanoma. Glitza IC, Davies MA. Chin Clin Oncol 3 27 (2014)
  641. Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screen. Newbatt Y, Burns S, Hayward R, Whittaker S, Kirk R, Marshall C, Springer C, McDonald E, Cancer Genome Project, Marais R, Workman P, Aherne W. J Biomol Screen 11 145-154 (2006)
  642. Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors. Gopalsamy A, Ciszewski G, Hu Y, Lee F, Feldberg L, Frommer E, Kim S, Collins K, Wojciechowicz D, Mallon R. Bioorg Med Chem Lett 19 2735-2738 (2009)
  643. Imidazo[4,5-b]pyridine inhibitors of B-Raf kinase. Newhouse BJ, Wenglowsky S, Grina J, Laird ER, Voegtli WC, Ren L, Ahrendt K, Buckmelter A, Gloor SL, Klopfenstein N, Rudolph J, Wen Z, Li X, Feng B. Bioorg Med Chem Lett 23 5896-5899 (2013)
  644. Investigation of BRAF V600E mutation in papillary thyroid carcinoma and tumor-surrounding nontumoral tissues. Dağlar-Aday A, Toptaş B, Oztürk T, Seyhan F, Saygili N, Eronat AP, Akadam-Teker B, Yilmaz-Aydoğan H, Aksoy F, Oztürk O. DNA Cell Biol 32 13-18 (2013)
  645. MALDI-TOF mass-spectrometry-based versatile method for the characterization of protein kinases. Kondo N, Nishimura S. Chemistry 15 1413-1421 (2009)
  646. Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy. Yang J, Zaja-Milatovic S, Thu YM, Lee F, Smykla R, Richmond A. Mol Cancer Ther 8 636-647 (2009)
  647. N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors. Li Y, Cheng H, Zhang Z, Zhuang X, Luo J, Long H, Zhou Y, Xu Y, Taghipouran R, Li D, Patterson A, Smaill J, Tu Z, Wu D, Ren X, Ding K. ACS Med Chem Lett 6 543-547 (2015)
  648. Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors. Chatelle CV, Hövermann D, Müller A, Wagner HJ, Weber W, Radziwill G. Sci Rep 6 23713 (2016)
  649. Pilocytic astrocytomas: BRAFV600E and BRAF fusion expression patterns in pediatric and adult age groups. Kurani H, Gurav M, Shetty O, Chinnaswamy G, Moiyadi A, Gupta T, Jalali R, Epari S. Childs Nerv Syst 35 1525-1536 (2019)
  650. RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy. Radaszkiewicz T, Nosková M, Gömöryová K, Vondálová Blanářová O, Radaszkiewicz KA, Picková M, Víchová R, Gybeľ T, Kaiser K, Demková L, Kučerová L, Bárta T, Potěšil D, Zdráhal Z, Souček K, Bryja V. Elife 10 e65759 (2021)
  651. Receptor for activated protein C kinase 1 (RACK1) is overexpressed in papillary thyroid carcinoma. Myklebust LM, Akslen LA, Varhaug JE, Lillehaug JR. Thyroid 21 1217-1225 (2011)
  652. Repositioning organohalogen drugs: a case study for identification of potent B-Raf V600E inhibitors via docking and bioassay. Li Y, Guo B, Xu Z, Li B, Cai T, Zhang X, Yu Y, Wang H, Shi J, Zhu W. Sci Rep 6 31074 (2016)
  653. Striated muscle activator of Rho signalling (STARS) is reduced in ageing human skeletal muscle and targeted by miR-628-5p. Russell AP, Wallace MA, Kalanon M, Zacharewicz E, Della Gatta PA, Garnham A, Lamon S. Acta Physiol (Oxf) 220 263-274 (2017)
  654. Synthesis, biological evaluation and 3D-QSAR studies of novel 4,5-dihydro-1H-pyrazole niacinamide derivatives as BRAF inhibitors. Li CY, Li QS, Yan L, Sun XG, Wei R, Gong HB, Zhu HL. Bioorg Med Chem 20 3746-3755 (2012)
  655. The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho-Ser-621 in the C terminus of CRAF. Yuan J, Ng WH, Yap J, Chia B, Huang X, Wang M, Hu J. J Biol Chem 293 14276-14284 (2018)
  656. 3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies. Thaimattam R, Daga P, Rajjak SA, Banerjee R, Iqbal J. Bioorg Med Chem 12 6415-6425 (2004)
  657. A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC. Occhi G, Barollo S, Regazzo D, Bertazza L, Galuppini F, Guzzardo V, Jaffrain-Rea ML, Vianello F, Ciato D, Ceccato F, Watutantrige-Fernando S, Bisognin A, Bortoluzzi S, Pennelli G, Boscaro M, Scaroni C, Mian C. Oncotarget 6 32104-32114 (2015)
  658. An integrated suite of modeling tools that empower scientists in structure- and property-based drug design. Feng JA, Aliagas I, Bergeron P, Blaney JM, Bradley EK, Koehler MF, Lee ML, Ortwine DF, Tsui V, Wu J, Gobbi A. J Comput Aided Mol Des 29 511-523 (2015)
  659. BRAF V600E mutant papillary craniopharyngiomas: a single-institutional case series. La Corte E, Younus I, Pivari F, Selimi A, Ottenhausen M, Forbes JA, Pisapia DJ, Dobri GA, Anand VK, Schwartz TH. Pituitary 21 571-583 (2018)
  660. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status. Paskaš S, Janković J, Marečko I, Išić Denčić T, Tatić S, Cvejić D, Savin S. Otolaryngol Head Neck Surg 150 201-209 (2014)
  661. Design, biological evaluation and 3D QSAR studies of novel dioxin-containing triaryl pyrazoline derivatives as potential B-Raf inhibitors. Yang YS, Yang B, Zou Y, Li G, Zhu HL. Bioorg Med Chem 24 3052-3061 (2016)
  662. EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile. Zhang J, Lu B, Liu D, Shen R, Yan Y, Yang L, Zhang M, Zhang L, Cao G, Cao H, Fu B, Gong A, Sun Q, Wan H, Zhang L, Tao W, Cao J. Cancer Biol Ther 17 199-207 (2016)
  663. ERK expression and its correlation with STAT1 in esophageal squamous cell carcinoma. Wang H, Zhang Y, Yun H, Chen S, Chen Y, Liu Z. Oncotarget 8 45249-45258 (2017)
  664. Gene integrated set profile analysis: a context-based approach for inferring biological endpoints. Kowalski J, Dwivedi B, Newman S, Switchenko JM, Pauly R, Gutman DA, Arora J, Gandhi K, Ainslie K, Doho G, Qin Z, Moreno CS, Rossi MR, Vertino PM, Lonial S, Bernal-Mizrachi L, Boise LH. Nucleic Acids Res 44 e69 (2016)
  665. Hierarchical Organization Endows the Kinase Domain with Regulatory Plasticity. Creixell P, Pandey JP, Palmeri A, Bhattacharyya M, Creixell M, Ranganathan R, Pincus D, Yaffe MB. Cell Syst 7 371-383.e4 (2018)
  666. Identification of Therapeutic and Prognostic Biomarkers of Lamin C (LAMC) Family Members in Head and Neck Squamous Cell Carcinoma. Jiang P, He S, Li Y, Xu Z. Med Sci Monit 26 e925735 (2020)
  667. K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy. Stec R, Bodnar L, Charkiewicz R, Korniluk J, Rokita M, Smoter M, Ciechowicz M, Chyczewski L, Nikliński J, Kozłowski W, Szczylik C. Cancer Biol Ther 13 1235-1243 (2012)
  668. KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness in Synchronous Metastatic Colorectal Cancer (mCRC): Retrospective Research. He K, Wang Y, Zhong Y, Pan X, Si L, Lu J. Onco Targets Ther 13 12601-12613 (2020)
  669. Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population. Argyropoulou M, Veskoukis AS, Karanatsiou PM, Manolakelli A, Kostoglou-Athanassiou I, Vilaras G, Karameris A, Liadaki K. Pathol Oncol Res 26 347-354 (2020)
  670. Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition. Liu C, Zeng Y, Dai LH, Cai TY, Zhu YM, Dou DQ, Ma LQ, Sun YX. Am J Cancer Res 5 1308-1318 (2015)
  671. Molecular bases of cutaneous and uveal melanomas. Gaudi S, Messina JL. Patholog Res Int 2011 159421 (2011)
  672. Multikinase inhibitors in thyroid cancer. Licitra L, Locati LD, Greco A, Granata R, Bossi P. Eur J Cancer 46 1012-1018 (2010)
  673. Phosphorylation-Dependent Conformations of the Disordered Carboxyl-Terminus Domain in the Epidermal Growth Factor Receptor. Regmi R, Srinivasan S, Latham AP, Kukshal V, Cui W, Zhang B, Bose R, Schlau-Cohen GS. J Phys Chem Lett 11 10037-10044 (2020)
  674. Podoplanin (PDPN) affects the invasiveness of thyroid carcinoma cells by inducing ezrin, radixin and moesin (E/R/M) phosphorylation in association with matrix metalloproteinases. Sikorska J, Gaweł D, Domek H, Rudzińska M, Czarnocka B. BMC Cancer 19 85 (2019)
  675. Quantifying information accumulation encoded in the dynamics of biochemical signaling. Tang Y, Adelaja A, Ye FX, Deeds E, Wollman R, Hoffmann A. Nat Commun 12 1272 (2021)
  676. Ran signaling in melanoma: implications for the development of alternative therapeutic strategies. Caputo E, Wang E, Valentino A, Crispi S, De Giorgi V, Fico A, Ficili B, Capone M, Anniciello A, Cavalcanti E, Botti G, Mozzillo N, Ascierto PA, Marincola FM, Travali S. Cancer Lett 357 286-296 (2015)
  677. Renal cell carcinoma and the use of sorafenib. Larkin JM, Eisen T. Ther Clin Risk Manag 2 87-98 (2006)
  678. Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study. Tibes R, Borad MJ, Dutcus CE, Reyderman L, Feit K, Eisen A, Verbel DA, Von Hoff DD. Br J Cancer 118 1580-1585 (2018)
  679. Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data. Chai YJ, Yi JW, Jee HG, Kim YA, Kim JH, Xing M, Lee KE. PLoS One 11 e0159235 (2016)
  680. Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF V600E -mutant melanoma. Harris AL, Lee SE, Dawson LK, Marlow LA, Edenfield BH, Durham WF, Flotte TJ, Thompson M, Small DL, Synnott AJ, Markovic SN, Copland JA. Oncotarget 9 10905-10919 (2018)
  681. Case Reports Two Case Reports of Rare BRAF Mutations in Exon 11 and Exon 15 with Discussion of Potential Treatment Options. Richtig G, Aigelsreiter A, Kashofer K, Talakic E, Kupsa R, Schaider H, Richtig E. Case Rep Oncol 9 543-546 (2016)
  682. Vitamin C sensitizes BRAFV600E thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032. Su X, Li P, Han B, Jia H, Liang Q, Wang H, Gu M, Cai J, Li S, Zhou Y, Yi X, Wei W. J Exp Clin Cancer Res 40 34 (2021)
  683. EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer. Dong YU, Ren W, Qi J, Jin BO, Li Y, Tao H, Xu R, Li Y, Zhang Q, Han B. Oncol Lett 11 2371-2378 (2016)
  684. Analysis of water patterns in protein kinase binding sites. Barillari C, Duncan AL, Westwood IM, Blagg J, van Montfort RL. Proteins 79 2109-2121 (2011)
  685. Anionic Lipids Impact RAS-Binding Site Accessibility and Membrane Binding Affinity of CRAF RBD-CRD. Travers T, López CA, Agamasu C, Hettige JJ, Messing S, García AE, Stephen AG, Gnanakaran S. Biophys J 119 525-538 (2020)
  686. Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors. Dietrich J, Gokhale V, Wang X, Hurley LH, Flynn GA. Bioorg Med Chem 18 292-304 (2010)
  687. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. Johnson B, Loree JM, Jacome AA, Mendis S, Syed M, Morris Ii VK, Parseghian CM, Dasari A, Pant S, Raymond VM, Vilar E, Overman M, Kee B, Eng C, Raghav K, Kopetz S. JCO Precis Oncol 3 PO.19.00102 (2019)
  688. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods. O'Brien O, Lyons T, Murphy S, Feeley L, Power D, Heffron CCBB. J Clin Pathol 70 935-940 (2017)
  689. Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm. Kowalewski A, Durślewicz J, Zdrenka M, Grzanka D, Szylberg Ł. Target Oncol 15 531-540 (2020)
  690. Combination molecularly targeted drug therapy in metastatic melanoma: progress to date. Lemech C, Infante J, Arkenau HT. Drugs 73 767-777 (2013)
  691. Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors. Yang W, Chen Y, Zhou X, Gu Y, Qian W, Zhang F, Han W, Lu T, Tang W. Eur J Med Chem 89 581-596 (2015)
  692. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers. Sadlecki P, Walentowicz P, Bodnar M, Marszalek A, Grabiec M, Walentowicz-Sadlecka M. Tumour Biol 39 1010428317706230 (2017)
  693. Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity. El-Damasy AK, Cho NC, Nam G, Pae AN, Keum G. ChemMedChem 11 1587-1595 (2016)
  694. Discovery of highly potent and selective type I B-Raf kinase inhibitors. Wang X, Berger DM, Salaski EJ, Torres N, Hu Y, Levin JI, Powell D, Wojciechowicz D, Collins K, Frommer E. Bioorg Med Chem Lett 19 6571-6574 (2009)
  695. Enzyme fragment complementation binding assay for p38alpha mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors. Zaman GJ, van der Lee MM, Kok JJ, Nelissen RL, Loomans EE. Assay Drug Dev Technol 4 411-420 (2006)
  696. Expression Profiling of a Human Thyroid Cell Line Stably Expressing the BRAFV600E Mutation. Kim BA, Jee HG, Yi JW, Kim SJ, Chai YJ, Choi JY, Lee KE. Cancer Genomics Proteomics 14 53-67 (2017)
  697. FAM129B-dependent activation of NRF2 promotes an invasive phenotype in BRAF mutant melanoma cells. Schmidlin CJ, Tian W, Dodson M, Chapman E, Zhang DD. Mol Carcinog 60 331-341 (2021)
  698. Functionalized Graphene Oxide Thin Films for Anti-tumor Drug Delivery to Melanoma Cells. Sima LE, Chiritoiu G, Negut I, Grumezescu V, Orobeti S, Munteanu CVA, Sima F, Axente E. Front Chem 8 184 (2020)
  699. G protein βγ translocation to the Golgi apparatus activates MAPK via p110γ-p101 heterodimers. Khater M, Wei Z, Xu X, Huang W, Lokeshwar BL, Lambert NA, Wu G. J Biol Chem 296 100325 (2021)
  700. In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. Ikediobi ON, Reimers M, Durinck S, Blower PE, Futreal AP, Stratton MR, Weinstein JN. Mol Cancer Ther 7 1337-1346 (2008)
  701. Indicators of multifocality in papillary thyroid carcinoma concurrent with Hashimoto's thyroiditis. Dong S, Xie XJ, Xia Q, Wu YJ. Am J Cancer Res 9 1786-1795 (2019)
  702. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM. Liao J, Hwang SH, Li H, Yang Y, Yang J, Wecksler AT, Liu JY, Hammock BD, Yang GY. Cancer Lett 371 187-193 (2016)
  703. KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K-MAPK1 inhibition. Janardhan HP, Meng X, Dresser K, Hutchinson L, Trivedi CM. J Exp Med 217 e20192205 (2020)
  704. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Henary H, Hong DS, Falchook GS, Tsimberidou A, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul S, Janku F, Kim KB, Hwu P, Kurzrock R. Ann Oncol 24 2158-2165 (2013)
  705. Microfluidic Droplet Digital PCR Is a Powerful Tool for Detection of BRAF and TERT Mutations in Papillary Thyroid Carcinomas. Ylli D, Patel A, Jensen K, Li ZZ, Mendonca-Torres MC, Costello J, Gomes-Lima CJ, Wartofsky L, Burman KD, Vasko VV. Cancers (Basel) 11 E1916 (2019)
  706. Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response. Li ZZ, Wang F, Zhang ZC, Wang F, Zhao Q, Zhang DS, Wang FH, Wang ZQ, Luo HY, He MM, Wang DS, Jin Y, Ren C, Qiu MZ, Ren J, Pan ZZ, Li YH, Shao JY, Xu RH. Oncotarget 7 28356-28368 (2016)
  707. Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies. Mayrhofer JE, Enzler F, Feichtner A, Röck R, Fleischmann J, Raffeiner A, Tschaikner P, Ogris E, Huber RG, Hartl M, Schneider R, Troppmair J, Torres-Quesada O, Stefan E. Proc Natl Acad Sci U S A 117 31105-31113 (2020)
  708. Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis. Otsubo K, Iwama E, Ijichi K, Kubo N, Yoneshima Y, Inoue H, Tanaka K, Osoegawa A, Tagawa T, Nakanishi Y, Okamoto I. Cancer Sci 111 2482-2487 (2020)
  709. Profiling of protein-protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors. Lee HW, Choi B, Kang HN, Kim H, Min A, Cha M, Ryu JY, Park S, Sohn J, Shin K, Yun MR, Han JY, Shon MJ, Jeong C, Chung J, Lee SH, Im SA, Cho BC, Yoon TY. Nat Biomed Eng 2 239-253 (2018)
  710. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability. Nazemalhosseini-Mojarad E, Kishani Farahani R, Mehrizi M, Baghaei K, Yaghoob Taleghani M, Golmohammadi M, Peyravian N, Ashtari S, Pourhoseingholi MA, Asadzadeh Aghdaei H, Zali MR. J Gastrointest Cancer 51 53-62 (2020)
  711. RUNX2 and LAMC2: promising pancreatic cancer biomarkers identified by an integrative data mining of pancreatic adenocarcinoma tissues. Jin G, Ruan Q, Shangguan F, Lan L. Aging (Albany NY) 13 22963-22984 (2021)
  712. Sorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosis. Li XF, Gong RY, Wang M, Yan ZL, Yuan B, Wang K, Shi LH. Biochem Biophys Res Commun 418 531-536 (2012)
  713. Structure-based de novo design and biochemical evaluation of novel BRAF kinase inhibitors. Park H, Jeong Y, Hong S. Bioorg Med Chem Lett 22 1027-1030 (2012)
  714. The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor. Harms FL, Alawi M, Amor DJ, Tan TY, Cuturilo G, Lissewski C, Brinkmann J, Schanze D, Kutsche K, Zenker M. Am J Med Genet A 176 470-476 (2018)
  715. The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of αC-β4 loop. Yap J, Deepak RNVK, Tian Z, Ng WH, Goh KC, Foo A, Tee ZH, Mohanam MP, Sim YRM, Degirmenci U, Lam P, Chen Z, Fan H, Hu J. Sci Adv 7 eabg0390 (2021)
  716. The yin-yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF. Kiel C, Benisty H, Lloréns-Rico V, Serrano L. Elife 5 e12814 (2016)
  717. Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Hallmeyer S, Gonzalez R, Lawson DH, Cranmer LD, Linette GP, Puzanov I, Taback B, Cowey CL, Ribas A, Daniels GA, Moore T, Gibney GT, Tawbi H, Whitman E, Lee G, Mun Y, Liu S, Hamid O. Melanoma Res 27 585-590 (2017)
  718. A Unified Approach to Couple Aromatic Heteronucleophiles to Azines and Pharmaceuticals. Anderson RG, Jett BM, McNally A. Angew Chem Int Ed Engl 57 12514-12518 (2018)
  719. A comprehensive immunophenotypic marker analysis of hairy cell leukemia in paraffin-embedded bone marrow trephine biopsies--a tissue microarray study. Tóth-Lipták J, Piukovics K, Borbényi Z, Demeter J, Bagdi E, Krenács L. Pathol Oncol Res 21 203-211 (2015)
  720. BRAF drives synovial fibroblast transformation in rheumatoid arthritis. Weisbart RH, Chan G, Heinze E, Mory R, Nishimura RN, Colburn K. J Biol Chem 285 34299-34303 (2010)
  721. Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers. De Marchi F, Haley L, Fryer H, Ibrahim J, Beierl K, Zheng G, Gocke CD, Eshleman JR, Belchis D, Illei P, Lin MT. Arch Pathol Lab Med 143 174-182 (2019)
  722. Deletion mutation of BRAF in a serrated adenoma from a patient with familial adenomatous polyposis. Lee EJ, Park CK, Kim JW, Chang DK, Kim KM. APMIS 115 982-986 (2007)
  723. Disruption of mutated BRAF signaling modulates thyroid cancer phenotype. Hanly EK, Rajoria S, Darzynkiewicz Z, Zhao H, Suriano R, Tuli N, George AL, Bednarczyk R, Shin EJ, Geliebter J, Tiwari RK. BMC Res Notes 7 187 (2014)
  724. Explaining cancer type specific mutations with transcriptomic and epigenomic features in normal tissues. Tiong KL, Yeang CH. Sci Rep 8 11456 (2018)
  725. High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. Cheng LY, Haydu LE, Song P, Nie J, Tetzlaff MT, Kwong LN, Gershenwald JE, Davies MA, Zhang DY. Sci Rep 11 9043 (2021)
  726. Identification of novel 3,5-diarylpyrazoline derivatives containing salicylamide moiety as potential anti-melanoma agents. Li QS, Lv XH, Zhang YB, Dong JJ, Zhou WP, Yang Y, Zhu HL. Bioorg Med Chem Lett 22 6596-6601 (2012)
  727. Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma. Tang HC, Chen YC, Chen YC. Int J Nanomedicine 10 3131-3146 (2015)
  728. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies. Dulgar O, Kutuk T, Eroglu Z. Am J Clin Dermatol 22 1-10 (2021)
  729. Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib? Porcelli L, Guida G, Tommasi S, Guida M, Azzariti A. Cancer Chemother Pharmacol 76 433-438 (2015)
  730. Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma. Bayraktar S, Rocha-Lima CM. World J Clin Oncol 4 29-42 (2013)
  731. Mutational Profile of Papillary Thyroid Carcinoma in an Endemic Goiter Region of North India. George N, Agarwal A, Kumari N, Agarwal S, Krisnani N, Gupta SK. Indian J Endocrinol Metab 22 505-510 (2018)
  732. Oncogenic RAF: a brief history of time. Solit D, Rosen N. Pigment Cell Melanoma Res 23 760-762 (2010)
  733. Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells. Molnár E, Rittler D, Baranyi M, Grusch M, Berger W, Döme B, Tóvári J, Aigner C, Tímár J, Garay T, Hegedűs B. BMC Cancer 18 542 (2018)
  734. Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Kline CL, El-Deiry WS. Pharmaceuticals (Basel) 6 988-1038 (2013)
  735. Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition. Allen A, Qin ACR, Raj N, Wang J, Uddin S, Yao Z, Tang L, Meyers PA, Taylor BS, Berger MF, Yaeger R, Reidy-Lagunes D, Pratilas CA. PLoS One 14 e0217399 (2019)
  736. Reconstitution of modular PDK1 functions on trans-splicing of the regulatory PH and catalytic kinase domains. Al-Ali H, Ragan TJ, Gao X, Harris TK. Bioconjug Chem 18 1294-1302 (2007)
  737. Single thyroid tumour showing multiple differentiated morphological patterns and intramorphological molecular genetic heterogeneity. Schopper HK, Stence A, Ma D, Pagedar NA, Robinson RA. J Clin Pathol 70 116-119 (2017)
  738. The Prognostic Influence of BRAF Mutation and other Molecular, Clinical and Laboratory Parameters in Stage IV Colorectal Cancer. Karadima ML, Saetta AA, Chatziandreou I, Lazaris AC, Patsouris E, Tsavaris N. Pathol Oncol Res 22 707-714 (2016)
  739. Letter The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene. Hou P, Liu D, Xing M. Leukemia 21 2216-2218 (2007)
  740. The mechanism of Raf activation through dimerization. Zhang M, Maloney R, Jang H, Nussinov R. Chem Sci 12 15609-15619 (2021)
  741. The mixed-lineage kinase 1-3 signalling pathway regulates stress response in cardiac myocytes via GATA-4 and AP-1 transcription factors. Ola A, Kerkelä R, Tokola H, Pikkarainen S, Skoumal R, Vuolteenaho O, Ruskoaho H. Br J Pharmacol 159 717-725 (2010)
  742. The phosphorylation specificity of B-RAF WT, B-RAF D594V, B-RAF V600E and B-RAF K601E kinases: an in silico study. Fratev F, Jónsdóttir SO. J Mol Graph Model 28 598-603 (2010)
  743. The role of autophagy in cytotoxicity induced by new oncogenic B-Raf inhibitor UI-152 in v-Ha-ras transformed fibroblasts. Ahn JH, Ahn SK, Lee M. Biochem Biophys Res Commun 417 857-863 (2012)
  744. Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. Rosenberg T, Yeo KK, Mauguen A, Alexandrescu S, Prabhu SP, Tsai JW, Malinowski S, Joshirao M, Parikh K, Farouk Sait S, Rosenblum MK, Benhamida JK, Michaiel G, Tran HN, Dahiya S, Kachurak K, Friedman GK, Krystal JI, Huang MA, Margol AS, Wright KD, Aguilera D, MacDonald TJ, Chi SN, Karajannis MA. Neuro Oncol 24 1964-1975 (2022)
  745. Upregulation of the Na⁺-coupled phosphate cotransporters NaPi-IIa and NaPi-IIb by B-RAF. Pakladok T, Hosseinzadeh Z, Lebedeva A, Alesutan I, Lang F. J Membr Biol 247 137-145 (2014)
  746. Letter XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation. Phadke M, Gibney GT, Rich CJ, Fedorenko IV, Chen YA, Kudchadkar RR, Sondak VK, Weber J, Messina JL, Smalley KSM, Smalley KSM. J Invest Dermatol 135 2542-2544 (2015)
  747. A Case of Multifocal Papillary Thyroid Carcinoma Consisting of One Encapsulated Follicular Variant with BRAF K601E Mutation and Three Conventional Types with BRAF V600E Mutation. Kim WY, Ko YS, Hwang TS, Han HS, Lim SD, Kim WS, Oh SY. Korean J Pathol 47 293-298 (2013)
  748. A Concise Atlas of Thyroid Cancer Next-Generation Sequencing Panel ThyroSeq v.2. Alsina J, Alsina R, Gulec S. Mol Imaging Radionucl Ther 26 102-117 (2017)
  749. A conserved mechanism of sirtuin signalling through steroid hormone receptors. Bayele HK. Biosci Rep 39 BSR20193535 (2019)
  750. A more sensitive platform for the detection of low-abundance BRAF(V⁶⁰⁰E) mutations. Jiang W, Wang W, Fu F, Teng X, Wang H, Wang H, Teng L. Mol Cell Biochem 366 49-58 (2012)
  751. Application of genomic principles to pharmacotherapy of cancer. Farrell CL, Pedigo NG, Messersmith AR. Am J Pharm Educ 78 55 (2014)
  752. Case Reports Are All Mutations the Same? A Rare Case Report of Coexisting Mutually Exclusive KRAS and BRAF Mutations in a Patient with Metastatic Colon Adenocarcinoma. Vittal A, Middinti A, Kasi Loknath Kumar A. Case Rep Oncol Med 2017 2321052 (2017)
  753. BRAF V600E mutation in epilepsy-associated glioneuronal tumors: Prevalence and correlation with clinical features in a Chinese population. Zhang YX, Shen CH, Guo Y, Zheng Y, Zhu JM, Ding Y, Tang YL, Wang S, Ding MP. Seizure 45 102-106 (2017)
  754. BRAF V600E potentially determines "Oncological Resectability" for "Technically Resectable" colorectal liver metastases. Kobayashi S, Takahashi S, Nomura S, Kojima M, Kudo M, Sugimoto M, Konishi M, Gotohda N, Taniguchi H, Yoshino T. Cancer Med 10 6998-7011 (2021)
  755. CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition. Noeparast A, Giron P, Noor A, Bahadur Shahi R, De Brakeleer S, Eggermont C, Vandenplas H, Boeckx B, Lambrechts D, De Grève J, Teugels E. Oncogene 38 5933-5941 (2019)
  756. CRISPR-induced RASGAP deficiencies in colorectal cancer organoids reveal that only loss of NF1 promotes resistance to EGFR inhibition. Post JB, Hami N, Mertens AEE, Elfrink S, Bos JL, Snippert HJG. Oncotarget 10 1440-1457 (2019)
  757. Clinical implications of the extent of BRAFV600E alleles in patients with papillary thyroid carcinoma. Liu L, Chang JW, Jung SN, Park HS, Oh T, Lim YC, Koo BS. Oral Oncol 62 72-77 (2016)
  758. Clinical neuropathology practice news 2-2012: BRAF V600E testing. Capper D, Berghoff AS, von Deimling A, Preusser M. Clin Neuropathol 31 64-66 (2012)
  759. Concomitant high expression of BRAFV600E, P-cadherin and cadherin 6 is associated with High TNM stage and lymph node metastasis in conventional papillary thyroid carcinoma. Zhao L, Jiang R, Xu M, Zhu P, Mo XM, Wang N, Chen GG, Liu ZM. Clin Endocrinol (Oxf) 84 748-755 (2016)
  760. Decatenation checkpoint-defective melanomas are dependent on PI3K for survival. Brooks K, Ranall M, Spoerri L, Stevenson A, Gunasingh G, Pavey S, Meunier F, Gonda TJ, Gabrielli B. Pigment Cell Melanoma Res 27 813-821 (2014)
  761. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives. Hirose M, Okaniwa M, Miyazaki T, Imada T, Ohashi T, Tanaka Y, Arita T, Yabuki M, Kawamoto T, Tsutsumi S, Sumita A, Takagi T, Sang BC, Yano J, Aertgeerts K, Yoshida S, Ishikawa T. Bioorg Med Chem 20 5600-5615 (2012)
  762. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents. Jiao Y, Xin BT, Zhang Y, Wu J, Lu X, Zheng Y, Tang W, Zhou X. Eur J Med Chem 90 170-183 (2015)
  763. Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents. Lu C, Tang K, Li Y, Li P, Lin Z, Yin D, Chen X, Huang H. Eur J Med Chem 77 351-360 (2014)
  764. Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma. Kim HK, Lee S, Kim K, Heo MH, Lee H, Cho J, Kim NKD, Park W, Lee SJ, Kim JH, Jang KT, Choi SH, Lee J. Transl Oncol 9 557-564 (2016)
  765. Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019. Auliac JB, Bayle S, Do P, Le Garff G, Roa M, Falchero L, Huchot E, Quéré G, Jeannin G, Métivier AC, Hobeika J, Guisier F, Chouaid C. Cancers (Basel) 12 E3608 (2020)
  766. Fluorescent cascade and direct assays for characterization of RAF signaling pathway inhibitors. Kupcho KR, Bruinsma R, Hallis TM, Lasky DA, Somberg RL, Turek-Etienne T, Vogel KW, Huwiler KG. Curr Chem Genomics 1 43-53 (2008)
  767. Congress Going beyond EGFR. Zimmermann S, Peters S. Ann Oncol 23 Suppl 10 x197-203 (2012)
  768. Growing indication for FNA to study and analyze tumor heterogeneity at metastatic sites. Beca F, Schmitt F, Schmitt F. Cancer Cytopathol 122 504-511 (2014)
  769. Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation. Saisana M, Griffin SM, May FE. Oncotarget 7 54445-54462 (2016)
  770. Kinetic analysis of RSK2 and Elk-1 interaction on the serum response element and implications for cellular engineering. Aksan Kurnaz I. Biotechnol Bioeng 88 890-900 (2004)
  771. Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation. Milewska M, Romano D, Herrero A, Guerriero ML, Birtwistle M, Quehenberger F, Hatzl S, Kholodenko BN, Segatto O, Kolch W, Zebisch A. PLoS One 10 e0129859 (2015)
  772. Novel pyrazolopyrimidines as highly potent B-Raf inhibitors. Di Grandi MJ, Berger DM, Hopper DW, Zhang C, Dutia M, Dunnick AL, Torres N, Levin JI, Diamantidis G, Zapf CW, Bloom JD, Hu Y, Powell D, Wojciechowicz D, Collins K, Frommer E. Bioorg Med Chem Lett 19 6957-6961 (2009)
  773. P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer. Venkatesha VA, Joshi A, Venkataraman M, Sonawane V, Bhatia D, Tannu P, Bose J, Choudhari S, Srivastava A, Pandey PK, Lad VJ, Sangana R, Ahmed T, Damre A, Deore V, Sahu B, Kumar S, Sharma S, Agarwal VR. Mol Cancer 13 259 (2014)
  774. PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc. Boi D, Souvalidou F, Capelli D, Polverino F, Marini G, Montanari R, Pochetti G, Tramonti A, Contestabile R, Trisciuoglio D, Carpinelli P, Ascanelli C, Lindon C, De Leo A, Saviano M, Di Santo R, Costi R, Guarguaglini G, Paiardini A. Int J Mol Sci 22 13122 (2021)
  775. Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14. Auliac JB, Bayle S, Vergnenegre A, Le Caer H, Falchero L, Gervais R, Doubre H, Vinas F, Marin B, Chouaid C. Curr Oncol 25 e398-e402 (2018)
  776. Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib. Hu L, Zhang J, Tian M, Kang N, Xu G, Zhi J, Ruan X, Hou X, Zhang W, Yi J, Ma W, Chang L, Tang T, Zheng X, Wei X, Gao M. Cell Death Dis 13 124 (2022)
  777. Probing a 3,4'-bis-guanidinium diaryl derivative as an allosteric inhibitor of the Ras pathway. Diez-Cecilia E, Carson R, Kelly B, van Schaeybroeck S, Murray JT, Rozas I. Bioorg Med Chem Lett 25 4287-4292 (2015)
  778. RAF dimers control vascular permeability and cytoskeletal rearrangements at endothelial cell-cell junctions. Dorard C, Cseh B, Ehrenreiter K, Wimmer R, Varga A, Hirschmugl T, Maier B, Kramer K, Fürlinger S, Doma E, Baccarini M. FEBS J 286 2277-2294 (2019)
  779. Stratification and delineation of gastric cancer signaling by in vitro transcription factor activity profiling and integrative genomics. Periasamy J, Muthuswami M, Rao DB, Tan P, Ganesan K. Cell Signal 26 880-894 (2014)
  780. Synthesis, anticancer activity and photostability of novel 3-ethyl-2-mercapto-thieno[2,3-d]pyrimidin-4(3H)-ones. Mavrova AT, Dimov S, Yancheva D, Rangelov M, Wesselinova D, Tsenov JA. Eur J Med Chem 123 69-79 (2016)
  781. T-cell Acute Lymphoblastic Leukemia Cells Display Activation of Different Survival Pathways. Moharram SA, Shah K, Kazi JU. J Cancer 8 4124 (2017)
  782. The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics. Jarell AD, Lawrence D, Tsao H. Biologics 1 407-414 (2007)
  783. Tumorigenesis of papillary thyroid cancer is not BRAF-dependent in patients with acromegaly. Kim HK, Lee JS, Park MH, Cho JS, Yoon JH, Kim SJ, Kang HC. PLoS One 9 e110241 (2014)
  784. Tyrosine kinase activating mutations in human malignancies: implications for diagnostic pathology. Holden JA, Willmore-Payne C, Layfield LJ. Exp Mol Pathol 85 68-75 (2008)
  785. Variant B cell receptor isotype functions differ in hairy cell leukemia with mutated BRAF and IGHV genes. Weston-Bell NJ, Forconi F, Kluin-Nelemans HC, Sahota SS. PLoS One 9 e86556 (2014)
  786. Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study. van der Hiel B, Haanen JBAG, Stokkel MPM, Peeper DS, Jimenez CR, Beijnen JH, van de Wiel BA, Boellaard R, van den Eertwegh AJM, REPOSIT study group. BMC Cancer 17 649 (2017)
  787. c-Myc modulation: a key role in melanoma drug response. Fico A, Alfano D, Valentino A, Vasta V, Cavalcanti E, Travali S, Patriarca EJ, Caputo E. Cancer Biol Ther 16 1375-1386 (2015)
  788. p53 loss does not permit escape from BrafV600E-induced senescence in a mouse model of lung cancer. Garnett S, Dutchak KL, McDonough RV, Dankort D. Oncogene 36 6325-6335 (2017)
  789. (E)-2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol suppresses ovarian cancer cell growth via inhibition of ERK and STAT3. Zheng J, Son DJ, Lee HL, Lee HP, Kim TH, Joo JH, Ham YW, Kim WJ, Jung JK, Han SB, Hong JT. Mol Carcinog 56 2003-2013 (2017)
  790. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model. Joshi SS, Jiang S, Unni E, Goding SR, Fan T, Antony PA, Hornyak TJ. PLoS One 13 e0191264 (2018)
  791. BRAF AMP Frequently Co-occurs With IDH1/2, TP53, and ATRX Mutations in Adult Patients With Gliomas and Is Associated With Poorer Survival Than That of Patients Harboring BRAF V600E. Da R, Wang M, Jiang H, Wang T, Wang W. Front Oncol 10 531968 (2020)
  792. Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases. Zhao Y, Yu H, Ida CM, Halling KC, Kipp BR, Geiersbach K, Rumilla KM, Gupta S, Lin MT, Zheng G. JAMA Netw Open 4 e2035479 (2021)
  793. BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer. Monti E, Bovero M, Mortara L, Pera G, Zupo S, Gugiatti E, Dono M, Massa B, Ansaldo GL, Massimo G. Int J Endocrinol 2015 138734 (2015)
  794. Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors. Dankner M, Wang Y, Fazelzad R, Johnson B, Nebhan CA, Dagogo-Jack I, Myall NJ, Richtig G, Bracht JWP, Gerlinger M, Shinozaki E, Yoshino T, Kotani D, Fangusaro JR, Gautschi O, Mazieres J, Sosman JA, Kopetz S, Subbiah V, Davies MA, Groover AL, Sullivan RJ, Flaherty KT, Johnson DB, Benedetti A, Cescon DW, Spreafico A, Zogopoulos G, Rose AAN. JCO Precis Oncol 6 e2200107 (2022)
  795. Letter Clinicopathologic features of V600E and V600K melanoma--letter. Jewell R, Chambers P, Harland M, Laye J, Conway C, Mitra A, Elliott F, Cook MG, Boon A, Newton-Bishop J. Clin Cancer Res 18 6792; author's reply p. 6793 (2012)
  796. Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma. Kim TW, Kim Y, Keum H, Jung W, Kang M, Jon S. Mol Ther Oncolytics 26 1-14 (2022)
  797. Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets. Khorsandi SE, Dokal AD, Rajeeve V, Britton DJ, Illingworth MS, Heaton N, Cutillas PR. Cancer Res 81 5765-5776 (2021)
  798. Copy number alteration and uniparental disomy analysis categorizes Japanese papillary thyroid carcinomas into distinct groups. Matsuse M, Sasaki K, Nishihara E, Minami S, Hayashida C, Kondo H, Suzuki K, Saenko V, Yoshiura K, Mitsutake N, Yamashita S. PLoS One 7 e36063 (2012)
  799. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report. Casadevall D, Vidal J, Gallardo F, Zuccarino F, Arumí-Uría M, Dalmases A, Bellosillo B, Montagut C. J Med Case Rep 10 158 (2016)
  800. Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors. Ramurthy S, Aikawa M, Amiri P, Costales A, Hashash A, Jansen JM, Lin S, Ma S, Renhowe PA, Shafer CM, Subramanian S, Sung L, Verhagen J. Bioorg Med Chem Lett 21 3286-3289 (2011)
  801. Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors. af Gennäs GB, Mologni L, Ahmed S, Rajaratnam M, Marin O, Lindholm N, Viltadi M, Gambacorti-Passerini C, Scapozza L, Yli-Kauhaluoma J. ChemMedChem 6 1680-1692 (2011)
  802. Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis. Emelyanova M, Ghukasyan L, Abramov I, Ryabaya O, Stepanova E, Kudryavtseva A, Sadritdinova A, Dzhumakova C, Belysheva T, Surzhikov S, Lyubchenko L, Zasedatelev A, Nasedkina T. Oncotarget 8 52304-52320 (2017)
  803. Development and validation of a rapid and simple LC-MS/MS method for quantification of vemurafenib in human plasma: application to a human pharmacokinetic study. Bihan K, Sauzay C, Goldwirt L, Charbonnier-Beaupel F, Hulot JS, Funck-Brentano C, Zahr N. Ther Drug Monit 37 132-136 (2015)
  804. Development of a yeast-based system to identify new hBRAFV600E functional interactors. Lubrano S, Comelli L, Piccirilli C, Marranci A, Dapporto F, Tantillo E, Gemignani F, Gutkind JS, Salvetti A, Chiorino G, Cozza G, Chiariello M, Galli A, Poliseno L, Cervelli T. Oncogene 38 1355-1366 (2019)
  805. Effects of rigidity on the selectivity of protein kinase inhibitors. Assadieskandar A, Yu C, Maisonneuve P, Liu X, Chen YC, Prakash GKS, Kurinov I, Sicheri F, Zhang C. Eur J Med Chem 146 519-528 (2018)
  806. Energetics and structural characterization of the "DFG-flip" conformational transition of B-RAF kinase: a SITS molecular dynamics study. Shao Q, Xu Z, Wang J, Shi J, Zhu W. Phys Chem Chem Phys 19 1257-1267 (2017)
  807. Evolving pharmacotherapies for the treatment of metastatic melanoma. Salama AK. Clin Med Insights Oncol 7 137-149 (2013)
  808. Genome sequencing identifies somatic BRAF duplication c.1794_1796dupTAC;p.Thr599dup in pediatric patient with low-grade ganglioglioma. Miller KE, Kelly B, Fitch J, Ross N, Avenarius MR, Varga E, Koboldt DC, Boué DR, Magrini V, Coven SL, Finlay JL, Cottrell CE, White P, Gastier-Foster JM, Wilson RK, Leonard J, Mardis ER. Cold Spring Harb Mol Case Stud 4 a002618 (2018)
  809. Increased BRAF copy number in lung adenocarcinoma. Sasaki H, Maekawa M, Tatematsu T, Okuda K, Moriyama S, Yano M, Fujii Y. Oncol Lett 9 709-712 (2015)
  810. K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth. Dalpa E, Gourvas V, Soulitzis N, Spandidos DA. Med Oncol 34 6 (2017)
  811. KSRP modulates melanoma growth and efficacy of vemurafenib. Liu W, Chou CF, Liu S, Crossman D, Yusuf N, Wu Y, Chen CY. Biochim Biophys Acta Gene Regul Mech 1862 759-770 (2019)
  812. Melanoma: targeting signaling pathways and RaLP. Pasini L, Turco MY, Luzi L, Aladowicz E, Fagiani E, Lanfrancone L. Expert Opin Ther Targets 13 93-104 (2009)
  813. Molecular Alterations Associated with Acquired Drug Resistance during Combined Treatment with Encorafenib and Binimetinib in Melanoma Cell Lines. Patel V, Szász I, Koroknai V, Kiss T, Balázs M. Cancers (Basel) 13 6058 (2021)
  814. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma. Carlson JA, Caldeira Xavier JC, Tarasen A, Sheehan CE, Otto G, Miller VA, Stephens PJ, Elvin JA, Vergilio JA, Suh J, Gay LM, Ross JS. Am J Dermatopathol 39 1-13 (2017)
  815. Novel BRAF mutation in melanoma: A case report. Trubini S, Ubiali A, Paties CT, Cavanna L. Mol Clin Oncol 8 460-462 (2018)
  816. Oncogenes are to lose control on signaling following mutation: should we aim off target? Hornberg JJ, Westerhoff HV. Mol Biotechnol 34 109-116 (2006)
  817. Polymerase-amplified release of ATP (POLARA) for detecting single nucleotide variants in RNA and DNA. Mohsen MG, Ji D, Kool ET. Chem Sci 10 3264-3270 (2019)
  818. Raf inhibition causes extensive multiple tissue hyperplasia and urinary bladder neoplasia in the rat. Wisler JA, Afshari C, Fielden M, Zimmermann C, Taylor S, Carnahan J, Vonderfecht S. Toxicol Pathol 39 809-822 (2011)
  819. Reversible and tissue-specific activation of MAP kinase signaling by tamoxifen in Braf(V637)ER(T2) mice. Ortiz O, Wurst W, Kühn R. Genesis 51 448-455 (2013)
  820. Sorafenib and its tosylate salt: a multikinase inhibitor for treating cancer. Ravikumar K, Sridhar B, Bhujanga Rao AK, Pulla Reddy M. Acta Crystallogr C 67 o29-32 (2011)
  821. Targeting SIRT2 Sensitizes Melanoma Cells to Cisplatin via an EGFR-Dependent Mechanism. Karwaciak I, Sałkowska A, Karaś K, Dastych J, Ratajewski M. Int J Mol Sci 22 5034 (2021)
  822. The EGF receptor Hokey-Cokey. Niculescu-Duvaz D, Whittaker S, Springer C, Marais R. Cancer Cell 11 209-211 (2007)
  823. Therapy response assessment in metastatic melanoma patients treated with a BRAF inhibitor: adapted Choi criteria can reflect early therapy response better than does RECIST. Uhrig M, Hassel JC, Schlemmer HP, Ganten MK. Acad Radiol 20 423-429 (2013)
  824. Letter (G12D) NRAS and kinase-dead BRAF cooperate to drive naevogenesis and melanomagenesis. Pedersen M, Viros A, Cook M, Marais R. Pigment Cell Melanoma Res 27 1162-1166 (2014)
  825. A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study. Tan L, Tran B, Tie J, Markman B, Ananda S, Tebbutt NC, Michael M, Link E, Wong SQ, Chandrashekar S, Guinto J, Ritchie D, Koldej R, Solomon BJ, McArthur GA, Hicks RJ, Gibbs P, Dawson SJ, Desai J. Clin Cancer Res 29 1017-1030 (2023)
  826. A highly sensitive and specific real-time quantitative PCR for BRAF V600E/K mutation screening. Lung J, Hung MS, Lin YC, Jiang YY, Fang YH, Lu MS, Hsieh CC, Wang CS, Kuan FC, Lu CH, Chen PT, Lin CM, Chou YL, Lin CK, Yang TM, Chen FF, Lin PY, Hsieh MJ, Tsai YH. Sci Rep 10 16943 (2020)
  827. A novel BRAF mutation in association with primary amelanotic melanoma with oral metastases. Zalaudek I, Ciarrocchi A, Piana S, Argenziano G, Torricelli F, Sancisi V, Gandolfi G, Longo C, Moscarella E, Banzi C, Nicoli D. J Eur Acad Dermatol Venereol 29 387-390 (2015)
  828. A novel RFLP-ARMS TaqMan PCR-based method for detecting the BRAF V600E mutation in melanoma. Zhang Y, Qu S, Zhao J, Yu T, Guo L, Yin S, Hu X, Chen W, Lai W, Huang J. Oncol Lett 16 1615-1621 (2018)
  829. AIM2 Inhibits BRAF-Mutant Colorectal Cancer Growth in a Caspase-1-Dependent Manner. Shah S, Qin S, Luo Y, Huang Y, Jing R, Shah JN, Chen J, Chen H, Zhong M. Front Cell Dev Biol 9 588278 (2021)
  830. Acetylation-dependent regulation of BRAF oncogenic function. Dai X, Zhang X, Yin Q, Hu J, Guo J, Gao Y, Snell AH, Inuzuka H, Wan L, Wei W. Cell Rep 38 110250 (2022)
  831. Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer. Nicoś M, Krawczyk P, Jarosz B, Sawicki M, Szumiłło J, Trojanowski T, Milanowski J. Clin Exp Med 16 169-176 (2016)
  832. Application of shape-based and pharmacophore-based in silico screens for identification of Type II protein kinase inhibitors. Mucs D, Bryce RA, Bonnet P. J Comput Aided Mol Des 25 569-581 (2011)
  833. Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. Loupakis F, Cremolini C, Fontanini G, Stasi I, Salvatore L, Falcone A. Ther Adv Med Oncol 1 167-181 (2009)
  834. News Cancer: enzymes play molecular tag. Morrison DK. Nature 428 813-815 (2004)
  835. Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with BRAF p.T599dup mutation. Miller KE, Schieffer KM, Grischow O, Rodriguez DP, Cottrell CE, Leonard JR, Finlay JL, Mardis ER. Cold Spring Harb Mol Case Stud 7 a006023 (2021)
  836. Clinical validation of coexisting driver mutations in colorectal cancers. Zheng G, Tseng LH, Haley L, Ibrahim J, Bynum J, Xian R, Gocke CD, Eshleman JR, Lin MT. Hum Pathol 86 12-20 (2019)
  837. Combining pharmacophore, docking and substructure search approaches to identify and optimize novel B-RafV600E inhibitors. Xu Z, Yan G, Wang G, Li B, Zhu J, Sun P, Zhang X, Luo C, Wang H, Zhu W. Bioorg Med Chem Lett 22 5428-5437 (2012)
  838. Design and synthesis of new 2-anilinoquinolines bearing N-methylpicolinamide moiety as potential antiproliferative agents. El-Damasy AK, Seo SH, Cho NC, Pae AN, Kim EE, Keum G. Chem Biol Drug Des 89 98-113 (2017)
  839. Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations. Kim HC, Kang YR, Ji W, Kim YJ, Yoon S, Lee JC, Choi CM. Onco Targets Ther 12 6045-6052 (2019)
  840. Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase. Wenglowsky S, Ren L, Grina J, Hansen JD, Laird ER, Moreno D, Dinkel V, Gloor SL, Hastings G, Rana S, Rasor K, Sturgis HL, Voegtli WC, Vigers G, Willis B, Mathieu S, Rudolph J. Bioorg Med Chem Lett 24 1923-1927 (2014)
  841. Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity. Lyne PD, Aquila B, Cook DJ, Dakin LA, Ezhuthachan J, Ioannidis S, Pontz T, Su M, Ye Q, Zheng X, Block MH, Cowen S, Deegan TL, Lee JW, Scott DA, Custeau D, Drew L, Poondru S, Shen M, Wu A. Bioorg Med Chem Lett 19 1026-1029 (2009)
  842. Identification of type II inhibitors targeting BRAF using privileged pharmacophores. Zhang Q, Wang J, Wang F, Chen X, He Y, You Q, Zhou H. Chem Biol Drug Des 83 27-36 (2014)
  843. In-depth proteomic profiling captures subtype-specific features of craniopharyngiomas. Kim JH, Kim H, Dan K, Kim SI, Park SH, Han D, Kim YH. Sci Rep 11 21206 (2021)
  844. Induction of Apoptosis by PQ1, a Gap Junction Enhancer that Upregulates Connexin 43 and Activates the MAPK Signaling Pathway in Mammary Carcinoma Cells. Shishido SN, Nguyen TA. Int J Mol Sci 17 E178 (2016)
  845. Integrated computational and Drosophila cancer model platform captures previously unappreciated chemicals perturbing a kinase network. Ung PMU, Sonoshita M, Scopton AP, Dar AC, Cagan RL, Schlessinger A. PLoS Comput Biol 15 e1006878 (2019)
  846. MEK inhibition suppresses cell invasion and migration in ovarian cancers with activation of ERK1/2. Katagiri A, Nakayama K, Rahman MT, Rahman M, Yeasmin S, Ishikawa M, Iida K, Nakayama N, Miyazaki K. Exp Ther Med 1 591-596 (2010)
  847. Case Reports Malignant Melanoma with Concurrent BRAF E586K and NRAS Q81K Mutations. Shackelford R, Pollen M, Vora M, Jusion TT, Cotelingam J, Nair B. Case Rep Oncol 7 297-300 (2014)
  848. Miquelianin Inhibits Allergic Responses in Mice by Suppressing CD4+ T Cell Proliferation. Choi DW, Jung SY, Kim GD, Lee SY, Shin HS. Antioxidants (Basel) 10 1120 (2021)
  849. N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers. Grasso M, Estrada MA, Berrios KN, Winkler JD, Marmorstein R. J Med Chem 61 5034-5046 (2018)
  850. Non-canonical Raf-1/p70S6K signalling in non-small-cell lung cancer. Qiu Z, Ye B, Zhao S, Li X, Li L, Mo X, Li W. J Cell Mol Med 23 7632-7640 (2019)
  851. Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas. Gouravan S, Meza-Zepeda LA, Myklebost O, Stratford EW, Munthe E. Int J Mol Sci 19 E969 (2018)
  852. Case Reports Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series. Naqvi MF, Vo HH, Vining D, Tsimberidou AM. Ther Adv Med Oncol 13 17588359211001538 (2021)
  853. Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance. Wang L, Zhu G, Zhang Q, Duan C, Zhang Y, Zhang Z, Zhou Y, Lu T, Tang W. Org Biomol Chem 15 3455-3465 (2017)
  854. TRPM1 promotes tumor progression in acral melanoma by activating the Ca2+/CaMKIIδ/AKT pathway. Hsieh CC, Su YC, Jiang KY, Ito T, Li TW, Kaku-Ito Y, Cheng ST, Chen LT, Hwang DY, Shen CH. J Adv Res 43 45-57 (2023)
  855. The ETS Inhibitor YK-4-279 Suppresses Thyroid Cancer Progression Independent of TERT Promoter Mutations. Xue J, Li S, Shi P, Chen M, Yu S, Hong S, Li Y, Liu R, Xiao H. Front Oncol 11 649323 (2021)
  856. The diagnostic role and clinical relevance of determination of BRAF status in brain tumors. Gessi M, Pietsch T. Per Med 10 405-412 (2013)
  857. The power of FDG-PET to detect treatment effects is increased by glucose correction using a Michaelis constant. Williams SP, Flores-Mercado JE, Baudy AR, Port RE, Bengtsson T. EJNMMI Res 2 35 (2012)
  858. Uncommon mutational profiles of metastatic colorectal cancer detected during routine genotyping using next generation sequencing. Franczak C, Kandathil SM, Gilson P, Husson M, Rouyer M, Demange J, Leroux A, Merlin JL, Harlé A. Sci Rep 9 7083 (2019)
  859. Upregulation of the novel lncRNA U731166 is associated with migration, invasion and vemurafenib resistance in melanoma. Siena ÁDD, Barros II, Storti CB, de Biagi Júnior CAO, da Costa Carvalho LA, Maria-Engler SS, Sousa JF, Silva WA. J Cell Mol Med 26 671-683 (2022)
  860. 1082-39, an analogue of sorafenib, inhibited human cancer cell growth more potently than sorafenib. Chu JH, Zhao CR, Song ZY, Wang RQ, Qin YZ, Li WB, Qu XJ. Biomed Pharmacother 68 335-341 (2014)
  861. BRAF V600 Mutation Detection in Plasma Cell-Free DNA: NCCTG N0879 (Alliance). Slostad JA, Liu MC, Allred JB, Erickson LA, Rumilla KM, Block MS, Keppen M, King D, Markovic SN, McWilliams RR. Mayo Clin Proc Innov Qual Outcomes 5 1012-1020 (2021)
  862. Case Reports KRAS and BRAF Concomitant Mutations in a Patient with Metastatic Colon Adenocarcinoma: An Interesting Case Report. Cafiero C, Re A, D'Amato G, Surico PL, Surico G, Pirrelli M, Pisconti S. Case Rep Oncol 13 595-600 (2020)
  863. A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies. Yao K, Zhou E, Cheng C. Cancer Med 11 1232-1243 (2022)
  864. A Microfluidic Device for Multiplex Single-Nucleotide Polymorphism Genotyping. Zhu J, Qiu C, Palla M, Nguyen T, Russo JJ, Ju J, Lin Q. RSC Adv 4 4269-4277 (2014)
  865. A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. Simeone E, Scognamiglio G, Capone M, Giannarelli D, Grimaldi AM, Mallardo D, Madonna G, Curvietto M, Esposito A, Sandomenico F, Sabbatino F, Bayless NL, Warren S, Ong S, Botti G, Flaherty KT, Ferrone S, Ascierto PA. J Transl Med 19 17 (2021)
  866. ATF-3 expression inhibits melanoma growth by downregulating ERK and AKT pathways. Zu T, Wang D, Xu S, Lee CAA, Zhen E, Yoon CH, Abarzua P, Wang S, Frank NY, Wu X, Lian CG, Murphy GF. Lab Invest 101 636-647 (2021)
  867. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. Heard JJ, Phung I, Potes MI, Tamanoi F. BMC Cancer 18 69 (2018)
  868. Autophosphorylation on S614 inhibits the activity and the transforming potential of BRAF. Dernayka L, Rauch N, Jarboui MA, Zebisch A, Texier Y, Horn N, Romano D, Gloeckner CJ, Kriegsheim AV, Ueffing M, Kolch W, Boldt K. Cell Signal 28 1432-1439 (2016)
  869. B-Raf mutation and papillary thyroid carcinoma patients. Jiang L, Chu H, Zheng H. Oncol Lett 11 2699-2705 (2016)
  870. BRAF Modulates Lipid Use and Accumulation. Turner JA, Paton EL, Van Gulick R, Stefanoni D, Cendali F, Reisz J, Tobin RP, McCarter M, D'Alessandro A, Torres RM, Robinson WA, Couts KL, Schlaepfer IR. Cancers (Basel) 14 2110 (2022)
  871. BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition. Obasaju P, Shahab S, Dunn E, Rhee DS, Jiang L, Dome JS, Friedman AD, Argani P, Pratilas CA. Cold Spring Harb Mol Case Stud 6 a004820 (2020)
  872. BRAF pyrosequencing analysis aided by a lookup table. Olson MT, Harrington C, Beierl K, Chen G, Thiess M, O'Neill A, Taube JM, Zeiger MA, Lin MT, Eshleman JR. Am J Clin Pathol 141 639-647 (2014)
  873. Bayesian networks elucidate complex genomic landscapes in cancer. Angelopoulos N, Chatzipli A, Nangalia J, Maura F, Campbell PJ. Commun Biol 5 306 (2022)
  874. Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients. Colombino M, Rozzo C, Paliogiannis P, Casula M, Manca A, Doneddu V, Fedeli MA, Sini MC, Palomba G, Pisano M, Ascierto PA, Caracò C, Lissia A, Cossu A, Palmieri G. J Clin Med 9 E2430 (2020)
  875. Design and synthesis of a new series of highly potent RAF kinase-inhibiting triarylpyrazole derivatives possessing antiproliferative activity against melanoma cells. Khan MA, El-Gamal MI, Tarazi H, Choi HS, Oh CH. Future Med Chem 8 2197-2211 (2016)
  876. Design and synthesis of isoquinolines and benzimidazoles as RAF kinase inhibitors. Buchstaller HP, Burgdorf L, Finsinger D, Stieber F, Sirrenberg C, Amendt C, Grell M, Zenke F, Krier M. Bioorg Med Chem Lett 21 2264-2269 (2011)
  877. Design, Synthesis and Anticancer Profile of New 4-(1H-benzo[d]imidazol-1-yl)pyrimidin-2-amine-Linked Sulfonamide Derivatives with V600EBRAF Inhibitory Effect. Abdel-Maksoud MS, Mohamed AAB, Hassan RM, Abdelgawad MA, Chilingaryan G, Selim S, Abdel-Bakky MS, Al-Sanea MM. Int J Mol Sci 22 10491 (2021)
  878. Discovery of Potent EGFR Inhibitors With 6-Arylureido-4-anilinoquinazoline Derivatives. Li M, Xue N, Liu X, Wang Q, Yan H, Liu Y, Wang L, Shi X, Cao D, Zhang K, Zhang Y. Front Pharmacol 12 647591 (2021)
  879. ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues. Kim SW, Kim HK, Lee JI, Jang HW, Choe JH, Kim JH, Kim JS, Hur KY, Kim JH, Chung JH. Endocr Res 38 89-97 (2013)
  880. Expression and purification of active receptor interacting protein 1 kinase using a baculovirus system. Maki JL, Tres Brazell J, Teng X, Cuny GD, Degterev A. Protein Expr Purif 89 156-161 (2013)
  881. Expression of B-RAF V600E in type II pneumocytes causes abnormalities in alveolar formation, airspace enlargement and tumor formation in mice. Zanucco E, Götz R, Potapenko T, Carraretto I, Ceteci S, Ceteci F, Seeger W, Savai R, Rapp UR. PLoS One 6 e29093 (2011)
  882. Expression of Clonorchis sinensis GIIIsPLA2 protein in baculovirus-infected insect cells and its overexpression facilitating epithelial-mesenchymal transition in Huh7 cells via AKT pathway. Shang M, Xie Z, Tang Z, He L, Wang X, Wang C, Wu Y, Li Y, Zhao L, Lv Z, Wu Z, Huang Y, Yu X, Li X. Parasitol Res 116 1307-1316 (2017)
  883. HSP-90/kinase complexes are stabilized by the large PPIase FKB-6. Sima S, Barkovits K, Marcus K, Schmauder L, Hacker SM, Hellwig N, Morgner N, Richter K. Sci Rep 11 12347 (2021)
  884. Identification and Characterization of a B-Raf Kinase α-Helix Critical for the Activity of MEK Kinase in MAPK Signaling. Nguyen D, Lin LY, Zhou JO, Kibby E, Sia TW, Tillis TD, Vapuryan N, Xu MR, Potluri R, Shin Y, Erler EA, Bronkema N, Boehlmer DJ, Chung CD, Burkhard C, Zeng SH, Grasso M, Acevedo LA, Marmorstein R, Fera D. Biochemistry 59 4755-4765 (2020)
  885. In vitro dimerization of human RIO2 kinase. Maurice F, Pérébaskine N, Thore S, Fribourg S. RNA Biol 16 1633-1642 (2019)
  886. Interaction of Masitinib with Organic Cation Transporters. Harrach S, Haag J, Steinbüchel M, Schröter R, Neugebauer U, Bertrand J, Ciarimboli G. Int J Mol Sci 23 14189 (2022)
  887. Lack of BRAFV600E mutation in stage I and II of colorectal cancer. Molaei M, Kishani Farahani R, Maftouh M, Taleghani MY, Vahdatinia M, Khatami F, Nazemalhosseini-Mojarad E, Asadzadeh Aghdae H, Aboutorabi A, Zali MR. Gastroenterol Hepatol Bed Bench 9 94-99 (2016)
  888. Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments. Zhang Q, Zhang X, You Q. Molecules 21 E879 (2016)
  889. Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation. Roh MR, Kim JM, Lee SH, Jang HS, Park KH, Chung KY, Rha SY. J Dermatol 42 881-888 (2015)
  890. MEK inhibitors in non-V600 BRAF mutations and fusions. Johnson DB, Nebhan CA, Noel MS. Oncotarget 11 3900-3903 (2020)
  891. MicroRNA-18a induces epithelial-mesenchymal transition like cancer stem cell phenotype via regulating RKIP pathway in pancreatic cancer. Kang H, Ma D, Zhang J, Zhao J, Yang M. Ann Transl Med 8 433 (2020)
  892. Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups. Perrone F, Mazzaschi G, Minari R, Verzè M, Azzoni C, Bottarelli L, Nizzoli R, Pluchino M, Altimari A, Gruppioni E, Sperandi F, Andrini E, Guaitoli G, Bertolini F, Barbieri F, Bettelli S, Longo L, Pagano M, Bonelli C, Tagliavini E, Nicoli D, Ubiali A, Zangrandi A, Trubini S, Proietto M, Gnetti L, Tiseo M. Cancers (Basel) 14 2019 (2022)
  893. Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect. Pulici M, Traquandi G, Marchionni C, Modugno M, Lupi R, Amboldi N, Casale E, Colombo N, Corti L, Fasolini M, Gasparri F, Pastori W, Scolaro A, Donati D, Felder E, Galvani A, Isacchi A, Pesenti E, Ciomei M. ChemMedChem 10 276-295 (2015)
  894. Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma. Hargrave DR, Terashima K, Hara J, Kordes UR, Upadhyaya SA, Sahm F, Bouffet E, Packer RJ, Witt O, Sandalic L, Kieloch A, Russo M, Cohen KJ, Investigators involved in the high-grade glioma cohort. J Clin Oncol 41 5174-5183 (2023)
  895. Letter Postzygotic BRAF p.Lys601Asn Mutation in Phacomatosis Pigmentokeratotica with Woolly Hair Nevus and Focal Cortical Dysplasia. Kuentz P, Mignot C, St-Onge J, Duffourd Y, Bonniaud B, Faivre L, Rivière JB, Vabres P. J Invest Dermatol 136 1060-1062 (2016)
  896. Rare case of triple mutant (KRAS + NRAS + BRAF) metastatic colon adenocarcinoma. Vittal A, Sharma D, Samanta I, Kasi A. BMJ Case Rep 12 e221816 (2019)
  897. Reversible Photoswitchable Inhibitors Generate Ultrasensitivity in Out-of-Equilibrium Enzymatic Reactions. Teders M, Pogodaev AA, Bojanov G, Huck WTS. J Am Chem Soc 143 5709-5716 (2021)
  898. Reviving B-Factors: Activating ALK Mutations Increase Protein Dynamics of the Unphosphorylated Kinase. Johnson TW, Bolanos B, Brooun A, Gallego RA, Gehlhaar D, Jalaie M, McTigue M, Timofeevski S. ACS Med Chem Lett 9 872-877 (2018)
  899. STOML2 interacts with PHB through activating MAPK signaling pathway to promote colorectal Cancer proliferation. Ma W, Chen Y, Xiong W, Li W, Xu Z, Wang Y, Wei Z, Mou T, Wu Z, Cheng M, Zou Y, Zhu Y, Zhou W, Liu F, Geng Y. J Exp Clin Cancer Res 40 359 (2021)
  900. Targeted treatment of differentiated and medullary thyroid cancer. Bales SR, Chopra IJ. J Thyroid Res 2011 102636 (2011)
  901. Teaching resources. Ras-MAPK pathways. Chan A. Sci STKE 2005 tr5 (2005)
  902. Letter Testing and clinical implications for non-V600 BRAF mutations in metastatic NRASmt melanoma. Richtig G, Richtig E, Kashofer K, Koch L, Winter G, Hoefler G, Pichler M, Ehall B, Grübler MR, Heinemann A, Aigelsreiter A. Br J Dermatol 177 860-861 (2017)
  903. The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer. Muhammad S, Jiang Z, Liu Z, Kaur K, Wang X. J Gastrointest Oncol 4 72-81 (2013)
  904. Timeline metastatic progression: in the wake of the « seed and soil » theory. Amelot A, Terrier LM, Mazeron JJ, Valery CA, Cornu P, Carpentier A, Leveque M. Med Oncol 34 185 (2017)
  905. Use of fluorescence in situ hybridization to distinguish metastatic uveal from cutaneous melanoma. Fang Y, Wang X, Dusza S, Jhanwar S, Abramson D, Busam KJ. Int J Surg Pathol 20 246-251 (2012)
  906. Case Reports A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report. Consoli F, Barbieri G, Picciolini M, Medicina D, Bugatti M, Tovazzi V, Liserre B, Zambelli C, Zorzi F, Berruti A, Giurisato E, Vermi W. Front Oncol 10 1056 (2020)
  907. A high throughput assay to identify substrate-selective inhibitors of the ERK protein kinases. Miller CJ, Muftuoglu Y, Turk BE. Biochem Pharmacol 142 39-45 (2017)
  908. A selective cellular screening assay for B-Raf and c-Raf kinases. Ish T, Sootome H, Yagi Y, Yamashita K, Noumi T, Noro N, Ishii T. J Biomol Screen 12 818-827 (2007)
  909. An application of competitive reporter monitored amplification (CMA) for rapid detection of single nucleotide polymorphisms (SNPs). Havlicek J, Rivera-Milla E, Slickers P, Andres S, Feuerriegel S, Niemann S, Merker M, Labugger I. PLoS One 12 e0183561 (2017)
  910. An integrated multi-molecular sensor for simultaneous BRAFV600E protein and DNA single point mutation detection in circulating tumour cells. Dey S, Koo KM, Wang Z, Sina AAI, Wuethrich A, Trau M. Lab Chip 19 738-748 (2019)
  911. BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report. Gallo S, Coha V, Caravelli D, Becco P, Venesio T, Zaccagna A, Giacone E, Marenco F, Pisacane A, Racca M, Gammaitoni L, Aglietta M, Carnevale-Schianca F. Melanoma Res 28 143-146 (2018)
  912. BRAFnon-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAFV600E but without a survival advantage. Wang W, Wang M, Jiang H, Wang T, Da R. BMC Neurol 21 195 (2021)
  913. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor. Curry JL, Falchook GS, Hwu WJ, Torres-Cabala CA, Duvic M, Tetzlaff MT, Prieto VG. Am J Dermatopathol 35 125-128 (2013)
  914. Clinicopathologic Features and Prognosis of BRAF Mutated Colorectal Cancer Patients. Guan WL, Qiu MZ, He CY, Yang LQ, Jin Y, Wang ZQ, Li YH, Xu RH, Wang FH. Front Oncol 10 563407 (2020)
  915. Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation. Patil K, Jordan EJ, Park JH, Suresh K, Smith CM, Lemmon AA, Mossé YP, Lemmon MA, Radhakrishnan R. Proc Natl Acad Sci U S A 118 e2019132118 (2021)
  916. Case Reports Concomitant BRAF Mutation in Hairy Cell Leukemia and Papillary Thyroid Cancer: Case Report. Mohamed SF, Helmi F, El-Akiki S, El Omri H, Nashwan A, Yassin MA. Case Rep Oncol 12 922-927 (2019)
  917. Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance. Wang L, Zhang Q, Zhu G, Zhang Z, Zhi Y, Zhang L, Mao T, Zhou X, Chen Y, Lu T, Tang W. Eur J Med Chem 130 86-106 (2017)
  918. Discovery and pharmacophore studies of novel pyrazole-based anti-melanoma agents. Li QS, Lü XH, Yang Y, Ruan BF, Yao RS, Liao CZ. Chem Biodivers 12 116-132 (2015)
  919. Discovery of New Quinolone-Based Diarylamides as Potent B-RAFV600E/C-RAF Kinase Inhibitors Endowed with Promising In Vitro Anticancer Activity. Kim HJ, Park JW, Seo S, Cho KH, Alanazi MM, Bang EK, Keum G, El-Damasy AK. Int J Mol Sci 24 3216 (2023)
  920. Dual binding site inhibitors of B-RAF kinase. Wolin RL, Bembenek SD, Wei J, Crawford S, Lundeen K, Brunmark A, Karlsson L, Edwards JP, Blevitt JM. Bioorg Med Chem Lett 18 2825-2829 (2008)
  921. From oncoproteins to spike proteins: the evaluation of intramolecular stability using hydropathic force field. Agosta F, Kellogg GE, Cozzini P. J Comput Aided Mol Des 36 797-804 (2022)
  922. Gliomatosis cerebri type 1 with extensive involvement of the spinal cord and BRAF V600E mutation. Fernandez-Vega I, Quirk J, Norwood FL, Sibtain NA, Laxton R, Bodi I. Pathol Oncol Res 20 215-220 (2014)
  923. Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer. Carter R, Cheraghchi-Bashi A, Westhorpe A, Yu S, Shanneik Y, Seraia E, Ouaret D, Inoue Y, Koch C, Wilding J, Ebner D, Ryan AJ, Buffa FM, Sharma RA. Cancer Biol Med 16 234-246 (2019)
  924. Identification of single amino acid polymorphisms in MS/MS spectra of peptides. Chernobrovkin AL, Mitkevich VA, Popov IA, Indeikina MI, Ilgisonis EV, Lisitsa AV, Archakov AI. Dokl Biochem Biophys 437 90-93 (2011)
  925. Impact of carboplatin plus paclitaxel combined with endostar against A375 melanoma cells: An in vitro and in vivo analysis. Zheng AW, Jia DD, Xia LM, Jin G, Wu H, Li T. Biomed Pharmacother 83 1321-1326 (2016)
  926. In silico binding free energy predictability with π-π interaction energy-augmented scoring function: benzimidazole Raf inhibitors as a case study. Chung JY, Cho SJ, Cho AE, Hah JM. Bioorg Med Chem Lett 22 3278-3283 (2012)
  927. In silico identification of novel kinase inhibitors by targeting B-Raf(v660e) from natural products database. Wang ZJ, Wan ZN, Chen XD, Wu CF, Gao GL, Liu R, Shi Z, Bao JK. J Mol Model 21 102 (2015)
  928. Insight into the structural features of pyrazolopyrimidine- and pyrazolopyridine-based B-Raf(V600E) kinase inhibitors by computational explorations. Li Y, Han C, Wang J, Yang Y, Zhang J, Zhang S, Yang L. Chem Biol Drug Des 83 643-655 (2014)
  929. Leucine-485 deletion variant of BRAF may exhibit the severe end of the clinical spectrum of CFC syndrome. Suzuki-Muromoto S, Miyabayashi T, Nagai K, Yamamura-Suzuki S, Anzai M, Takezawa Y, Sato R, Okubo Y, Endo W, Inui T, Togashi N, Kikuchi A, Niihori T, Aoki Y, Kure S, Haginoya K. J Hum Genet 64 499-504 (2019)
  930. Case Reports Multidisciplinary Therapy Managed Recurrent Glioblastoma in a BRAF-V600E Mutant Pregnant Female: A Case Report and Review of the Literature. Qin C, Long W, Zhang C, Xie Y, Wu C, Li Y, Xiao Q, Ji N, Liu Q. Front Oncol 10 522816 (2020)
  931. Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population. Gutiérrez-Castañeda LD, Gamboa M, Nova JA, Pulido L, Tovar-Parra JD. Biomed Res Int 2020 2046947 (2020)
  932. NLRP1 Functions Downstream of the MAPK/ERK Signaling via ATF4 and Contributes to Acquired Targeted Therapy Resistance in Human Metastatic Melanoma. Zhai Z, Vaddi PK, Samson JM, Takegami T, Fujita M. Pharmaceuticals (Basel) 14 23 (2020)
  933. Comment Not All BRAF-Mutant Metastatic Colorectal Cancers Are Identical: Distinct Clinical Consequences of non-V600 BRAF Mutations. Van Cutsem E, Dekervel J. J Clin Oncol 35 2598-2599 (2017)
  934. Novel BRAFI599Ins Mutation Identified in a Follicular Variant of a Papillary Thyroid Carcinoma: A Molecular Modeling Approach. Cañadas-Garre M, Fernandez-Escamilla AM, Fernandez-Ballester G, Becerra-Massare P, García-Calvente C, Ramos JL, Llamas-Elvira JM. Endocr Pract 20 e75-9 (2014)
  935. P16 overexpression in BRAF-mutated gastrointestinal stromal tumors. Shi SS, Wang X, Xia QY, Rao Q, Shen Q, Ye SB, Li R, Shi QL, Lu ZF, Ma HH, Zhou XJ. Expert Rev Mol Diagn 17 195-201 (2017)
  936. Prognostic Significance of COX-2 Overexpression in BRAF-Mutated Middle Eastern Papillary Thyroid Carcinoma. Parvathareddy SK, Siraj AK, Annaiyappanaidu P, Al-Sobhi SS, Al-Dayel F, Al-Kuraya KS. Int J Mol Sci 21 E9498 (2020)
  937. Rational drug design of indazole-based diarylurea derivatives as anticancer agents. Chu YY, Cheng HJ, Tian ZH, Zhao JC, Li G, Chu YY, Sun CJ, Li WB. Chem Biol Drug Des 90 609-617 (2017)
  938. Regulation of signal transduction pathways in colorectal cancer: implications for therapeutic resistance. Yeoh Y, Low TY, Abu N, Lee PY. PeerJ 9 e12338 (2021)
  939. SGSM2 inhibits thyroid cancer progression by activating RAP1 and enhancing competitive RAS inhibition. Su X, Chen D, Zhu L, Jia H, Cai J, Li P, Han B, Wang D, Li H, Fan J, Gu M, Zhou Y, Guan H, Wei W. Cell Death Dis 13 218 (2022)
  940. Snowball: resampling combined with distance-based regression to discover transcriptional consequences of a driver mutation. Xu Y, Guo X, Sun J, Zhao Z. Bioinformatics 31 84-93 (2015)
  941. Structural elaboration of a natural product: identification of 3,3'-diindolylmethane aminophosphonate and urea derivatives as potent anticancer agents. Kandekar S, Preet R, Kashyap M, Renu Prasad MU, Mohapatra P, Das D, Satapathy SR, Siddharth S, Jain V, Choudhuri M, Kundu CN, Guchhait SK, Bharatam PV. ChemMedChem 8 1873-1884 (2013)
  942. Structural insights and influence of V599 mutations on the overall dynamics of BRAF protein against its kinase domains. Mayank, Kaur N, Singh N. Integr Biol (Camb) 10 646-657 (2018)
  943. Synchronous ipsilateral sebaceous lymphadenoma and membranous basal cell adenoma of the parotid. Scheller EL, Pritchett CV, Shukla A, Pepper JP, Marentette LJ, McHugh JB. Oral Surg Oral Med Oral Pathol Oral Radiol 115 e41-6 (2013)
  944. Voting-based cancer module identification by combining topological and data-driven properties. Azad AK, Lee H. PLoS One 8 e70498 (2013)
  945. News [It takes two RAFs to tango]. Lavoie H, Therrien M. Med Sci (Paris) 26 459-460 (2010)
  946. A Novel System for Functional Determination of Variants of Uncertain Significance using Deep Convolutional Neural Networks. Zimmerman L, Zelichov O, Aizenmann A, Barbash Z, Vidne M, Tarcic G. Sci Rep 10 4192 (2020)
  947. A multistep docking and scoring protocol for congeneric series: Implementation on kinase DFG-out type II inhibitors. Granadino-Roldán JM, Garzón A, Gomez-Gutierrez P, Pasamontes-Funez I, Santos Tomas M, Rubio-Martinez J. Future Med Chem 10 297-318 (2018)
  948. AK2 is an AMP-sensing negative regulator of BRAF in tumorigenesis. Kim H, Jeong M, Na DH, Ryu SH, Jeong EI, Jung K, Kang J, Lee HJ, Sim T, Yu DY, Yu HC, Cho BH, Jung YK. Cell Death Dis 13 469 (2022)
  949. Absence of BRAF exon 15 mutations in multiple myeloma and Waldenström's macroglobulinemia questions its validity as a therapeutic target in plasma cell neoplasias. Hatzimichael E, Murray S, Briasoulis E. Am J Blood Res 3 181-185 (2013)
  950. Alternative assay formats to identify diverse inhibitors of protein kinases. Singh P, Ward WH. Expert Opin Drug Discov 3 819-831 (2008)
  951. Association between BRAF mutant classification and the efficacy of pemetrexed-based chemotherapy in Chinese advanced non-small cell lung cancer patients: a multicenter retrospective study. Lei L, Wang WX, Zhu YC, Pu XX, Fang Y, Wang H, Zhuang W, Zhang YB, Wang LP, Xu CW, Fang MY. Transl Cancer Res 9 6039-6049 (2020)
  952. Case Reports BRAF p.V600E associated poly-neoplastic syndrome. Alhaj Moustafa M, Jiang L, Kuhlman JJ, Jones J, Lou Y, Sokumbi O, Tun HW. Rare Tumors 13 20363613211012929 (2021)
  953. Characterization of BRAF mutation in patients older than 45 years with well-differentiated thyroid carcinoma. Barreno LRQ, Mello JBH, Barros-Filho MC, Francisco AL, Chulam TC, Pinto CAL, Gonçalves-Filho J, Kowalski LP. Braz J Otorhinolaryngol 88 523-528 (2022)
  954. Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation. Qu J, Shen Q, Li Y, Kalyani FS, Liu L, Zhou J, Zhou J. Front Oncol 12 911303 (2022)
  955. Clinicopathological, Radiological, and Genetic Analyses of Cerebellar Gangliogliomas with Long-Term Survival. Liu B, Arakawa Y, Murata D, Mineharu Y, Yokogawa R, Tanji M, Fujimoto KI, Fukui N, Terada Y, Miyamoto S. World Neurosurg 94 521-528 (2016)
  956. Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node: Report of a Case. Tavallaee M, Steiner DF, Zehnder JL, Folkins AK, Karam AK. Int J Gynecol Pathol 38 386-392 (2019)
  957. Coincidence of v-raf murine sarcoma viral oncogene homolog B mutation (V595E) with phosphorylated v-raf murine sarcoma viral oncogene homolog B in urothelial carcinoma in dogs. Yamasaki H, Uematsu Y, Hayashi Y, Yamashita M, Tei M, Uchida K, Ono K, Hirao H. Can J Vet Res 86 286-293 (2022)
  958. Letter Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'. Dankner M, Rose AAN. Br J Cancer 118 1276-1277 (2018)
  959. Correlation of the Expression of BRAF V600E Mutation With Various Phenotypic Expressions of Thyroid Neoplasms. Harikrishnan V, Kumari S, Ramkumar S, Sankaran R, Ramalingam S, Sairam T. Cureus 13 e16048 (2021)
  960. Development of the first model of a phosphorylated, ATP/Mg2+-containing B-Raf monomer by molecular dynamics simulations: a tool for structure-based design. Previtali V, Trujillo C, Boisson JC, Khartabil H, Hénon E, Rozas I. Phys Chem Chem Phys 19 31177-31185 (2017)
  961. Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors. Liu G, Abraham S, Liu X, Xu S, Rooks AM, Nepomuceno R, Dao A, Brigham D, Gitnick D, Insko DE, Gardner MF, Zarrinkar PP, Christopher R, Belli B, Armstrong RC, Holladay MW. Bioorg Med Chem Lett 25 3436-3441 (2015)
  962. Finding the way in the jungle of kinase drug targets. Oxelmark E, Hornberg JJ. Drug Discov Today Technol 4 e89-e108 (2007)
  963. Hairy cell leukaemia with unusual BRAF mutations. Maitre E, Macro M, Troussard X. J Cell Mol Med 27 2626-2630 (2023)
  964. Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma. Nickoloff BJ, Vande Woude G. Pigment Cell Melanoma Res 25 758-761 (2012)
  965. Identification of guanylate cyclases and related signaling proteins in sperm tail from sea stars by mass spectrometry. Nakachi M, Matsumoto M, Terry PM, Cerny RL, Moriyama H. Mar Biotechnol (NY) 10 564-571 (2008)
  966. Information Fragmentation, Encryption and Information Flow in Complex Biological Networks. Bohm C, Kirkpatrick D, Cao V, Adami C. Entropy (Basel) 24 735 (2022)
  967. Case Reports KRAS Mutation in Serous Borderline Tumor of the Testis: Report of a Case and Review of the Literature. Bouri S, Noël JC, Catteau X, Al Hajj Obeid W, Svistakov I, Roumeguère T, D'Haene N, Rorive S. Case Rep Urol 2020 5419707 (2020)
  968. LCK-Mediated RIPK3 Activation Controls Double-Positive Thymocyte Proliferation and Restrains Thymic Lymphoma by Regulating the PP2A-ERK Axis. Hwang SM, Ha YJ, Koo GB, Noh HJ, Lee AY, Kim BJ, Hong SM, Morgan MJ, Eyun SI, Lee D, Roe JS, Lee Y, Kim YS. Adv Sci (Weinh) 9 e2204522 (2022)
  969. Modification, biological evaluation and 3D QSAR studies of novel 2-(1,3-diaryl- 4,5-dihydro-1H-pyrazol-5-yl)phenol derivatives as inhibitors of B-Raf kinase. Yang YS, Zhang F, Tang DJ, Yang YH, Zhu HL. PLoS One 9 e95702 (2014)
  970. Congress Molecular mechanisms in signal transduction and cancer. Bos JL, Burgering BM. EMBO Rep 5 855-859 (2004)
  971. Congress Multikinase inhibitors in thyroid cancer. Licitra L, Locati LD. Ann Oncol 23 Suppl 10 x328-33 (2012)
  972. Newly Identified BRAF Mutation in Rheumatoid Arthritis. Arnoux F, Fina F, Lambert N, Balandraud N, Martin M, Ouafik L, Kanaan SB, Roudier J, Auger I. Arthritis Rheumatol 68 1377-1383 (2016)
  973. On the development of B-Raf inhibitors acting through innovative mechanisms. Pinzi L. F1000Res 11 237 (2022)
  974. Oncogenic BRAFV600E induces microglial proliferation through extracellular signal-regulated kinase and neuronal death through c-Jun N-terminal kinase. Ye Q, Srivastava P, Al-Kuwari N, Chen X. Neural Regen Res 18 1613-1622 (2023)
  975. Case Reports Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review. Piringer G, Decker J, Trommet V, Kühr T, Heibl S, Dörfler K, Thaler J. Front Oncol 13 1166545 (2023)
  976. Outcomes of Patients with Metastatic Melanoma-A Single-Institution Retrospective Analysis. Szatkowska L, Sieczek J, Tekiela K, Ziętek M, Stachyra-Strawa P, Cisek P, Matkowski R. Cancers (Basel) 14 1672 (2022)
  977. Over-expressed, N-terminally truncated BRAF is detected in the nucleus of cells with nuclear phosphorylated MEK and ERK. Hey F, Andreadi C, Noble C, Patel B, Jin H, Kamata T, Straatman K, Luo J, Balmanno K, Jones DTW, Collins VP, Cook SJ, Caunt CJ, Pritchard C. Heliyon 4 e01065 (2018)
  978. Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl ester as ATP-competitive inhibitors of BRAF: A bioinformatics study. Malik V, Kumar V, Kaul SC, Wadhwa R, Sundar D. Curr Res Struct Biol 3 301-311 (2021)
  979. Prediction of BRAF V600E variant from cancer gene expression data. Kang J, Lee J, Lee A, Lee YS. Transl Cancer Res 11 4051-4056 (2022)
  980. RAF kinase inhibitors in cancer treatment: like a bull in a China shop? Robubi A, Waldmann H, Rauh D. Chembiochem 11 1645-1648 (2010)
  981. Recognition of BRAF by CDC37 and Re-Evaluation of the Activation Mechanism for the Class 2 BRAF-L597R Mutant. Bjorklund DM, Morgan RML, Oberoi J, Day KLIM, Galliou PA, Prodromou C. Biomolecules 12 905 (2022)
  982. Sensitivities and Dependencies of BRAF Mutant Colorectal Cancer Cell Lines with or without PIK3CA Mutations for Discovery of Vulnerabilities with Therapeutic Potential. Voutsadakis IA. Medicina (Kaunas) 58 1498 (2022)
  983. Sorafenib as an Inhibitor of RUVBL2. Nano N, Ugwu F, Seraphim TV, Li T, Azer G, Isaac M, Prakesch M, Barbosa LRS, Ramos CHI, Datti A, Houry WA. Biomolecules 10 E605 (2020)
  984. Structure-based prediction of BRAF mutation classes using machine-learning approaches. Krebs FS, Britschgi C, Pradervand S, Achermann R, Tsantoulis P, Haefliger S, Wicki A, Michielin O, Zoete V. Sci Rep 12 12528 (2022)
  985. Synthesis and biological evaluation of a new series of 1-aryl-3-[4-(pyridin-2-ylmethoxy)phenyl]urea derivatives as new anticancer agents. Feng J, Li T, Liang S, Zhang C, Tan X, Ding N, Wang X, Liu X, Hu C. Med Chem Res 29 1413-1423 (2020)
  986. Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies. Morris VK. Curr Colorectal Cancer Rep 15 53-60 (2019)
  987. The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study. Beypinar I, Demir H, Sakin A, Taskoylu BY, Sakalar T, Ergun Y, Korkmaz M, Ates O, Eren T, Turhal S, Artac M. J Gastrointest Cancer 52 932-939 (2021)
  988. Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In Vivo. Niessner H, Burkard M, Leischner C, Renner O, Plöger S, Meraz-Torres F, Böcker M, Hirn C, Lauer UM, Venturelli S, Busch C, Sinnberg T. Cells 11 1229 (2022)
  989. Thyroid Cancer-Associated Mitochondrial DNA Mutation G3842A Promotes Tumorigenicity via ROS-Mediated ERK1/2 Activation. Chen S, Bao X, Chen H, Jia M, Li W, Zhang L, Fan R, Fang H, Jin L. Oxid Med Cell Longev 2022 9982449 (2022)
  990. Transcription factor ZNF488 accelerates cervical cancer progression through regulating the MEK/ERK signaling pathway. Weng K, Li L, Zhou H. Histol Histopathol 38 1381-1390 (2023)
  991. Variations in MAP kinase gladiators and risk of differentiated thyroid carcinoma. Rashid FA, Bhat GH, Khan MS, Tabassum S, Bhat MH. Mol Clin Oncol 16 45 (2022)
  992. Vemurafenib and Dabrafenib Downregulates RIPK4 Level. Madej E, Brożyna AA, Adamczyk A, Wronski N, Harazin-Lechowska A, Muzyk A, Makuch K, Markiewicz M, Rys J, Wolnicka-Glubisz A. Cancers (Basel) 15 918 (2023)
  993. [Advances in molecular biology and their application in the diagnosis and treatment of melanoma]. Martorell-Calatayud A, Requena C, Botella-Estrada R, Sangüeza OP. Actas Dermosifiliogr 100 Suppl 1 52-65 (2009)
  994. [Triple therapy for metastatic melanoma]. Zacher M, Heppt M, Berking C. Hautarzt 69 25-27 (2018)
  995. p90RSK Regulates p53 Pathway by MDM2 Phosphorylation in Thyroid Tumors. Maietta I, Del Peschio F, Buonocore P, Viscusi E, Laudati S, Iannaci G, Minopoli M, Motti ML, De Falco V. Cancers (Basel) 15 121 (2022)
  996. A new model to evaluate Raf signaling in hematopoietic cells. Okuda K. Int J Oncol 43 903-910 (2013)
  997. Case Reports Anaplastic glioneuronal tumor with KIAA1549/BRAF fusion. Liu L, Narayan P, Xiong J, Xiong Z. Intractable Rare Dis Res 8 279-282 (2019)
  998. Case Reports BRAF L485-P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review. Zhang S, Yang Z, Cheng Y, Guo X, Liu C, Wang S, Zhang L. Front Pharmacol 13 1019217 (2022)
  999. Case Reports BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report. Moisset L, Raimbourg J, Hiret S, Dauve J, Boisdron-Celle M, Senellart H, Raoul JL. Case Rep Oncol 12 426-429 (2019)
  1000. BRAFV600E mutation in papillary thyroid carcinoma: a potential target for therapy? Soares P, Preto A, Sobrinho-Simões M. Expert Rev Endocrinol Metab 4 467-480 (2009)
  1001. BRAFV600E Expression Is Homogenous and Associated with Nonrecurrent Disease and Better Survival in Primary Melanoma. Naimy S, Bzorek M, Eriksen JO, Dyring-Andersen B, Rahbek Gjerdrum LM. Dermatology 239 409-421 (2023)
  1002. Case Reports Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma. Dong W, Lei P, Liu X, Li Q, Cheng X. Front Immunol 12 686057 (2021)
  1003. Changes in antioxidant status and DNA repair capacity are corroborated with molecular alterations in malignant thyroid tissue of patients with papillary thyroid cancer. Eng ZH, Abdul Aziz A, Ng KL, Mat Junit S. Front Mol Biosci 10 1237548 (2023)
  1004. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. Morris V, Kee B, Overman M, Dasari A, Raghav K, Johnson B, Parseghian C, Wolff RA, Garg N, Eng C, Kopetz S. J Gastrointest Oncol 13 647-656 (2022)
  1005. Clinical associations and genetic interactions of oncogenic BRAF alleles. Wagner SA. PeerJ 10 e14126 (2022)
  1006. Clinical practice guidelines for molecular tumor markers, 2nd edition review part 1. Kikuchi Y, Shimada H, Hatanaka Y, Kinoshita I, Ikarashi D, Nakatsura T, Kitano S, Naito Y, Tanaka T, Yamashita K, Oshima Y, Nanami T. Int J Clin Oncol (2023)
  1007. Co-dependent regulation of p-BRAF and potassium channel KCNMA1 levels drives glioma progression. Xie S, Xu C, Wu C, Lou Y, Duan J, Sang R, Lou Z, Hou J, Ge W, Xi Y, Yang X. Cell Mol Life Sci 80 61 (2023)
  1008. Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers. Rustgi N, Maria A, Toumbacaris N, Zhao H, Kargus K, Bryant M, Waksmundzki A, Aricescu I, Lefkowitz RA, Li BT, Chou J, Capanu M, de Stanchina E, Misale S, Shia J, Yaeger R. Oncologist 29 15-24 (2024)
  1009. Conformational control and regulation of the pseudokinase KSR via small molecule binding interactions. Chow A, Khan ZM, Marsiglia WM, Dar AC. Methods Enzymol 667 365-402 (2022)
  1010. DCMP: database of cancer mutant protein domains. Emerson IA, Chitluri KK. Database (Oxford) 2021 baab066 (2021)
  1011. DeKinomics pulse-chases kinase functions in living cells. Weng Y, Chen W, Kong Q, Wang R, Zeng R, He A, Liu Y, Mao Y, Qin Y, Ngai WSC, Zhang H, Ke M, Wang J, Tian R, Chen PR. Nat Chem Biol (2024)
  1012. Developing Models to Predict BRAFV600E and RAS Mutational Status in Papillary Thyroid Carcinoma Using Clinicopathological Features and pERK1/2 Immunohistochemistry Expression. Harahap AS, Subekti I, Panigoro SS, Asmarinah, Lisnawati, Werdhani RA, Agustina H, Khoirunnisa D, Mutmainnah M, Gultom FL, Assadyk AH, Ham MF. Biomedicines 11 2803 (2023)
  1013. Comment Effectively targeting CRAF: rational serendipity targeting SRC? Flaherty KT. Pigment Cell Melanoma Res 28 242-243 (2015)
  1014. Evaluation of the RAS signaling network in response to MEK inhibition using organoids derived from a familial adenomatous polyposis patient. Osumi H, Muroi A, Sakahara M, Kawachi H, Okamoto T, Natsume Y, Yamanaka H, Takano H, Kusama D, Shinozaki E, Ooki A, Yamaguchi K, Ueno M, Takeuchi K, Noda T, Nagayama S, Koshikawa N, Yao R. Sci Rep 10 17455 (2020)
  1015. First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors. Dienstmann R, Lassen U, Cebon J, Desai J, Brown MP, Evers S, Su F, Zhang W, Boisserie F, Lestini B, Schostack K, Meresse V, Tabernero J. Target Oncol 11 149-156 (2016)
  1016. Genomic landscape of Epstein-Barr virus-positive extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue. Rea B, Liu YC, Maguire A, Soma LA, Bacon CM, Bayerl MG, Smith MH, Barrett MT, Swerdlow SH, Gibson SE. Mod Pathol 35 938-945 (2022)
  1017. In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors. Żołek T, Mazurek A, Grudzinski IP. Molecules 28 5273 (2023)
  1018. In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation. Chen J, Zhai J, Li M, Liu S, Gong X, Yu H, Wei H, Chen W. Cancer Cell Int 23 21 (2023)
  1019. Insight of novel biomarkers for papillary thyroid carcinoma through multiomics. Liu W, Zhu J, Wu Z, Yin Y, Wu Q, Wu Y, Zheng J, Wang C, Chen H, Qazi TJ, Wu J, Zhang Y, Liu H, Yang J, Lu D, Zhang X, Ai Z. Front Oncol 13 1269751 (2023)
  1020. Integrated Transcriptome and Molecular Docking to Identify the Hub Superimposed Attenuation Targets of Curcumin in Breast Cancer Cells. Wang R, Yu H, Chen P, Yuan T, Zhang J. Int J Mol Sci 24 12479 (2023)
  1021. KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania. Brinzan CS, Aschie M, Cozaru GC, Deacu M, Dumitru E, Burlacu I, Mitroi A. Medicine (Baltimore) 101 e30979 (2022)
  1022. Live-cell target engagement of allosteric MEKi on MEK-RAF/KSR-14-3-3 complexes. Marsiglia WM, Chow A, Khan ZM, He L, Dar AC. Nat Chem Biol (2023)
  1023. Models for prediction of (V)600(E)BRAF and melanoma cells growth inhibitory activities of pyridoimidazolones. Dutt R, Madan AK. Arch Pharm (Weinheim) 343 664-679 (2010)
  1024. Molecular determination of benign and malignant thyroid tumors. Führer D. Expert Rev Endocrinol Metab 1 763-773 (2006)
  1025. NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases. Kobayashi S, Bando H, Taketomi A, Takamoto T, Shinozaki E, Shiozawa M, Hara H, Yamazaki K, Komori K, Matsuhashi N, Kato T, Kagawa Y, Yokota M, Oki E, Komine K, Takahashi S, Wakabayashi M, Yoshino T. BMC Cancer 23 779 (2023)
  1026. Ocular side effects of Trametinib and Dabrafenib: a case report. Tarım B, Kılıç M. J Ophthalmic Inflamm Infect 13 17 (2023)
  1027. Oncogenic Mutation BRAF V600E Changes Phenotypic Behavior of THLE-2 Liver Cells through Alteration of Gene Expression. Śmiech M, Leszczyński P, Wardell C, Poznański P, Pierzchała M, Taniguchi H. Int J Mol Sci 23 1548 (2022)
  1028. Phospho-Specific Flow Cytometry Reveals Signaling Heterogeneity in T-Cell Acute Lymphoblastic Leukemia Cell Lines. Perbellini O, Cavallini C, Chignola R, Galasso M, Scupoli MT. Cells 11 2072 (2022)
  1029. RAS-independent ERK activation by constitutively active KSR3 in non-chordate metazoa. Chessel A, De Crozé N, Molina MD, Taberner L, Dru P, Martin L, Lepage T. Nat Commun 14 3970 (2023)
  1030. Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma. Bui Dang Minh T, Nghiem Duc T, Phan Nguyen Thanh V, Dinh Le T, Duc Tong M, Hoang Nguyen T, Tuan AL, Xuan Nguyen K, Tran Viet T, Ba Ta T, Tien Nguyen S, Anh Vu H, Van Nguyen B, Nguyen Thi Ngoc D, Tran Quoc V, Bui Duc T. Clin Med Insights Oncol 17 11795549231203503 (2023)
  1031. Resolving the role of podoplanin in the motility of papillary thyroid carcinoma-derived cells using RNA sequencing. Mielecki D, Gajda E, Sikorska J, Betkowska A, Rozwadowski M, Gawel AM, Kulecka M, Zeber-Lubecka N, Godlewska M, Gawel D. Comput Struct Biotechnol J 21 3810-3826 (2023)
  1032. Response of BRAF inhibitor-associated squamous cell lung carcinoma to drug withdrawal. Blackmon JT, Dhawan R, Terry NL, Conry RM. Melanoma Res 27 159-163 (2017)
  1033. Roles of epidermal growth factor receptor, claudin-1 and occludin in multi-step entry of hepatitis C virus into polarized hepatoma spheroids. So CW, Sourisseau M, Sarwar S, Evans MJ, Randall G. PLoS Pathog 19 e1011887 (2023)
  1034. SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma. Valencia-Sama I, Kee L, Christopher G, Ohh M, Layeghifard M, Shlien A, Hayes MN, Irwin MS. Cancer Res Commun 3 2608-2622 (2023)
  1035. SPOP inhibits BRAF-dependent tumorigenesis through promoting non-degradative ubiquitination of BRAF. Feng K, Shi Q, Jiao D, Chen Y, Yang W, Su K, Wang Y, Huang Y, Zhang P, Li Y, Wang C. Cell Biosci 12 211 (2022)
  1036. Simple and Ultrasensitive Detection of Glioma-Related ctDNAs in Mice Serum by SERS-Based Catalytic Hairpin Assembly Signal Amplification Coupled with Magnetic Aggregation. Wang Y, Yang Y, Cao X, Liu Z, Chen B, Du Q, Lu X. Int J Nanomedicine 18 3211-3230 (2023)
  1037. The Sensitivity and Specificity of Novel Primers for Detection of BRAFV600E Mutation. Tayeb BA, Pringle HJ. Asian Pac J Cancer Prev 21 3191-3198 (2020)
  1038. The future of targeted therapy approaches in melanoma. Cantini LP, Meier F, Sondak VK, Smalley KS. Expert Opin Drug Discov 4 445-456 (2009)
  1039. Transcriptional and post-translational modifications of B-Raf in quinol-thioether induced tuberous sclerosis renal cell carcinoma. Cohen JD, Labenski M, Mastrandrea NJ, Canatsey RD, Monks TJ, Lau SS. Mol Carcinog 55 1243-1250 (2016)
  1040. Unique Spectrum of Activating BRAF Alterations in Prostate Cancer. Chehrazi-Raffle A, Tukachinsky H, Toye E, Sivakumar S, Schrock AB, Bergom HE, Ebrahimi H, Pal S, Dorff T, Agarwal N, Mahal BA, Oxnard GR, Hwang J, Antonarakis ES. Clin Cancer Res 29 3948-3957 (2023)
  1041. Update on the molecular signature of differentiated thyroid cancer: clinical implications and potential opportunities. Bauer AJ, Francis GL. Expert Rev Endocrinol Metab 6 819-834 (2011)


Quick links